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Abstract 
A major cause of cancer in humans is exposure to mutagenic compounds. This raises the question 
of how humans can be protected from these environmental mutagens. Bile pigments (BPs) such as 
biliverdin, unconjugated bilirubin and protoporphyrin and their derivatives have recently been 
found to act as antioxidants and inhibit the mutagenic effects of several known environmental 
mutagens including 2-aminofluorene, benzo[α]pyrene, and 2-amino-1-methyl-6-phenylimido[4,5-
b]pyridine. Despite these promising results, very little is known about the mechanisms by which 
this inhibition is achieved. Understanding these mechanisms would be useful for future drug 
development. Therefore, this PhD thesis aims to explore physical and chemical interactions between 
BPs and mutagens. Effects of BPs on the bioavailability and metabolism of mutagens were also 
examined in vitro using the colorectal adenocarcinoma (Caco-2 cell) monolayer model and the 
human liver S9 fraction. 
The physical interactions between mutagens and BPs were examined using three different methods: 
NMR, UV and effects of bioavailability. The results of the comparison of the NMR spectra of 
mutagens in the absence and presence of BPs showed very little changes in the chemical shifts of 
the protons and the changes that did occur were the result of acid/base interactions between the BPs 
and mutagens. The UV spectrum of each mutagen was measured in the presence and absence of 
varying concentrations of BPs, and there were no changes to the UV spectra of any of the 
compounds. Strong physical interactions or aggregation of compounds can also affect their 
absorption across cell monolayers and so the apparent permeability of mutagens across Caco-2 cell 
monolayers in the presence and absence of BPs were measured. The results indicated that BPs 
increased the permeability of the mutagens slightly and effected how much of the compounds 
remained in tight association with the monolayer but the effects were small. These experiments 
provided evidence to suggest that physical interactions and aggregations are unlikely to be a major 
contributing mechanism of the inhibitory effects of BPs on environmental mutagens. 
Chemical reactions between BPs and the DNA modifying metabolites of mutagens (epoxides) were 
studied using styrene epoxide as a model for the reactive metabolites. Styrene epoxide is 
commercially available, stable and less toxic than the reactive metabolites of the mutagens.  
Competitive reactions were performed in which BPs and their derivatives were placed in solution 
with guanine and allowed to react with styrene epoxide. These reactions showed that BPs and their 
dimethyl esters are more reactive to the epoxide than guanine. Bile pigments primarily react 
through their carboxylic acid groups with the mono- and di-styrene epoxide esters being the major 
products isolated form the reactions. The pyrrole rings in bilirubin also showed some evidence of 
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reaction with styrene epoxide though the products were too unstable to isolate. Thus, it was clear 
that BPs can effectively scavenge reactive metabolites, but the free carboxylic acids were 
significantly more effective at this than the dimethyl ester derivatives. This is not reflected in the 
anti-mutagenic activities of the compounds. Also, the ubiquitous nature of carboxylic acid groups in 
the cellular environment makes it unlikely that this reaction with activated epoxides would be 
unique to BPs. For these reasons we concluded that it is unlikely that chemical scavenging of 
reactive metabolites is the sole or even major mechanism of the inhibition of BPs.  
Another possible mechanism of action of the BPs is that they inhibit the formation of the DNA 
modifying metabolites of the mutagens. We investigated this by performing in vitro experiments in 
which mutagens were co-incubated in the human liver S9 fraction in the presence and absence of 
BPs. The results indicated BPs were inhibitors of the metabolism of benzo[a]pyrene and 2-amino-1-
methyl-6-phenylimido[4,5-b]pyridine by liver enzymes. The order of inhibitory effectiveness was 
bilirubin > protoporphyrin > biliverdin. Molecular modelling studies which examined the docking 
of the various BPs into the active sites of published crystal structures of the enzymes known to be 
responsible for the metabolism of the mutagens, suggested BPs could bind to the active sites of 
CYP1A1, 1A2, 1B1 and 3A4. 
In summary, we conducted a series of experiments to evaluate the likely mechanisms of the 
inhibitory effects of BPs on known environmental mutagens. There are several theories postulated 
to explain the anti-mutagenic effects of BPs including the physical -stacking driven aggregation of 
BPs with the polyaromatic mutagens, the chemical scavenging of BPs towards reactive metabolites, 
and the inhibition of BPs of the P450 mediated activation of the mutagens. We have systematically 
tested each of these and found that the latter appears to be the most likely mechanism to explain the 
effects reported. In broader terms, this research will aid in understanding how BPs inhibit 
mutagenesis and thus may lead to the development of synthetic compounds that could decrease the 
risk to humans exposed to these environmental mutagens. 
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Chapter 1: Introduction and literature review 
1.1 Bile pigments 
Bile pigments (BPs) are the main chemical components of animal bile and have been popularly 
used in traditional medicine for centuries.
1,2
 BPs are endogenous compounds that are produced in 
the metabolism of hemoglobin from red blood cells recycled in the liver. This class of compounds 
includes biliverdin (1.2, BV), produced from haem by the action of haem oxygenase and NADPH 
reductase with a release of carbon monoxide and iron. Unconjugated bilirubin (1.1, UCB) is a 
product of further reduction of 1.2 (BV) by biliverdin reductase (Figure 1.1).
3,4
 Unconjugated 
bilirubin (1.1, UCB) is a highly hydrophobic compound which is conjugated to glycose by UDP-
glucoronosyl transferase to form bilirubin diglucoronide (a hydrophilic compound) and excreted 
from the body. The degradation of haem produces approximately 300 mg of 1.1 (UCB) per day.
5,6
  
 
Figure 1.1:  The metabolism of haem to form BPs (1.1 and 1.2) in mammals. 
While senescent red blood cells release haemoglobin, enzymes open the protoporphyrin-IX (1.3, 
PRO) ring at different carbon bridge positions (α, β, γ, δ). These two processes create isomers of 1.2 
(biliverdin IXα, IXβ, IXγ, IXδ).7,8 These compounds were detected by HPLC in human serum from 
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jaundice patients by Adachi et al.
8
 Biliverdin IXβ and IXα reductase then catalyses the reduction of 
biliverdin IX (1.2, BV) and biliverdin IXβ to the corresponding isomers of 1.1 (UCB) (Figure 
1.2).
7,9
 Biliverdin isomers have identical polarity and are therefore very difficult to be isolated by 
column chromatography. To obtain pure 1.2 (BV), McDonagh conducted dehydrogenation of 
purified 1.1 (UCB) in DMSO solvent with 2,3-dichloro-5,6-dicyanobenzoquinone under argon 
atmosphere and obtained 70% yield.

 
  
Figure 1.2: Isomers of 1.2 (BV) produce from the breakdown of haem and the opening of protoporphyrin-IX at 
different carbon bridges by haem oxygenase.
7-9
  
Bile pigments (BPs), 1.1 (UCB), 1.2 (BV), and 1.3 (PRO) are biochemicals found in mammals. 
Unconjugated bilirubin and biliverdin are formed from the metabolism of haem and are the main 
components in animal bile
1
 whereas 1.3 (PRO) is a biosynthetic intermediate in the production of 
haem and its synthesis is conserved in a wide range of organisms from bacteria to mammals.
11-13
 All 
α 
β 
γ 
δ 
Biliverdin-IXα  
Biliverdin-IXβ 
Biliverdin-IXγ 
Biliverdin-IXδ 
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of these compounds are often referred to as tetrapyrroles although compounds 1.1 (UCB) and 1.2 
(BV) are in fact not tetrapyrroles as their structures consist of two conjugated pyrroles and two 
unsaturated lactam rings. As products of haem catabolism (1.1 (UCB) and 1.2 (BV)) and a haem 
precursor 1.3 (PRO), we prefer to use BPs to refer to these three compounds throughout our studies. 
It is to be noted that these compounds will be differently numbered in each chapter.  
1.2 The biological properties of bile pigments and their derivatives  
Bile pigments (BPs) are known to be toxic to human beings at high concentrations,
3,14,15
 but are 
currently recognised as having potentially beneficial biological properties at low levels in blood.
15-21
  
High concentrations of 1.1 (UCB) in the blood and bodily tissues leads to serious health problems 
such as jaundice, athetoid cerebral palsy, and hearing loss or deafness, particularly in newborn 
infants where the blood-brain barrier is not yet well formed and so may allow bilirubin to enter the 
brain.
3,15
 The beneficial biological effects of BPs and their derivatives have been of mounting 
interest recently as their potent anti-mutagenicity,
15,18,19,21
 and anti-oxidant properties
18,22-28
 come to 
light as well as their ability to bind to certain important enzymes.
29-31
 The chemical details and their 
potential physiology properties will be reviewed in the following section. 
1.2.1 Anti-mutagenic effects of bile pigments 
Numerous studies have recently shown that BPs are important endogenous compounds with 
antioxidant, anti-mutagenic, and anti-cancer activities.
14,17,22-28
  Bulmer et al.
15,18
 showed that BPs 
effectively inhibited the genotoxic effects of tertiary-butyl hydroperoxide induced oxidative stress. 
Compound 1.1 (UCB) is proposed to act as an antioxidant by donation of a hydrogen radical from 
the C10-bridge
15,18
 or amide groups
32
 to free radicals to form stable carbon-centered radicals that 
then react with either other free radicals to form new covalent bonds or free oxygen.
22,33
   
The anti-mutagenic property of BPs was explored by Arimoto et al.
34,35
 who used benzo[α]pyrene 
(1.7) to promote the formation and development of revertants; in Salmonella strains TA100 and 
TA98 1.1 (UCB), 1.2 (BV), 1.3 (PRO),  and hemin were then used as inhibitors of the growth of 
these revertants. Manually counting and comparing the revertants formed in each experiment 
provided clear evidences to conclude the order of effectiveness of BPs on the B[]P-induced 
mutagenesis: Hemin = 1.3 (PRO) > 1.1 (UCB) > 1.2 (BV). The same experiments were performed 
in the presence of a highly mutagenic metabolite of 1.7, which showed the order of effectiveness at 
inhibiting DNA damage caused by mutagen: Hemin > 1.3 (PRO) > 1.1 (UCB) = 1.2(BV). PhD 
work of our collaborator, Dr. Andrew Bulmer
2
, studied the effects of BPs on the mutagenicity of 
some common environmental mutagens, 1.7, 2,4,7-trinitro-9H-fluoren-9-one (1.4), and 2-
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aminofluorene (1.5). The compounds were tested using the Salmonella reverse mutation assay using 
bacterial strains TA98, TA100, and TA102. The mutagens were used to promote revertant 
formation and growth on plates. The level of bacterial cell growth was determined by manual cell 
counting and the results for cells treated only with mutagens were compared to the results obtained 
from the same experiments with the addition of different BPs. The final results showed that the BPs 
were all effective at inhibiting the DNA damage caused by the mutagens and the order of 
effectiveness at inhibiting the mutagenic effects of 1.4 was: 1.1 (UCB) ≥ bilirubin ditaurate (1.6) ≥ 
1.2 (BV); and the order of effectiveness against 1.5 was: 1.1 (UCB) ≥ 1.2 (BV) ≥ 1.6 in all strains 
(TA98, TA100, and TA102).
18
 Overall, the above-mentioned results indicated that 1.3 (PRO) has 
higher anti-mutagenic activation than 1.1 (UCB), followed by 1.2 (BV). 
In a follow-up study, Molzer et al.,
11,13
 who used the same method, performed the experiments on 
Salmonella Typhimurium strains (TA102 and TA98) in the presence of rat liver S9 as a method of 
activating the mutagens. The study used aflatoxin B1 (AfB1) and 2-amino-1-methyl-6-
phenylimidazo[4,5-b]pyridine (1.8) as environmental mutagens and a number of inhibitors such as 
1.1 (UCB), 1.2 (BV), and 1.3 (PRO); bilirubin dimethyl ester (1.9); and biliverdin dimethyl ester 
(1.10) in order to test the promotion and inhibition of revertant growth. Comparing the number of 
revertant formation in each experiment indicated the order of effectiveness of the above inhibitors 
on the growth of mutagenesis in the presence of AfB1, to be 1.3 (PRO) > 1.1 (UCB) = 1.6 > 1.2 
(BV) > 1.9 > 1.10 in strain TA102 and 1.10 > 1.9 > 1.3 (PRO) and 1.1 (UCB), 1.2 (BV), 1.6 did not 
inhibit any AfB1-induced mutagenesis in strain TA98. The studies also showed the order 
effectiveness of inhibitors on PhIP-induced mutagenesis was 1.3 (PRO) > 1.1 (UCB) > 1.2 (BV) > 
1.9 > 1.6 > 1.10 in strain TA98. It is concluded that the inhibitory action of these compounds 
depends on bacterial species, environmental mutagens, and the purity of inhibitors. 
In general, the inhibitory effects of BPs on the revertant growth were investigated in many studies 
using bacteria.
14,15,17,19,34,36,37
 and all provided support for the powerful anti-mutagenicity of BPs. 
However, the mechanism by which this inhibition is achieved has not been illucidated.  
Understanding the inhibitory mechanism of BPs toward the action of environmental mutagens will 
greatly aid in our ability to combat these toxins 
1.2.2 Physical interactions between mutagens and bile pigments 
There have been many hypotheses put forward for the mechanism of action of BP‘s inhibition of 
mutagenesis.  One such theory is that there are significant non-covalent attractive forces between 
the polyaromatic mutagens and the -systems of the BPs resulting in aggregation. Although this is a 
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popular hypothesis,
2,15,19,21
 very few reports present evidence that these physical interactions 
contribute to the activity.
21,38
 Haino et al.
38
 used variable temperature 
1
H NMR in toluene-d8 to 
detect stacked structures between 2,4,7-trinitro-9H-fluoren-9-one (1.4) and bisporphyrin, a 
compound belonging to the same class as BPs. Bulmer et al.
15,18
 recently hypothesised that physical 
interactions between BPs and mutagens may contribute to the inhibitory effects of BPs on 
environmental mutagens. In addition, Mölzer et al.
21
 used circular dichroism (CD) spectroscopy, 
vibrational circular dichroism (VCD), and infrared (IR) spectroscopy to explore the interactions 
between BPs and 1.4. The spectra of some BPs and their derivatives in the presence and absence of 
1.4 were compared. The results showed that the addition of 1.4 into the samples of BPs and their 
derivatives led to the variation of CD intensity of the blue band of BPs and significant changes in 
VCD and IR spectra. The studies suggested physical interactions between BPs and 1.4 are the cause 
of the modifications in CD, VCD, and IR spectra of BPs and their derivatives, and concluded that 
physical interactions could give rise to the anti-mutagenic actions of BPs.
21
  
1.2.3 Bilirubin is substrate of cytochrome 1A2 (CYP 1A2), CYP 1A1, 2A6 
Many previous studies have suggested that 1.1 (UCB) is a substrate for uridine 5‘-diphospho-
glucuronosyltransferase 1A1 (UGT-1A1)
39-42
, CYP2A5
43
, and some other enzymes, such as CYP 
1A1,
29,44-47
 1A2,
44,48
 and 2A6,
30,31,49
 that are responsible for the metabolism of mutagens. Phelan et 
al.
29
 incubated guinea pig, rat, and human cells with 1 nM, 3 nM, and 5 nM of the environmental 
contaminant, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), respectively and co-incubated with 1.1 
(UCB)  (50 μM) and 1.2 (BV) (50 μM) for 4 hours at 37 ºC. TCDD is a substrate for CYP1A1 
which converts it to reactive epoxide and then 8-OH-2,2,7-triCDD and 2-OH-1,3,7,8-tetraCDD.
50
 
Cells should increase the expression of this enzyme in response to exposure to TCDD or any of its 
other substrates. This was indeed found to be the case in these experiments. The study found the 
presence of 1.1 (UCB) (50 μM) can induce CYP1A1-luciderase to approximately 74%, 83%, and 
100% of that induced from the activation of TCDD in the rat, guinea pig, and human cells 
respectively. The presence of 1.2 (BV) contributed to 80%, 76%, and 26% that of induced from 
TCDD. Therefore, the expression of the enzyme was also stimulated by the presence of 1.1 (UCB) 
and 1.2 (BV), with 1.1 (UCB) having a greater effect than 1.2 (BV). The study suggested that 1.1 
(UCB) and 1.2 (BV) can act as competitive inhibitors of CYP1A1 slowing the metabolism of 
TCDD.
29
   
Christopher and John
45
 determined the expression of CYP1A1 in Hepa 1c1c7 cell lines and 
recognised that the level of CYP1A1 increased significantly after 1 hour exposure to 1.1 (UCB) 
(100 μM) and 1.2 (BV) (100 μM), and after 2 hours exposure to hemin (100 μM). The presence of 
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1.1 (UCB) induced higher expression levels of CYP1A1 genes than 1.2 (BV) or hemin. Similarly to 
Phelan et al‘s study, 1.1 (UCB) and 1.2 (BV) were substrates of CYP1A1.45 Kapitulnik and 
Gonzalez
47
 measured the levels of CYP1A1 and 1A2 at 10 days to one month of age of non-
jaundiced and jaundiced rats. The findings indicated that the levels of CYP1A1 and 1A2 were 
increased in jaundiced rats (high accumulation of 1.1 (UCB) in order to facilitate degradation of 1.1 
(UCB) and elimination of the endogenously toxic chemical from the body of young rats.
47
 All the 
above findings have been reviewed by Linh and Christopher
51
 and later by Bock.
39
 
Bilirubin was also believed to be a potent substrate for CYP2A6. Abu-Bakar et al.
30,49
 co-incubated 
1.1 (UCB) and coumarin with CYP2A6 from mouse recombinant yeast microsomes and found that 
1.1 (UCB) (at 10 μM) can inhibit approximately 100% of coumarin 7-hydroxylation by CYP2A6. 
Similarly, Hiromi et al.
31
 conducted in vitro experiments with human hepatocytes within and 
without of 40 μM of 1.1 (UCB) and found that the level of CYP2A6 increased to 1.7-fold compared 
to the control experiments. The study suggested 1.1 (UCB) induced CYP2A6 gene expression.
31
 
In general, BPs could be inhibitors for a variety of enzymes that possess active functions for the 
metabolism of mutagens (see chapter IV for more details). Therefore, the presence of BPs could 
affect the rate of metabolism of mutagens. 
1.3 Chemical studies of bile pigments 
In order to understand how bile pigments (BPs) might interact with mutagens in biological systems, 
it is necessary to investigate the unique structures and physical and chemical properties of BPs. A 
summary of BPs‘ properties provides a useful background about the isomerization phenomenon and 
photooxidation of BPs facilitating further experimental designs. 
The use of the terms biliverdin and bilirubin alone refer to biliverdin IXα and unconjugated 
bilirubin IXα. All their isomers for example; bilirubin included unconjugated bilirubin IIIα, XIIIα, 
IXβ, IXδ, and IXγ and the 4E,15E-; 4E,15Z-; 4Z,15Z-; 4Z,15E-configurational isomers and the 
enantiomers of (4Z, 15Z)-bilirubin IXα are denoted by their complete nomenclature.   
1.3.1 Unconjugated bilirubin-IX  
Unconjugated bilirubin has long been considered only in terms of its toxicity. The accumulation of 
1.1 (UCB) in mammalian blood leads to diseases such as jaundice which is the yellow colouration 
of the sclera of skin and eyes. Newborn infants might also be subjected to unconjugated 
hyperbilirubinaemia that leads to accumulation of bilirubin in the brain, resulting in serious 
neurological defects such as abnormal reflexes, eyes movements, seizures, permanent neurological 
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dysfunction, and encephalopathy.
52
 Studies have shown that the level of 1.1 (UCB) in the blood of a 
healthy human adult can vary from 1.7-20 μM.53-55  While the toxic effects of elevated levels of BPs 
are well documented, many papers recently reported that BPs are essential endogenous compounds 
that can inhibit the action of some mutagenic compounds, acting as anti-oxidants and having anti-
inflammatory properties.
14,27,56
  
The presence of a saturated methylene group at the C10-bridge of 1.1 (UCB) blocks conjugation 
between the two halves of the molecule. Isomers of 1.1 (UCB) are described using notations such as 
IXα (Z,Z). The Greek letter (eg ‗α‘) refers to the site of cleavage of the precursor protoporphyrin as 
discussed above. The ‗Z,Z‘ refers to the configuration of the C4-C5 and C15-C16 double bonds.7,9,57 
This Z,Z configuration allows intramolecular hydrogen bonding between nitrogens in the pyrrole 
rings and the carboxyl groups leading to folded structures with the lipophilic parts of the molecule 
exposed and the hydrophilicity of the molecule reduced.
57-59
 Thus, in spite of having two carboxyl 
groups and two lactam groups, (Z,Z)- 1.1 (UCB) is virtually insoluble in water. Its water solubility 
was assessed in a range of concentrations, from 7 nM to 70 nM.
60,61
 In general, six intramolecular 
hydrogen bonds of (Z,Z)- 1.1 (UCB) generate a number of conformational isomers that vary in their 
physical, chemical, and biological properties (Figure 1.5).
57-59,62-64
 (4Z, 15Z)- 1.1 (UCB), in which 
six intramolecular hydrogen bonds are formed between carboxylic acid and amide pyrrole N-H 
groups to create a ‗ridge-tile‘ shape in the central molecule and form enantiomeric conformations 
(M and P).
58-60,65 
 
Figure 1.3: The enantiomers of (4Z, 15Z)-bilirubin (P=plus, M=minus) demonstrate the presence of ‗ridge-tile‘ 
conformers via the formation of six intramolecular hydrogen bonds.
58,59 
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Photochemical isomerisation of unconjugated bilirubin  
When (Z,Z)- 1.1 (UCB) is exposed to light, the Z,Z configuration is isomerised to (Z,E)-, (E,Z)-, 
(E,E)- 1.1 (UCB) (Figure 1.4).
66,67
 The mixture of photobilirubin isomers will convert back to the 
(Z,Z) isomer in the dark.
66
 All bilirubin photoisomers were detected by HPLC analysis of the 
exposure of 1.1 (UCB) in DMSO to light for 60 min.
8
 Light also activates the -bonds in the vinyl 
groups which leads to the formation of adducts with the pyrrole rings nearby and produces a new 
ring and releases one of the carboxyl groups which can now be deprotonated (Figure 1.4).
68,69
 As a 
result of this transformation, the polar groups (carboxylic and amide) are exposed and this leads to 
an increase in water solubility and the compound becomes easier to excrete through the urine and 
faeces.
62,70,71
 
 
Figure 1.4: Configurational photo-isomerisation of (4Z,15Z)-bilirubin, leading to the formation of four isomers, 
(4E,15Z)-, (4Z,15E)- and (4E,15E)-bilirubin.
8,66,67
 
 
Figure 1.5: The formation of adducts with the pyrrole rings nearby producing a new ring. 
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Unconjugated bilirubin-IXα (1.1, UCB) is unstable to pH changes and isomerises to bilirubin-III 
and XIIIin acid and alkaline solutions (Figure 1.6). The process of isomerisation starts with the 
dissociation of 1.1 (UCB) into four different dipyrrolic units which then randomly reassemble the 
C10 covalent bond between two symmetrical dipyrrolic units to create symmetric bilirubin-III and 
XIII7,16,66,72,73 The photochemical isomers, bilirubin-XIIIWhich exhibit no exo-vinyl groups, 
are more unstable than bilirubin-IXα which have one exo-vinyl and one endo-vinyl group and 
bilirubin-III which contain two endo-vinyl group (Figure 1.6).67 In a similar fashion to 1.1 (UCB),  
(Z,Z)-bilirubin-III and XIII isomerise in the presence of light to (Z,E)- and (E,E)-bilirubin-
IIIand XIII  
 
 
Figure 1.6: The isomerisation of 1.1 (UCB) in acidic environment in which the protonation of carbons nearby C10 to 
break the C10-bridge covalent bond and produce four different dipyrrolic units and then randomly reassemble the C10 
covalent bond.
66,68,69,74
 
Adding to the complexity of the bilirubin family of compounds, bilirubin IXβ, IXγ, and IXδ also 
photo-isomerize to produce a similar mixture of compounds. However, the principal BPs in human 
adult biles are 1.1 (UCB) with 95-97% and 3-5% of bilirubin-IX.75 The isomerisation reaction 
creates numerous bilirubin isomers in nature.  
 
 
 
Bilirubin-IXα (1.1) 
Bilirubin-IIIα  Bilirubin-XIIIα  
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Photooxidation of unconjugated bilirubin 
Bilirubin is not only complicated because of the formation of several isomers but is also unstable 
when exposed to air. Unconjugated bilirubin is oxidized to a variety of small molecules in the 
presence of light and oxygen. The oxidization reactions mainly occur at carbon-bridges including 
C5, C10, and C15 to produce substituted dipyrroles, pyrroles, and highly polar materials (Figure 
1.7).
66
   
 
Figure 1.7: The photooxidation products of 1.1 (UCB) in the exposure to air and light.
66
 
Purification of bilirubin 
The isomerization and instability of bilirubin‘s isomers result in difficulties in purifying the 
compound. Bilirubin-IXα is converted to 1.2 (BV) when in contact with silica (from column 
chromatography, see chapter III) and the compound is highly water insoluble and exhibits low 
solubility in organic solvents.
76,77
 It is, therefore, difficult to find suitable solvents for 
chromatography. The most efficient method for producing highly pure (4Z,15Z)-bilirubin is 
crystallisation by slow diffusion of n-hexane into chloroform or dichloromethane solution.
58,78
 
(4E,15Z)-Bilirubin was obtained using this method in dim white light.
58
 
1.3.2 Biliverdin  
Biliverdin IX (1.2) and biliverdinX are major products obtained from the metabolism of haem 
in mammals or oxidization of 1.1 (UCB) andbilirubin-X at the C10-bridge.10,79 Biliverdin 
hν + O2 
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contains a fully conjugated aromatic system bearing 26 electrons (4n+2). Biliverdin IXγ and IXδ 
are also formed from haem breakdown but are minor products (Figure 1.2).
7-9
 The C10 unsaturation 
of 1.2 (BV) and its derivatives prevent the dipyrrolic units from rotating freely around the C10-
bridge. As a result, it does not form the complex hydrogen bonds system described for 1.1 (UCB) 
and so exhibits increased water solubility. Biliverdin not only has anti-mutagenic, and anti-oxidant 
properties
80,81
 but also inhibits vascular stenosis.
82
  
Biliverdin-IX exposed to light can generate nine isomers; (Z,Z,Z)-, (Z,Z,E)-, (Z,E,Z), (Z,E,E)-, 
(E,Z,Z)-, (E,Z,E)-, (E,E,Z)-, (E,E,E)-biliverdin (Figure 1.8).
66,83,84
  These isomers exhibit very little 
differences in their solubilities and other properties as they are all planar structures. In comparison 
to 1.1 (UCB), 1.2 (BV) is more stable to light. However, 1.2 (BV) still loses about 7.1% at 4 °C 
over 20 days and can be stable at -80 C for a period of 40 days.
79
 
 
Figure 1.8: Photoisomerisation of 1.2 (BV). 
1.3.3 Protoporphyrin  
Protoporphyrin IX (1.3, PRO), a large macrocycle of the porphyrin moiety, has 26 π-electrons and 4 
electrons from two of the pyrrole nitrogen atoms in conjugation creating a fully aromatic 
macrocycle. It is an important precursor of haem in biological systems and is biosynthesised from 
glycine and succinyl CoA or glutamate. Glycine combines with succinyl CoA under catalysis of 
aminolevulinic acid synthase to produce aminolevulinic acid.
11,13,85,86
 Aminolevulinic acid 
dehydratase converts aminolevulinic acid to porphobilinogen and then hydroxymethylbilance is 
produced by the action of porphobilinogen deaminase. Enzymes (uroporphyrinogen III synthase, 
uroporphyrinogen decarboxylase, and coproporphyrinogen oxidase) catalyze the formation of 
protoporphyrinogen IX from hydroxymethylbilane and then produce haem (Figure 1.9).
11,13,85,86
 The 
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compound was tested against a variety of tumor cell lines and exhibited strong anti-mutagenic 
properties.
19
 
 
Figure 1.9: Haem biosynthetic pathway from protoporphyrinogen IX.
87
 
Chemistry of protoporphyrin IX: 
A highly conjugated aromatic planar macrocyle, 1.3 (PRO) consists of four CH-bridges connecting 
four fully substituted pyrrolic rings exhibits unique physical and chemical properties. The formation 
of many stable metal complexes (with Mg
2+,
 Fe
2+
, Cu
2
+ and Zn
2+
) is one of the most important 
properties. 
1
H NMR studies of 1.3 (PRO) show four proton signals corresponding to the CH-bridges 
very downfield (10.00 ppm) whereas the CH-bridge of dipyrrolic units exhibit a singlet signal in the 
aromatic region around 7.00 ppm (see Chapter II for more details). The unique in 
1
H NMR 
spectrum of four CH-bridges indicate the low electron density of the positions and the high 
reactivity of the hydrogens. Protoporphyrin-IX and its derivatives exhibit strong intramolecular 
forces consisting of  stacking interactions, hydrogen bond, hydrophilic balance, charge transfer, 
and van der Waals forces with other chemicals.
88,89
 
In a similar manner to 1.1 (UCB) and 1.2 (BV) 1.3 (PRO) forms biproducts when exposed to light 
and oxygen.  Specifically, the major photooxidation products are hydroxyaldehydes and mono and 
diformyldeuteroporphyrin (Figure 1.10).
88,90
 Therefore, Bhosale et al.
88
 suggested that experiments 
involving in 1.3 (PRO) should be performed in the dark to avoid the formation of photooxidation 
products. 
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Figure 1.10: Products of the photooxidation of 1.3 (PRO) in the presence of light and oxygen. 
In conclusion, BPs possess unique structures, physical and chemical properties which have led to 
the hypotheses that physical and chemical interactions between BPs and mutagens may be the key 
to the inhibitory effects of BPs on environmental mutagens. The mysterious mechanism of the 
inhibition needs to be explored. 
1.4 Mutagens 
1.4.1 Benzo[]pyrene 
Benzo[]pyrene (BP, 1.7; C20H12; molecular weight: 252.31 g/mol) is a polycyclic aromatic 
hydrocarbon consisting of a planar five-ring aromatic system. The compound was discovered in 
1933 in coal tar and automobile exhaust fumes from diesel engines being the main source. The 
combustion of organic materials (cigarette smoke, wood burning, incomplete combustion of meat 
between 300 ºC and 600 ºC) is the main source of 1.7 (BP) in nature. Benzo[]pyrene constitutes 
approximately 24.7 ng of a cigarette,
91
 5.5 ng in each gram of fried chicken,
92
 and 62.6 ng in every 
gram of overcooked charcoal barbecued beef.
93
  In the early 19
th
 century in England an increased 
level of colon cancer
94
 and high rates of skin cancers were reported among fuel industry workers 
and those who had been exposed to high levels of pollutants like 1.7 (BP). Benzo[]pyrene is 
metabolized in vivo by cytochrome P450 enzymes (CYP1A1 and 1B1) into a dangerous mutagen.
95-
97
 The mammal‘s body attempts to excrete the substance, so 1.7 (BP) is oxidized to more polar 
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compounds, benzo[]pyrene-7,8-dihydrodiol and then benzo[]pyrene-7,8-dihydrodiol-9,10-
epoxide, which are easier to eliminate from the body. However, benzo[]pyrene-7,8-dihydrodiol-
9,10-epoxide is not only more polar but also significantly more reactive. It can react with DNA 
leading to DNA damage and resulting in cancer (Figure 1.11).
72,98-103
 Thus, the International 
Agency for Research on Cancer (IARC) classified 1.7 (BP) as a Group 1 carcinogen, a compound 
that has sufficient evidence to show causes cancer in humans. (carcinogenic to human).
103
 
 
Figure 1.11: The metabolism of 1.7 (BP) by P450 enzymes and the formation of products when benzo[]pyrene-7,8-
diol-9,10-epoxide reacts with DNA.
99,104
 
1.4.2 2-Aminofluorene  
2-Aminofluorene (2AF, 1.5) (C13H11N; formula weight: 181.23 g/mol) is a synthetic aromatic 
arylamine. It has been used in the laboratory as a research chemical and the metabolic activation of 
1.5 (2AF) by cytochrome P450 enzymes is well studied. DNA-2AF adducts are found in some 
cancer cells particularly associated with deoxyguaninosine.
105-107
 It is important to note that 1.5 
(2AF) is oxidized by cytochrome P450 enzymes to the more active electrophilic agent, N-hydroxy-
2-aminofluorene (N-OH-2-AF) and then HOSO2O-NH-2-AF under the action of sulfotransferase or 
N-acyltransferase. They are both considered the most likely to attack the nucleophilic positions in 
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DNA such as C8-arylamine-dG, C8-arylamine-dA, and the amino group of deoxyguaninosine as 
depicted in Figure 1.12.
105,108-110
 As a consequence of DNA modification, there are some changes in 
the cell‘s structure causing cancer.105,106,111,112  
 
Figure 1.12: The metabolism of 1.5 (2AF) by P450 enzymes and some nucleophilic positions of deoxyguaninosine in 
DNA that can be attacked by oxidization products of 1.5 (2AF), N-acyltransferase (NAT), sulfotransferase 
(ST).
105,108,109
 
1.4.3 2-Amino-1-methyl-6-phenylimido[4,5-b]pyridine  
2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhiP, 1.8) (C13H12N4; formula weight: 224.26 
g/mol) is a carcinogenic compound found in high-temperature-cooked meat and cigarette smoke. 
The level of 1.8 (PhIP) in food varies greatly depending on type of food and cooking method.
113-117
 
Studies found high concentration of 1.8 (PhIP) in the urine of human volunteers who had eaten a 
normal diet but were cigarette smokers.
118
 The compound was also detected in breast, colon, and 
prostate tumors.
114,115,117,119,120
 This mutagenic chemical is believed to cause cell damage in humans 
by attacking and binding to guanine in DNA after being metabolized into bio-activated metabolites, 
N-hydroxy-PhIP and N-acetoxyl-PhIP by various cytochrome P450 enzymes, CYP1A1, 1A2, 1B1, 
N-acetyl transferases (NAT) and sulfotransferases (ST) in the liver.
121-125
 Although many reports 
indicated that N-OH-PhIP is responsible for binding to DNA,
105,108,109
 it is thought that this 
compound requires further activation by the action of NAT and ST before attacking.
120,126,127
 
Indeed, reports have recently found arylamine-DNA adducts (dG-C8-PhIP) in human tissues.
124,125
 
For these reasons, 1.8 (PhIP) has been believed a potent carcinogen.  The risk of cancer increases to 
those who frequently exposed to high levels of 1.8 (PhIP). Therefore, the International Agency for 
Research on Cancer (IARC) classified 1.8 (PhIP) as a Group 2B carcinogen (may be carcinogenic 
to human).
103
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Figure 1.13: Proposed pathway of oxidization and DNA conjugation of PhIP. 
1.5 Caco-2 cell monolayers 
The human colonic adenocarcinoma (Caco-2) cell line has been developed from human large 
intestine cells by Jorgen and Trempe
128
 at the Sloan-Kettering Institute Cancer Research, New 
York, The United States. During long-term culturing and passaging under specific conditions the 
cells differentiated into a polarized functional mimic of the small intestine.
129,130
  Caco-2 cell lines 
are seeded and cultured onto insert membranes in a well plate which divides the system into an 
apical chamber (AP) and a basolateral chamber (BL) and the cells are allowed to grow for at least 
21 days when they are fully differentiated and provide the characteristic brush border of the small 
intestine epithelia. Caco-2 cell monolayers provide a physical and biochemical barrier for passing 
small molecules through a polarized epithelial cell.
131,132
 The AP represents the intestine and the BL 
mimics the blood supply. Caco-2 cells have been used as an in vitro model of the small intestinal 
epithelium for over a decade. The apparent permeability of compounds across the monolayer has 
been considered a good indication of the oral bioavailablity of a compound.
133-136
 If the interactions 
between two compounds affect the permeability of any compound through the Caco-2 cells 
monolayers, this can be used as an indication that there may be similar effects occurring in 
vivo.
130,133,137
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1.6 Conclusion and Hypothesis  
In summary, the above pro-mutagenic environmental pollutants require metabolic activation from 
cytochrome P450 enzymes to be able to functionalize their carcinogenic activities. Their 
metabolites include hydrophobic and lipophilic parts with condensed planar aromatic rings. Many 
previous reports indicated that condensed aromatic hydrocarbons can form strong  stacking 
interactions.  
These characteristics have led to the hypothesis that physical interactions in which the large 
lipophilic -system of the BPs interacts with the lipophilic -system of the polycyclic aromatic 
mutagens, causing aggregation of the molecules. This hypothesis is presented to explain the 
observed anti-mutagenic effects of BPs. These aggregates could then present the more polar groups 
(e.g. carboxyl groups in BPs and amine groups in the mutagens) to the outside surface which leads 
to increased hydrophilicity and more rapid excretion from the body through urine and faeces.  
The second possible mechanism of inhibition is via chemical interactions. Mutagens of interest are 
oxidized in the liver by CYP P450 enzymes to produce more reactive agents that modify the DNA 
of cells by attaching to guanine and adenine bases. It is hypothesised that the electron rich aromatic 
system of BPs is more reactive towards these carcinogenic agents and thus act as scavengers of the 
mutagenic metabolites. Moreover, guanine and adenine bases in DNA are bound to sugars and 
phosphate groups which produce considerable crowd around the bases, while the BPs would offer a 
significantly less sterically crowded target for the electrophilic agents. The hydrogen bonding (H-
bonding) of guanine and adenine with their based pair partners, cytosine, and thymine would also 
reduce their reactivity towards reactive carcinogenic agents compared to the pyrrole rings in BPs. 
Therefore, it is hypothesised that chemical interactions are a major contributing mechanism of 
inhibition of the mutagens by BPs.  
The metabolism of mutagens such as 1.7 (BP) and 1.8 (PhIP)5,70,98-100,105,111,138,139 by CYP enzymes 
have been well studied in relation to the mechanism of their mutagenicity.
70,72,98,140
 All of the 
environmental mutagens studied are in fact precursor molecules to the actual carcinogenic 
compounds which are formed by the action of CYP enzymes. Thus, another possible mechanism of 
inhibition may be that the BPs inhibit this conversion to carcinogenic metabolites. More work is 
required to fully understand the effect that BPs, bilirubin dimethyl ester, and biliverdin dimethyl 
ester might have on the metabolism of mutagens or on the reactive metabolites produced.  
The hypothesis is that BPs are competitive inhibitors that have strong interactions with amino acid 
residues in the active site of enzymes. Bile pigments could also be non-competitive inhibitors with 
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strong binding to amino acids on the surface that modifies the active site of the enzymes. As a 
result, BPs inhibit the metabolic action of cytochrome P450 enzymes towards mutagens.     
1.7 Research Aims and Plans 
The inhibitory effects of BPs on the DNA modification activity of certain environmental mutagens 
are investigated. The most common hypotheses for the mechanism of inhibition were studies in an 
attempt to increase our understanding of the beneficial effects of BPs in vivo. This increased 
understanding may lead to further clinical studies on the use of BPs as dietary supplements.  
1.8 Determining physical interactions between mutagens and bile pigments and their dimethyl 
esters 
The study will identify whether the -bond system of polyaromatic rings of mutagens participate in 
strong non-covalent interactions with BPs and their dimethyl esters. To achieve this, the 
experimental strategies involve three parts: 1) comparison of NMR spectra of mutagens alone with 
those of the mutagens in the presence of BPs; 2) documenting changes in the UV spectra of the 
mutagens upon addition of the BPs; and 3) using Caco-2 cell monolayers to measure and compare 
the apparent permeability of mutagens in the presence and absence of BPs and BPs dimethyl esters. 
The results obtained will clarify the physiological effects of BPs and provide evidence to support 
the beneficial effects of BPs in mammals. 
1.9 Determining chemical interactions between mutagens and bile pigments and their dimethyl 
esters 
Indole and imidazole will be used as the model of BPs and styrene epoxide as the model of the 
reactive epoxide metabolites of aflatoxin B1 and 1.7 (BP), in order to identify the potential 
positions of indole and imidazole that can react with styrene epoxide. Then, the reaction between 
BPs and styrene epoxide will be conducted under the same conditions. Competitive reactions will 
then be conducted to evaluate the relative reactivity of indole, imidazole, BPs, BPs dimethyl ester, 
and guanine with styrene epoxide. The order of effectiveness of BPs on intercepting mutagens will 
be explored. The identification of the functional groups on BPs that are most likely to react with 
metabolites (epoxide) will be determined. 
1.10 Investigating the inhibitory effects of BPs on the mechanism of mutagens in the human liver 
S9 fraction 
The inhibitory effects of BPs on the metabolism of mutagens by cytochrome P450 enzymes are 
investigated. The comparison of results of the incubation between mutagens and the human liver S9 
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fraction in the presence and absence of BPs will postulate the role of BPs in inhibition of mutagenic 
metabolism. The docking studies of known enzymes‘ crystal structures from the protein data bank 
(PDB) with mutagens and BPs support these in vitro metabolism studies. 
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Chapter 2: Physical interactions between bile pigments, biliverdin, unconjugated bilirubin, 
protoporphyrin and environmental mutagens, 2AF, PhIP, B[]P 
2.1 Introduction 
Intramolecular forcesare the attractive and repulsive forces among molecules in close proximity. 
There are many types of non-covalent interactions such as ionic, hydrogen bonding, halogen 
bonding, dipole-dipole, dipole-induced dipole, London dispersion forces,  interactions, cation 
and anion interactions, polar and hydrophobic effects. They were classified into four 
categories of interactions: electrostatic, van der Waals forces, effects, and hydrophobic effects.141 
Non-covalent interactions have apparently become important areas of study in recent years because 
of their importance in biochemical systems and materials chemistry.
21,142-146
 Physical interactions 
have been widely reported in both theoretical
147,148
 and experimental studies.
149-151
 Particularly, 
attractive -stacking forces occur between electron-rich and electron-deficient aromatic molecules 
when the delocalized p-orbitals of each aromatic molecule interact with an electron donor-acceptor 
fashion.
145,152
 Non-covalent interactions were also considered to be an important contribution for 
inhibitory action of bile pigments (BPs) to mutagens in biological systems.
15,19,21
  
The most common experimental methods that are applied to study physical interactions between 
chemical molecules are 
1
H NMR
149,150,153-155
 and UV-Vis spectroscopies,
149,154-157
 CD 
spectroscopy,
21
 and X-ray techniques.
149,158
  For example, Jennings et al.
151
 used 
1
H NMR and X-
ray to explore the CH- interactions in phenylalanine derivatives and observed that the proton 
signal of Ho (ortho proton) significantly shifted upfield from δH 7.14-7.17 to 5.5-5.8 in CD2Cl2 
solvent as a result of these interactions. X-ray crystallography also showed evidence of CH- 
interactions in phenylalanine derivatives with a distance of only 2.6 Å from Ho to the ring 
centroid.
151
 
 
Sun et al.
153
 used variable temperature (from 298 K to 213 K) for 
1
H NMR spectroscopy to 
determine the aggregation of N,N‘-di(n-butyl) quinacridone (DBQA) and its derivatives in CDCl3. 
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The study found the  interactions could be clearly observed at a temperature between 228 - 213 
K by splitting of proton signals into new groups with different chemical shifts.  
Ye et al.
157
 described the  interactions between tetracationic porphyrins and graphene in 
aqueous medium using UV-Vis spectroscopy. The study found that Δλmax of 5,10,15,20-tetra (4-
pyridyl)-21H,23H-porphine was increased when the concentrations of carboxylic acid that modified 
graphene oxide, chemically converted graphene and graphene oxide increased.
157
 Mölzer et al.
21
 
suggested that one of the important factors that linked to the anti-mutagenicity of BPs was physical 
interactions occurring between BPs and 2,4,7-trinitro-9H-fluoren-9-one (TNFone). The  
interactions were detected in aqueous solutions using CD and UV spectroscopy and confirmed by a 
negative VCD signal at 1620 cm
-1
 which ultimately indicated changes in the vibrations of 
C=C/C=N groups in the presence of TNFone.
21
 
Bile pigments, especially protoporphyrin IXα (2.1, PRO), unconjugated bilirubin (2.2, UCB ) and 
biliverdin (2.3, BV) have been recently reported to possess potential antioxidants and anti-
mutagenic effects.
14,19-21,34,36,37,159-161
 Although various beneficial activities of BPs were discovered, 
a few studies suggested that the physical interactions between BPs and mutagens may be an 
important factor contributing to the inhibitory action of BPs.
15,19,21
 Therefore, exploration of 
physical interactions between BPs and polyaromatic environmental mutagens such as 2-Amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine (PhiP, 2.7), benzopyrene (2.8, BP), 2-aminofluorene (2.9, 
2AF) and their likely contribution to the inhibition of mutagens is the aim of this chapter.  
It is hypothesised that the intermolecular physical interactions between these compounds are 
stronger than in other compounds due to the unique aromatic surface of BPs and the electron rich 
polyaromatic nature of the environmental mutagens. Moreover, they have poor solubility in the 
aqueous biological environment due to their lipophilicity and so may aggregate to minimize 
exposure to water. Thus the physical interactions (non-covalent interactions, particularly  
stacking) may be strong enough to change the λmax of the compounds and/or the chemical shifts of 
some of the protons in the structures.  
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R: H; protoporphyrin (2.1)    R: H; unconjugated bilirubin (2.2)          R: H; biliverdin (2.3) 
R: CH3; (2.4)     R: CH3; (2.5)               R: CH3; (2.6) 
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2.2 Results and Discussion 
2.2.1 Biliverdin and 2AF, PhIP, BP 
The studies were performed in methanol and repeated in aqueous phosphate buffer because aqueous 
phosphate more closely mimics biological conditions. Furthermore, since the polyaromatic 
mutagens and BPs have a lipophilic nature, they are more likely to aggregate in an aqueous 
environment in order to minimize exposure to the solution. The results showed that there was no 
change to the λmax of 2.7 (PhIP), 2.8 (BP) or 2.9 (2AF) corresponding to 317 nm, 295 nm and 288 
nm, respectively) upon addition of increasing amounts of 2.3 (BV). Likewise, the UV absorption 
spectrum of 2.3 (BV) remained unchanged (λmax = 375 nm) upon mixing with the polyaromatic 
mutagens (Figure 2.2, Figure 2.3 and Figure 2.4). It can be concluded that, in polar organic solvents 
with the polyaromatic mutagens examined, the -system of 2.3 (BV) did not participate in --
interactions that are sufficiently strong to cause changes in the UV-absorbance spectrum of the 
compounds. 
Possible interactions between 2.3 (BV) and 2.7 (PhIP), 2.8 (BP), and 2.9 (2AF) were initially 
investigated using UV-spectroscopy. Indeed, the UV-Vis results did not show any evidence of 
strong interactions between the aromatic ring systems of 2.3 (BV) and mutagens. The second 
method was applied for this test in which solutions of 2.3 (BV) and the varous mutagens were 
examined by 
1
H NMR to determine whether or not there were detectible shifts in any of the signals 
which could be atributed to -stacking interactions. 
The
 1
H NMR spectrum of 2.3 (BV) in neat DMSO-d6 (Sol A) was used as the reference data for the 
experiments examining physical interactions between 2.3 (BV) and mutagens in 80% DMSO-d6 and 
20% D2O (Sol B). In order to increase the polarity of the solvent, which consequently stimulate 
aggregations of the lipophilic -systems of both 2.3 (BV) and mutagens, D2O was added to the 
experiments.  
1
H NMR results of 2.3 in Sol A and in Sol B indicated that all the proton chemical shifts of 2.3 
(BV) shifted upfield in the presence of D2O, especially those corresponding to H-10, H-5, H-18
1
,  
H-17
1
,H-2, H-2
1
, H-2
2
 (Table 2.1). This result indicated that these protons‘ chemical shifts are 
sensitive to the environmental change as D2O had a strong effect on these chemical shifts values.
 1
H 
NMR of 2.3 (BV) in the presence of different mutagens showed that the chemical shifts of all BV‘s 
protons remained the same or changed slightly only in a narrow range of 0.15 ppm when in solution 
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with 2.8 (BP). These data suggested that the wide aromatic surface of 2.8 (BP) did not have any 
strong interactions with the -bond aromatic system of 2.3 (BV). 
(2.3, BV) 
Table 2.1: A comparison of selected proton signals of 2.3 (BV) in the presence of different mutagens.  
           2.3 (Sol A)            2.3 (Sol B)          2.3+2.9 (Sol B)       2.3+2.7 (Sol B)     2.3+2.8 (Sol B) 
H     δH (ppm), mult.,   δH (ppm), mult.,     δH (ppm), mult.,     δH (ppm), mult.,     δH (ppm), mult., 
        J (Hz)
a
      J (Hz)
a
                 J (Hz)
a                                
 J (Hz)
a                              
 J (Hz)
a 
 
2
1
 6.89, dd, 17.5, 
11.5 
6.73, brt 6.67, dd, 17.5, 
11.5 
6.68, dd, 17.9, 
12.0 
6.78, dd, 17.5, 
11.5 
2
2
 5.53, d, 11.5 5.42, brd 5.36, brd 5.37, d, 12.0  5.46, brd 
2
2‘
 6.30, d, 17.5 6.08, brd 5.92, brd 5.91, d, 17.9 6.14, brd 
3
1
 2.24, s 2.13, s 2.08, s 2.08, s 2.16, s 
5 6.30, s 6.18, s 6.10, s 6.10, s 6.17, s 
7
1
 2.16, s 2.09, s 2.03, s  2.02, s 2.08, s 
8
1
 2.52, t, 7.2 2.50, brs 2.45, t, 7.0 2.43, t, 7.0 2.46, brs 
8
2
 3.03, t, 7.2 2.95, brs 2.85, brs 2.81, brt 2.91, brs 
10 7.54, s 7.41, brs 7.08, brs 6.98, s 7.26, brs 
12
1
 2.52, t, 7.2 2.50, brs 2.45, t, 7.0 2.43, t, 7.0 2.46, brs 
12
2
 3.03, t, 7.2 2.95, brs 2.85, brs 2.81, brt 2.91, brs 
13
1
 2.14, s 2.06, s 2.00, s 1.99, s 2.05, s 
15 6.28, s 6.18, s 6.10, s 6.10, s 6.17, s 
17
1
 6.66, dd, 17.5, 
11.5 
6.49, brt 6.43, brt 6.45, dd, 17.9, 
12.0 
6.55, dd, 17.5, 
11.5 
17
2
 5.77, d, 11.5  5.72, brt 5.64, d, 18.5 5.65, m 5.70, m 
17
2
 5.77, d, 17.5 5.68, brt 5.67, d, 12.0 5.65, m 5.70, m 
18
1
 1.99, s 1.81, s 1.72, s 1.72, s 1.86, s 
          
     a
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 were taken from 1D NMR (DMSO-d6, 500 MHz). 
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In order to clarify the effect of the pH of the environment on the proton chemical shifts of both BPs 
and mutagens, a mixture of 2.3 (BV) and CH3NH2 in equal concentrations in Sol B was examined 
by 
1
H NMR (Table 2.2). 
Table 2.2: A comparison of selected proton signals of 2.3 (BV) in the absence and presence of 2.9 and CH3NH2. 
                         2.3 (Sol B)           2.3+2.9 (Sol B)   2.3+CH3NH2 (Sol B)      
H               δH (ppm), mult., J (Hz)
a
     δH (ppm), mult., J (Hz)
a
               δH (ppm), mult., J (Hz)
a
       
        
2
1
 6.73, brt 6.67, dd, 17.5, 11.5 6.64, brs 
2
2
 5.42, brd 5.36, brd 5.29, brs 
2
2‘
 6.08, brd 5.92, brd 5.89, brs 
3
1
 2.13, s 2.08, s 2.06, s 
5 6.18, s 6.10, s 6.10, s 
7
1
 2.09, s 2.03, s 2.06, s 
8
1
 2.50, brs 2.45, t, 7.0 2.46, brs 
8
2
 2.95, brs 2.85, brs 2.90 brt 
10 7.41, brs 7.08, brs 6.98, s 
12
1
 2.50, brs 2.45, t, 7.0 2.46, brs 
12
2
 2.95, brs 2.85, brs 2.90 brt 
13
1
 2.06, s 2.00, s 2.01, s 
15 6.18, s 6.10, s 6.10, s 
17
1
 6.49, brt 6.43, brt 6.36, brd 
17
2
 5.72, brt 5.64, d, 18.5 5.61, m 
17
2‘
 5.68, brt 5.67, d, 12.0 5.69, m 
18
1
 1.81, s 1.72, s 1.67, s 
          
     a
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 were taken from 1D NMR (DMSO-d6, 500 MHz). 
In contrast, all 2.3 (BV) proton signals shifted upfield in the presence of basic mutagens 2.9 (PhIP) 
and 2.7 (2AF). If the changes in the 2.3 (BV) spectrum were due to interactions of the -systems, 
then we would expect to see the greatest shifts in the aromatic proton signals. However, the most 
significant shifts appeared in the signals corresponding to the protons in the carboxylic acid 
sidechains, H-8
1
, H-8
2
, H-12
1
, and H-12
2
 (Table 2.1). Both 2.9 (2AF) and 2.7 (PhIP) contain a basic 
amine group which can deprotonate the carboxylic acid groups of 2.3 (BV). Deprotonation causes 
an increase in pH of environment and this affects the chemical shifts of the protons in the 
tetrapyrrole and vinyl groups. 
1
H NMR results of bilirubin dimethyl ester and biliverdin dimethyl 
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ester in chapter IV can clarify the hypothesis. This would explain the shifts that we observed: 1) H-
10 was shielded from δH 7.41 to 7.08 and 6.98 in the mixture with 2.9 (2AF) and 2.7 (PhIP), 
respectively, 2) H-5 and H-15 were shielded from δH 6.18 to 6.10, and 3) H-12
2
 and H-8
2
 were 
shifted from δH 2.95 to 2.85 and 2.81, respectively (Table 2.1). All protons exhibiting a shift in their 
resonance frequency are in close proximity to the acidic or basic groups of 2.3 (BV). Thus, these 
mutagens may simply be participating in a simple acid-base reaction with the bile pigment. In order 
to test this hypothesis, the 
1
H NMR spectrum of 2.3 (BV) in the presence of CH3NH2 was 
measured. The results showed extremely similar changes in the chemical shifts of the 2.3 (BV) 
protons to those seen in the presence of the basic mutagens (Table 2.2). These results indicated that 
the changes in the 
1
H NMR signals in the presence of 2.7 (PhIP) and 2.9 (2AF) were predominately 
caused by deprotonation of 2.3 (BV) but not any significant -stacking interactions. 
In the presence of 2.3 (BV), the H-1 and H-3 signals of 2.9 (2AF) shifted slightly downfield (from 
δH 6.88 and 6.68 ppm to δH 7.01 and 6.82 ppm, respectively). Biliverdin hydrochloride was used to 
formulate the solution used in these experiments. As a result, there are two protonated carboxylic 
acid moieties and one molecule of HCl per molecule of biliverdin. This excess of acid would ensure 
that the amine group of 2.9 (2AF) was protonated to a NH3
+
 group. The protonation of the amine 
group of 2.9 will result in less electron density to the aryl system and chemical shifts will move 
downfield. Another possible reason for the changes in the 
1
H NMR signals is that the -system of 
2.3 (2AF) was interacting with the conjugated π-system of 2.9 (2AF). To evaluate how much of the 
changes to the NMR spectrum of 2.9 (2AF) were caused by the presence of acid, 10 μL of LiOH 
(0.1 M) was added to the solutions. All the 
1
H NMR signals corresponding to 2.9 (2AF) returned to 
the original values for 2.9 (2AF) in Sol B alone (Figure 2.5).  
In order to further evaluate the effect of acid on 2.9 (2AF), the 
1
H NMR of a mixture of 2.9 (2AF), 
acetic acid and HCl in a ratio of 1:2:1 was measured. This ratio was chosen to mimic the two 
carboxylic acid groups and one HCl moiety of the 2.3 (BV) solution. The evidence indicated that 
salt formation had a strong effect on proton chemical signals of 2.9 (2AF). In fact, all proton signals 
of 2.9 (2AF) shifted downfield in a similar fashion to that observed when 2.3 (BV) was added to 2.9 
(2AF). This is in agreement with the pH data of mutagens and BPs collected in Sol A and Sol B 
(Table 2.8).   
2.2.2 BRU and 2AF, PhiP, BP  
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The UV results show that the λmax (450 nm) of 2.2 (UCB) did not change in the presence of 2.7 
(PhIP), 2.8 (BP) and 2.9 (2AF) in both methanol and phosphate buffer. Likewise, the UV 
absorbance spectra of the polyaromatic mutagens were not modified in the presence of increasing 
concentrations of 2.2 (UCB). This indicates that the -bond systems in BPs and mutagens do not 
exhibit any strong physical interactions in both methanol and buffer. 
       
Figure 2.1: Overlay of the UV spectra of the mixtures of 2.9 (2AF, 1μM in methanol, 0.5 μM in buffer) and varying 
concentrations of 2.2 (UCB, from 0.5 μM to 2.5 μM  in methanol (left) and from 0.25 μM to 0.5 μM in buffer (right)). 
The red line close to the baseline (λmax 288 nm) was the UV spectra of 2.9 (2AF). The introduction of 2.2 (UCB, from 
0.25 μM to 2.5 μM) in the mixture was detected by the increasing UV absorbance at 450 nm. 
In order to verify the UV results, the mixtures of 2.2 (UCB) and mutagens were tested by 
1
H NMR. 
A solution of Sol B was used to dissolve 2.2 (UCB) as well as the mutagens to produce a mixture in 
which the concentration of 2.2 (UCB) and mutagens were sufficient for NMR analyses. The above 
results were compared to 
1
H NMR data of 2.2 (UCB) and mutagens only (control experiments) in 
Sol B and Sol A. It is important to compare the results from the control experiments performed in 
Sol A and Sol B to clarify the effect of water on the chemical shifts of the protons in the compounds 
which were being examined. 
1
H NMR data collected in Sol B (Table 2.3) indicated that the addition 
of D2O affected the chemical shifts of most of the protons in 2.2 (UCB). While most of the signals 
were shifted upfield when D2O was added, the signals corresponding to H-2
2‘
, H-5, H-15 and H-17
2
 
shifted slightly upfield. For example, slight changes to the signals belonging to H-17
2
 (shifted from 
δH 6.16 to δH 6.10), H-2
1
, H-17
1
, and H-10 which respectively shifted from 0.06, 0.05, and 0.05 
ppm upfield were observed. In contrast, addition of 20% D2O resulted in signals for H-2
2
, H-5, H-
15, and H-17
2
 shifting 0.01 ppm downfield. The results led us to the conclusion that the change of 
NMR solvent environment is the cause of a slight modification of the 
1
H NMR spectrum of 2.2 
(UCB). The conclusion was supported by the change of pH in the presence of D2O and BPs (Table 
2.8).  
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(2.2 (UCB) 
Table 2.3: A comparison of selected proton signals of 2.2 (UCB) with different mutagens present.  
           2.2 (Sol A)            2.2 (Sol B)          2.2+2.9 (Sol B)       2.2+2.7 (Sol B)     2.2+2.8 (Sol B) 
H     δH (ppm), mult.,     δH (ppm), mult.,     δH (ppm), mult.,    δH (ppm), mult.,    δH (ppm), mult., 
           J (Hz)
a
        J (Hz)
a
                  J (Hz)
a                           
 J (Hz)
a                          
   J (Hz)
a 
 
2
1
 6.81, dd, 17.5, 
11.5 
6.75, dd, 17.8, 
11.5 
6.73, dd, 17.8, 
(11.5) 
6.74, dd, 17.5, 
11.5 
6.73, dd, 17.5, 
11.5 
2
2
 5.63, dd, 11.5, 
1.6 
5.59, d, 11.5 5.59, d, 11.5 5.58, d, 11.5 5.59, d, 11.5 
2
2‘
 5.62, dd, 17.5, 
1.6 
5.63, d, 17.8 5.63, d, 17.9 5.63, d, 17.5 5.63, d, 17.5 
3
1
 2.15, s 2.11, s 2.11, s 2.11, s 2.11, s 
5 6.08, s 6.09, s 6.10, s 6.10, s 6.10s 
7
1
 1.99, s 1.95, s 1.95, s 1.94, s 1.95, s 
8
1
 2.40, t, 7.5 2.40, brt 2.40, brt 2.38, brt 2.40, brt 
8
2
 1.92, t, 8.0 1.91, brs 1.93, brs 1.89, brs 1.93, brs 
10 3.98, s 3.93, s 3.69, s 3.56, s 3.92, s 
12
1
 2.40, t, 7.5 2.40, brs 2.40, m 2.38, s 2.40, m 
12
2
 1.92, t, 8.0 1.91, brs 1.93, brs 1.89, m 1.93, m 
13
1
 2.02, s 1.98, s 1.98, s 1.98, s 1.98, s 
15 6.08, s 6.09, s 6.10, s 6.10, s 6.10, s 
17
1
 6.57, dd, 17.5, 
11.5 
6.52, dd, 17.5, 
11.5 
6.52, dd, 17.5, 
11.5 
6.52, dd, 17.5, 
(11.5) 
6.51, dd, 17.5, 
11.5 
17
2
 6.18, dd, 17.5, 
2.8 
6.10, d, 17.8 6.08, d, 17.9 6.08, d, 17.8 6.07, d, 17.5 
17
2‘
 5.28, dd, 11.5, 5.29, d, 11.5 5.29, d, 11.5 5.29, d, (11.5) 5.29, d, 11.5 
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2.8 
18
1
 1.91, s 1.89, s 1.87, s 1.87, s 1.87, s 
          
     a
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 were taken from 1D NMR (DMSO-d6, 500 MHz). 
The mixture of 2.2 (UCB) and mutagens 2.7 (PhIP) and 2.9 (2AF) in Sol B showed that most of the 
proton chemical shifts of 2.2 (UCB) remained unchanged, except the H-10 signal which shifted 
considerably upfield from δH 3.93 ppm to 3.56 ppm (Table 2.3). In contrast, the signal of H-10 in 
the mixture with 2.8 (BP) remained at δH 3.92. This observation suggested that H-10 is very 
susceptible to the changes in the pH of the solution because both 2.7 (PhIP) and 2.9 (2AF) are basic 
compounds. Proton chemical shifts of other positions only exhibited slight variations that are 
consistent with those observed in the control experiment. Likewise, only the proton signals 
corresponding to H-1 (δH 6.76) and H-3 (δH 6.58) in 2.9 (2AF) shifted downfield to δH 6.78 and δH 
6.59, respectively, in the presence of 2.2 (UCB) (Figure 2.8 and Table 2.5). These protons are 
located ortho to the amine group of 2.9 (2AF) and so would be mostly affected by the protonation 
of the amine caused by the presence of 2.2 (UCB). 
Not less changes were recognized in the 
1
H NMR spectrum of 2.2 (UCB) in the presence of the 
mutagens than those of 2.3 (BV). It may be a result of unique dimensional isomers of 2.2 (UCB) 
present in solution (see Chapter 1 for details). The formation of these structures in solution 
significantly reduced the acidity of the carboxylic acid groups in 2.2 (UCB) due to their 
participation in intramolecular hydrogen bonds (see Chapter 1 for details). Thus, the NMR spectrum 
of the basic 2.7 (PhIP) was eventually unchanged in the presence of 2.2 (UCB) as was that of 2.8 
(BP) (Figure 2.6 and Figure 2.7). The NMR data combined with the UV-Vis results confirmed 
that physical interactions or -stacking were not strong or did not occur between 2.2 (UCB) and 
the examined mutagens to a great enough extent to perturb the NMR or UV characteristics of 2.2 
(UCB).    
2.2.3 Protoporphyrin (2.1) and 2AF, PhiP, BP  
The interactions of 2.1 (PRO) with mutagens were also examined by UV-Vis spectroscopy in both 
methanol (λmax of 2.1 = 401 nm) and aqueous phosphate buffer (λmax of 2.1 = 386 nm). Once again, 
no changes to the UV absorbance of 2.1 (PRO) or the mutagens were observed in solutions that 
varied in the molar ratio of 2.1 (PRO) to mutagens from 1:1 to 3:1 (Figure 2.9).   
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 2.1 (PRO) 
Table 2.4: A comparison of selected proton signals of 2.1 with different mutagens present. 
 
           2.1 (Sol A)            2.1 (Sol B)          2.1+2.9 (Sol B)       2.1+2.7 (Sol B)     2.1+2.8 (Sol B) 
H     δH (ppm), mult.,    δH (ppm), mult.,     δH (ppm), mult.,     δH (ppm), mult.,    δH (ppm), mult., 
         J (Hz)
a
                      J (Hz)
a
               J (Hz)
a                               
J (Hz)
a                              
J (Hz)
a 
 
2
1
 8.47, dd, 17.6, 11.6 8.33, brs 8.29, m 8.32, m 8.31, brs 
2
2
 6.21, d, 11.6 6.20, brs 6.18, d, 11.5 6.19, d, 11.5 6.18, brs 
2
2
 6.43, d, 17.6 6.38, brs 6.35, d, 17.5 6.37, d, 17.5 6.35, brs 
3
1
 3.71, s 3.60, brs 3.58, brs 3.61, brs 3.58, brs 
5 10.21, brs 10.05, brs 9.96, brs 10.00, brs 9.96, brs 
7
1
 3.60, s 3.51, brs 3.49, brs 3.50, brs 3.49, brs 
8
1
 3.18, 7.2 3.09, brs 3.09, brs 3.13, brs 3.09, brs 
8
2
 4.33, t, 7.2 4.24, brs 4.21, brs 4.23, brs 4.22, brs 
10 10.21, brs 10.04, brs 9.96, brs 10.01, brs 9.96, brs 
12
1
 3.18, t, 7.2 3.09, brs 3.09, brs 3.13, brs 3.09, brs 
12
2
 4.33, t, 7.2 4.24, brs 4.21, brs 4.23, brs 4.22, brs 
13
1
 3.61, s 3.51, brs 3.49, brs 3.50, brs 3.49, brs 
15 10.19, brs 10.02, brs 9.93, brs 9.98, brs 9.93, brs 
17
1
 8.47, dd, 17.6, 11.6 8.28, brs 8.29, m 8.32, m 8.31, brs 
17
2
 6.21, d, 11.6 6.20, brs 6.18, d, 11.5 6.18, d, 11.5 6.16, brs 
17
2
 6.43, d, 17.6 6.38, brs 6.35, d, 17.5 6.37, d, 17.5 6.33, brs 
 10.26, brs 10.07, brs 9.97, brs 10.04, brs 9.97, brs 
18
1
 3.69 s 3.62, brs 3.56, brs 3.58, brs 3.56, brs 
          
     a
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 were taken from 1D NMR (DMSO-d6, 500 MHz). 
The UV results were again verified by examination of mixtures of 2.1 (PRO) and each mutagen in 
Sol B by 
1
H NMR. The comparison of the NMR data of 2.1 (PRO) in Sol A and Sol B indicated 
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that D2O had an effect on proton signals of 2.1 (PRO). Most of the proton chemical shifts moved 
upfield in the presence of D2O, especially H-20 and H-17
1
 which shifted 0.19 ppm from δH 10.26 
and 8.47 ppm to δH 10.07 and 8.28 ppm, respectively, H-5 and H-10 which shifted 0.17 ppm from 
δH 10.19 and 10.21 to δH 10.02 and 10.04 ppm, and H-15 which shifted 0.16 ppm upfield.  
In the presence of each mutagen (2.7 (PhIP), 2.8 (BP) and 2.9 (2AF) in Sol B, the changes in 
chemical shift values of 2.1 (PRO) were slightly again (Table 2.4). For example, H-2
1
 and H-17
1 
shifted from δH 8.29 to 8.33 and H-2
2
 and H-17
2
 shifted from δH 6.16 to δH 6.20. 
1
H NMR results of 
each mutagen in the mixture were similar to those of the control experiments and thus were 
attributed to the increased concentration of D2O in the samples and not to any substantial 
interactions with 2.1 (PRO). As seen in Figure 2.9, there were no significant differences in the 
NMR spectrum of 2.9 (2AF) in Sol B in the presence of increasing concentrations of 2.9 (2AF).  
Likewise, Figure 2.11 and Figure 7.2 (in appendix-A) demonstrate that the NMR spectra of 2.7 
(PhIP) and 2.8 (BP) did not change in the presence of 2.1 (PRO). These NMR data were in 
agreement with the UV results which indicated that there were no significant --stacking 
interactions occurring between 2.1 (PRO) and the mutagens examined under the conditions of the 
experiments.  
2.2.4 Dimethyl ester of BPs and 2AF, PhiP, BP  
1
H NMR showed that there were no changes in the spectra of the dimethyl esters of BPs (2.4 
(PRODE), 2.5 (UCBDE), 2.6 (BVDE)) in the presence of each mutagen (Figure 2.12-Figure 2.13 
and Figure 7.4- 7.6 in appendix-A). Similarly, the addition of dimethyl ester of BPs did not modify 
the proton signals of 2.7 (PhIP), 2.8 (BP) and 2.9 (2AF). The results suggested that the physical 
interactions between mutagens and dimethyl esters of BPs were not strong enough to create changes 
in the proton chemical shifts of the compounds, in Sol A. 
2.3 Conclusion 
It was hypothesized that polyaromatic mutagens and BPs would seek to minimize their exposure to 
water and other polar solvents by forming aggregates via π-stacking interactions. The UV and 1H 
NMR spectra in the presence of water showed that the electron-rich aromatic surface of BPs and π 
system of mutagens did not have any strong interactions that were sufficient to alter the UV- 
and 
1
H NMR spectra of the compounds. It is unlikely, therefore, that physical interactions or 
aggregations are a major contributing mechanism to the anti-mutagenic effects of the BPs. 
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2.4 Experimental 
Materials and Methods Solvents and mutagens were purchased from Sigma Aldrich Pty Ltd 
(Melbourne, Vic, Australia) and 2.7 (PhIP) from Wako pure chemical industries, Japan unless 
otherwise stated. Bile pigments were purchased from Frontier Scientific (Logan, UT, USA) unless 
otherwise stated. All bile pigments and mutagens are visualized with 254 nm UV light (λmax: 2.2 
(UCB) = 450 nm, 2.3 (BV) = 375 nm, 2.1 (PRO) = 409 nm, 2.6 (BVDE) = 375 nm, 2.5 (UCBDE) = 
450 nm, 2.4 (PRODE) = 409 nm). 1D and 2D NMR experiments were performed on either a Bruker 
Advance 500 MHz spectrometer, with Topspin NMR and Mestranova 9.1 software. The solvents 
were DMSO-d6 (δH 2.49 ppm and δC 35.95 ppm) and D2O. Ultraviolet/Visible Spectroscopy was 
conducted using a Shimadzu UV-Vis Spectrophotometer Model UV-1600 for measuring 
absorbance with slit width 2.0 nm, light source change wavelength 340.8 nm. Measurement 
parameters included a λmax range from 200 nm to 700 nm, fast speed, 0.5 of sampling interval, 
enabled or auto sampling interval and single scan mode.  
The UV tests were performed in both methanol and aqueous phosphate buffer. Stock solutions of 
2.7 (PhIP), 2.8 (BP) and 2.9 (2AF) at concentrations of 1.0 mM were prepared in DMSO and 1 L 
of each solution was added to 1 mL of methanol and phosphate buffer to provide solutions of 1.0 
μM. The absorbance spectrum of each solution was measured from 200 nm to 700 nm. Solutions of 
2.1 (PRO), 2.2 (UCB) and 2.3 (BV) in DMSO at concentrations of 1 mM, 2 mM, and 3 mM were 
prepared, and 1 L of each bile pigment solution was added to a solution of a mutagen in order to 
have a final concentration of 0.25 μM, 0.5 μM, 1 μM, 1.5 μM, 2 μM, 3 μM (addition of the BPs 
solutions continued until the concentration of BPs was double or three times higher than that of the 
mutagen). All mixtures were measured and λmax of both BPs and mutagens was recorded. Samples 
were then stored overnight at 4
 
ºC before the UV spectrum was measured again. 
The 
1
H NMR spectrum of each mutagen and BP in Sol B was measured on a Bruker Advance 500 
MHz spectrometer. A solution of the BPs being studied in Sol B was added to the mutagen sample 
in such a way that the molar ratio of BP to mutagen was raised from approximately 2:1 to 1:1 and 
then 1:2. The 
1
H NMR spectra of these mixtures were then collected. Likewise, the experiments of 
dimethyl ester of BPs and mutagens were performed, however, instead of using Sol B, Sol A was 
utilized because dimethyl ester of BPs are sparingly soluble in the presence of D2O.  
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2.4.1 BV and 2AF, PhiP, BP  
    
Figure 2.2: Overlay of the UV spectra of the mixtures of 2.9 (2AF, 1μM) and varying concentrations of 2.3 (BV, from 
0.5μM to 0.75, 1, 1.5, 2 μM) in methanol (left) and buffer (right). The red line with a signal peak at 288 nm was the UV 
spectra of 2.9 (2AF). The introduction of 2.3 (BV, from 0.5 μM to 0.75, 1, 1.5, 2 μM) in the mixture was detected by 
the increasing UV absorbance at 350 nm. 
    
Figure 2.3: Overlay of the UV spectra of the mixtures of 2.7 (PhIP, 1 μM) and varying concentrations of 2.3 (BV, 1 
μM) in methanol (left) and buffer (right). The red line (right) and blue line (left) with signal peaks at 317 nm was the 
UV spectra of 2.7 (PhIP). The introduction of 2.3 (BV, from 1 μM to 3 μM) in the mixture was detected by the 
increasing UV absorbance at 350 nm. 
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Figure 2.4: Overlay of the UV spectra of the mixtures of 2.8 (BP, 1 μM) and varying concentrations of 2.3 (BV, 1 
μM) in methanol (left) and buffer (right). The red line that was in close proximity to baseline (λmax 295 nm) was the UV 
spectra of 2.8 (BP). The introduction of 2.3 (BV, from 1 μM to 2 μM) in the mixture was detected by the increasing 
UV absorbance at 350 nm. 
 
Figure 2.5: Overlay of the 
1
H NMR spectra of 2.9 (2AF, blue) and its mixtures with varying concentrations of 2.3 (BV) 
performed at 500 MHz in Sol B. The molar ratios of 2.9 (2AF) and 2.3 (BV are 2:1 (pink), 1:1 (red), 1:2 (yellow), 1:0 
(blue in the presence of HCl and acetic acid) and 1:2 (green in the presence of 10 μL of LiOH). 
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2.4.2 BRU and 2AF, PhiP, BP  
 
 
 
 
 
Figure 2.6: Overlay of the 
1
H NMR spectra of 2.8 (BP, blue) and its mixtures with varying concentrations of 2.2 
(UCB) performed at 500 MHz in Sol B. The molar ratios of 2.8 (BP) and 2.2 (UCB) are 2:1 (red), 1:1 (green), 1:2 
(purple).  
 
 
 
 
 
 
Figure 2.7: Overlay of the 
1
H NMR spectra of 2.7 (PhIP, blue) and its mixtures with varying concentrations of 2.2 
(UCB) performed at 500 MHz in Sol B. The molar ratios of 2.7 (PhIP) and 2.2 (UCB) are 2:0.5 (red), 2:0.75 (green), 
1:1.5 (purple).  
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Figure 2.8: Overlay of the 
1
H NMR spectra of 2.9 (AF, blue) and its mixtures with varying concentrations of 2.2 
(UCB) performed at 500 MHz in Sol B. The molar ratios of 2.8 (BP) and 2.2 (UCB) are 2:1 (red), 1:1 (green), 1:2 
(purple). 
2.4.3 PRO and 2AF, PhiP, BP  
     
Figure 2.9: The overlay of spectra of 2.8 (BP, 1 μM in methanol, 0.5 μM in buffer) and varying concentrations of 2.1 
(PRO, from 0.5 μM to 3.0 μM in methanol (left) and from 0.25 μM to 0.75 μM in buffer (right)). The red line (left) and 
black line (left) close to the baseline (λmax 295 nm) was the UV spectra of 2.8 (BP). The introduction of 2.1 (PRO, 
from 0.5 μM to 3 μM) in the mixture was detected by the increasing UV absorbance at 401 nm (left) and 385 nm 
(right). 
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Figure 2.10: Overlay of the 
1
H NMR spectra of 2.9 (2AF, green) and its mixtures with varying concentrations of 2.1 
(PRO) performed at 500 MHz in Sol B. The molar ratios of 2.1 (PRO) and 2.7 (PhIP) are 1:1 (purple), 1:2 (blue). 
 
Figure 2.11: Overlay of the 
1
H NMR spectra of 2.7 (PhIP, green) and its mixtures with varying concentrations of 2.1 
(PRO) performed at 500 MHz in Sol B. The molar ratios of 2.1 (PRO) and 2.7 (PhIP) are 1:1 (purple, yellow), 1:2 
(blue). 
2.4.4 Dimethyl ester of BPs and 2AF, PhiP, BP  
 
Figure 2.12: Overlay of the 
1
H NMR spectra of 2.5 (UCBDE, yellow) and the mixtures of 2.8 (BP) with varying 
concentrations of 2.5 (UCBDE, performed at 500 MHz in Sol A. The molar ratios of 2.5 (UBCDE) and 2.8 BP) are 
1:2 (blue), 1:1 (purple), 1:2 (green). 
2AF in Sol 
B 
2AF-PRO in Sol B 
2AF-PRO in Sol B 
PhIP in Sol 
B 
PhIP-PRO in Sol B 
PhIP-PRO in Sol B 
PhIP in Sol 
B 
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Figure 2.13: Overlay of the 
1
H NMR spectra of 2.5 (UCBDE, purple) and the mixtures of 2.9 (2AF) with varying 
concentrations of 2.5 (UCBDE, performed at 500 MHz in Sol A. The molar ratios of 2.9 (2AF) and 2.5 (UCBDE) are 
0.5:1 (green), 1:1 (brown). 
 
Figure 2.14: Overlay of the 
1
H NMR spectra of 2.5 (UCBDE, blue) and its mixtures 2.7 (PhIP, performed at 500 MHz 
in Sol A). 
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2.4.5 2AF and BV, BRU, PRO  
Table 2.5: A comparison of selected proton signals of 2.9 (2AF) with different BPs present. 
           2.9 (Sol A)            2.9 (Sol B)          2.9+2.3 (Sol B)       2.9+2.1 (Sol B)     2.9+2.2 (Sol B) 
H     δH (ppm), mult.,   δH (ppm), mult.,     δH (ppm), mult.,      δH (ppm), mult.,    δH (ppm), mult., 
          J (Hz)
a
                  J (Hz)
a
                 J (Hz)
a                               
J (Hz)
a                                
J (Hz)
a 
 
1 6.76, s 6.88, s 7.01 s 6.76, s 6.75, s 
3 6.58, dd, 8.0, 2.0 6.68, dd, 8.0, 2.0 6.82, d, 8.0 6.58,dd, 8.0, 2.0 6.58,dd, 8.0, 2.0 
4 7.50, d, 8.0 7.52, d, 8.0 7.61, d, 8.0 7.49, d, 8.0 7.49, d, 8.0 
5 7.59, d, 7.5 7.58, d, 7.5 7.65, d, 7.5 7.58, d, 7.5 7.58, d, 7.5 
 7.24, t, 7.5 7.23, d, 7.5 7,27, t, 7.5 7.23, t, 7.5 7.23, t, 7.5 
7 7.10, dt, 7.5, 1.0 7.11, d, 7.5 7.16, t, 7.5 7.09, t, 7.5 7.10, t, 7.5 
8 7.42, d, 7.5 7.42, d, 7.5 7.45, d, 7.5 7.41, d, 7.5 7.41, d, 7.5 
9 3.72, s 3.70, s 3.75, s 3.71, s 3.71, s 
          
     a
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 were taken from 1D NMR (DMSO-d6, 500 MHz).
       
2.4.6 PhiP and BV, BRU, PRO  
Table 2.6: A comparison of selected proton signals of 2.7 (PhIP) with different BPs present. 
           2.7 (Sol A)            2.7 (Sol B)          2.7+2.3 (Sol B)       2.7+2.1 (Sol B)     2.7+2.2 (Sol B) 
H     δH (ppm), mult.,    δH (ppm), mult.,    δH (ppm), mult.,      δH (ppm), mult.,    δH (ppm), mult., 
         J (Hz)
a
                  J (Hz)
a
                 J (Hz)
a                                   
J (Hz)
a                              
J (Hz)
a 
 
1
1
 3.66, s 3.57, s 3.54, s 3.55, s 3.57, s 
2
1
 8.53, brs     
5a 8.43, s 8.29, s 8.25, s 8.26, d, 2.0 8.28, d, 2.0 
 8.00, s 7.99, s 7.93, s 7.92, d, 2.0 7.93, d, 2.0 
2‘ 7.76, d, 7.5 7.67, d, 7.5 7.65, d, 7.4 7.65, d, 7.5 7.67, d, 7.4 
3‘ 7.51, t, 7.8 7.47, t, 7.8 7.46, t, 7.8 7.46, t, 7.8 7.46, t, 7.8 
4‘ 7.42, t, 7.5 7.36, t, 7.5 7.35, t, 7.5 7.35, t, 7.5 7.35, t, 7.5 
5‘ 7.51, t, 7.8 7.47, t, 7.8 7.46, t, 7.8 7.46, t, 7.8 7.46, t, 7.8 
6‘ 7.76, d, 7.5 7.67, d, 7.5 7.65, d, 7.4 7.68, d, 7.5 7.67, d, 7.4 
          
     a
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 were taken from 1D NMR (DMSO-d6, 500 MHz). 
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2.4.7 B[]P and BV, BRU, PRO  
Table 2.7: A comparison of selected proton signals of 2.8 (BP) in the presence of different BPs. 
           2.8 (Sol A)            2.8 (Sol B)          2.8+2.3 (Sol B)       2.8+2.1 (Sol B)     2.8+2.2 (Sol B) 
H     δH (ppm), mult.,    δH (ppm), mult.,    δH (ppm), mult.,      δH (ppm), mult.,     δH (ppm), mult., 
           J (Hz)
a
        J (Hz)
a
                   J (Hz)
a                           
   J (Hz)
a                          
   J (Hz)
a 
 
1 8.36, d, 7.6 8.32, d, 7.8 8.33, d, 7.8 8.30, d, 7.8 8.33, d, 7.8 
2 8.06, t, 7.5 8.03, d, 7.7 8.03, d, 7.7 8.02, d, 7.7 8.04, d, 7.7 
3 8.21, d, 7.6 8.18, d, 7.4 8.18, d, 7.4 8.17, d, 7.4 8.19, d, 7.4 
 8.05, d, 9.1 8.01, d, 9.1 8.01, d, 9.1 7.99, d, 9.1 8.01, d, 9.1 
5 8.12, d, 9.1 8.09, d, 9.1 8.09, d, 9.1 8.06, d, 9.1 8.10, d, 9.1 
6 8.71, s 8.66, s 8.67, s 6.64, s 8.68, s 
7 8.39, d, 8.0 8.36, d, 7.9 8.37, d, 7.9 8.35, d, 7.9 8.37, d, 7.9 
8 7.84, m 7.82, m 7.82, t, 7.0 7.81, t, 7.0 7.83, m 
9 7.89, m 7.87, m 7.87, m 7.86, t, 7.0 7.88, m 
10 9.22, d, 8.5 9.14, d, 8.4 9.15, d, 8.4 9.12 brd 9.17, d, 8.4 
11 9.24, d, 9.2 9.16, d, 9.2 9.18, d, 9.2 9.14 brd 9.19, d, 9.2 
12 8.46, d, 9.2 8.42, d, 9.2 8.43, d, 9.2 8.40, d, 9.2 8.43, d, 9.2 
          
     a
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 were taken from 1D NMR (DMSO-d6, 500 MHz). 
 
pH measurement: 
Table 2.8: The pH of mutagens in the presence of BPs in sol A and sol B. 
Solution 
pH 
Solution 
pH 
Sol A Sol B Sol A Sol B 
2.1 8.8 6.2 2.1 + 2.7 8.2 7.9 
2.2 8.2 6.9 2.1 + 2.8 8.0 6.3 
2.3 4.0 3.8 2.1 + 2.9 8.2 7.2 
2.7 8.0 8.9 2.2 + 2.7 8.2 7.8 
2.8 7.3 6.9 2.2 + 2.8 8.3 7.1 
2.9 7.6 8.1 2.2 + 2.9 8.0 8.0 
2.3 + 2.7 5.9 4.9 2.3 + 2.9 4.9 5.0 
2.3 + 2.8 4.4 3.9    
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Chapter 3: Investigation of the effects of bile pigments on the permeability of PhIP across 
intestinal epithelial cells. 
3.1 Introduction 
Physical interactions between molecules, such as van der Waals forces, electrostatic forces, and π-
stacking, play an important role in biology, biochemistry, and chemistry. These intermolecular 
interactions strongly affect the bioactivity of organic compounds in vitro and in vivo. Of these 
intermolecular interactions, the attractive forces between aromatic compounds, or π-stacking, have 
recently been the subject of a number of biochemical studies.
21,143,149,151,153,162-165
 Mölzer et al.
21
 and 
Bulmer et al.
14,15
 also hypothesised that π-stacking interactions were factors in the inhibitory action 
of BPs. All the above-mentioned findings hypothesised that physical interactions may have a 
significant contribution to the anti-mutagenic property of BPs. 
The physical interactions between BPs and mutagens have been mentioned in a variety of 
biochemical studies.
2,15,18,21,38
 UV and 
1
H NMR methods have also been used in other studies to 
determine the physical interactions between organic molecules.
150,153,155 
Our previous study (see 
Chapter II) used two methods (UV and 
1
H NMR spectroscopy) to detect intermolecular interactions 
between mutagens (2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (3.6, PhIP) and 
benzo[]pyrene (3.7, BP) and BPs (protoporphyrin IX (3.1, PRO), unconjugated bilirubin IX 
(3.2, UCB), biliverdin IX (3.3, BV) bilirubin dimethyl ester (3.4, UCBDE), and biliverdin 
dimethyl ester (3.5, BVDE)). The results of the study were negative; no evidence was found in the 
1
H NMR or UV spectra to indicate that strongly sustained  interactions were occurring. Some 
slight changes in the proton chemical shifts of the BPs were determined to be the result of changes 
in the protonation state of the compounds and not from  interactions. However, due to the low 
water solubility of the compounds, these studies were performed in organic solvents (DMSO, D2O 
and MeOH), and therefore there remains some uncertainty about what might occur in a biological 
system. Furthermore, Mölzer et al.
21
 reported that the physical interactions between TNFone and 
BPs might result in the anti-mutagenicity of BPs. Therefore, it was necessary to discover another 
method to test the weaker physical interactions occurring between BPs and polycyclic aromatic 
mutagens
 
Caco-2 cells are derived from human colorectal carcinoma cells cultured under appropriate 
conditions to form fully functional polarised monolayers that mimic the small intestinal 
epithelia.
129,130
 The monolayers exhibit the brush border associated with the intestinal epithelia on 
the apical membrane and express most of the digestive enzymes and transporters present in the 
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small intestine.
20,21
 The apparent permeability (Papp) of small molecules across the monolayer has 
been shown to directly correlate to the compound‘s in vivo oral bioavailability.166-170  
 
Figure 3.1: Diagram of a well and an insert membrane used for culturing Caco-2 cell monolayers. 
Our hypothesis for this study was that if a molecule experiences significant physical interactions 
with another compound in the apical compartment of the transwell, its Papp and the fraction 
absorbed will be affected.
136,171-173
 Therefore, we used the Caco-2 cell monolayers to determine the 
effects of physical interactions between 3.6 (PhIP) and 3.7 (BP) on their apparent permeability in 
the presence and absence of BPs. 
 
 
  
 
 
 
 
 
 Protoporphyrin IX (3.1)       Unconjugated bilirubin IX (3.2)          Biliverdin IX (3.3) 
 
Biliverdin dimethyl ester (3.5) Bilirubin dimethyl ester (3.4) 
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3.2 Results and discussion  
The experiments were conducted by placing a solution of the mutagen (10 μM) being examined in 
the apical chamber (AP) and placing fresh buffer in the basolateral chamber (BL) and taking 
samples from the BL every 30 min and determining the concentration of mutagen by analytical 
HPLC. Each experiment was performed in the presence of any BP and then with varying 
concentrations of BP (5 μM, 10 μM and 20 μM for 3.2 (UCB) and 10 μM for others) added to the 
AP with the mutagen at the start of the experiment.   
3.2.1 Permeability of PhIP in the presence and absence of bile pigments. 
At the conclusion of the experiments (t = 180 min), the number of moles of each of the compounds 
in the apical chamber (AP), and in the basolateral chamber (BL) was determined (Figure 3.1).  If the 
total of these does not equate to the number of moles of compound initially added to the apical 
layer, it is assumed that the compound has been absorbed into, or adhered onto, the Caco-2 cell 
monolayers. This is known to be a significant issue when studying the permeability of very 
lipophilic compounds.
174,175
 The detailed data in Table 3.5 show the differences in the rate of 
absorbance, Papp, and transport of 3.6 (PhIP) in the presence of BPs and their dimethyl esters. The 
absorption of 3.6 (PhIP) across a confluent Caco-2 cell monolayer was measured in the absence of 
any other additive and it exhibited a very high rate of transport from AP to BL, with total amount 
increasing from 0 to 180 min and reaching nearly 70% of 3.6 (PhIP) crossing to the BL after 180 
min and with a Papp of 1.74 x 10
-5
 cm/s (Table 3.1 and Table 3.5).  
Table 3.1: Total amount of 3.6 (PhIP) transferred to BL and remained in the AP chamber and associated with the cell 
monolayers (nmol) from 0 to 180 min in control experiments (n = 3).  
t 
(min) 
Total amount transferred to receiver chamber 
(nmol) 
Remained in apical chamber and 
associated with monolayers (nmol) 
 
Well-1 Well-2 Well-3 Well-1 Well-2 Well-3 
0 0 0 0 0.999 0.999 0.999 
30 0.165 0.158 0.189 0.835 0.842 0.811 
60 0.322 0.297 0.338 0.678 0.703 0.662 
90 0.452 0.417 0.478 0.548 0.583 0.522 
120 0.536 0.528 0.567 0.464 0.472 0.434 
150 0.628 0.604 0.658 0.372 0.396 0.342 
180 0.699 0.674 0.704 0.300 0.326 0.296 
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Figure 3.2 shows the permeability of 3.6 (PhIP) increased slightly in the presence of 3.3 (BV), 3.4 
(UCBDE), and 3.5 (BVDE), with the total fraction transported across the monolayer in 180 min 
increasing, to 82.1%, 83.1%, and 79.9% respectively (Figure 3.2, Figure 3.3 and Table 3.5) (see 
appendix-B for more details). The total amount of 3.6 (PhIP) transferred to the BL in the presence 
of 3.4 (UCBDE) increased steadily over the incubation period from about 0.211 nmol after 30 min 
to just under 0.854 nmol after 180 min (Table 3.2). The amount transferred was slightly higher than 
that transferred in the control experiments (Table 3.1). In contrast, the total amount of 3.6 (PhIP) 
remained in the AP and associated with monolayers decreased significantly from 0.999 to 0.145 
nmol (Table 3.2). This amount at 180 min was about 50% smaller than that of control reaction 
(0.145 compared to 0.326 nmol) (Table 3.1 and Table 3.2). 
Table 3.2: Total amount of 3.6 (PhIP) transferred to BL and remained in the AP chamber and associated with the cell 
monolayers (nmol) in the presence of 3.4 (UCBDE) from 0 to 180 min (n = 3).   
t 
(min) 
Total amount of 3.6 in the presence of 3.4 
transferred to receiver chamber (nmol) 
Remained in apical chamber and associated 
with monolayers (nmol) 
 
Well-1 Well-2 Well-3 Well-1 Well-2 Well-3 
0 0 0 0 0.999 0.999 0.999 
30 0.211 0.229 0.270 0.789 0.771 0.729 
60 0.404 0.423 0.459 0.596 0.577 0.540 
90 0.533 0.568 0.599 0.467 0.432 0.400 
120 0.663 0.664 0.685 0.337 0.336 0.315 
150 0.758 0.759 0.774 0.242 0.240 0.226 
180 0.809 0.831 0.854 0.192 0.169 0.146 
 
In the control experiment, 6.4% of 3.6 (PhIP) was assumed to be associated with the monolayer and 
this rate fell to 0% in the presence of 3.3 (BV), 3.5 (BVDE) and 3.4 (UCBDE) in Table 3.5). The 
Papp of 3.6 (PhIP) also underwent a considerable increase from 1.74 x 10
-5 
cm/s in the absence of 
BPs to approximately 2.27 x 10
-5 
cm/s in the presence of 3.3 (BV), 3.5 (BVDE) and 3.4 (UCBDE) 
in Table 3.5). Therefore, BPs (3.3 (BV), 3.5 (BVDE) and 3.4 (UCBDE)) appeared to slightly 
support the transport of 3.6 (PhIP) across the cell monolayer which may be due to the effects of 
physical interactions between the compounds.  
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Figure 3.2: A comparison the percentage of 3.6 (PhIP) (10 μM) transported from AP to BL over 180 min in the absence 
and presence of 3.1 (PRO), 3.2 (UCB), 3.3 (BV) with 10 μM). 
 
Figure 3.3: A comparison the percentage of 3.6 (PhIP) transported from AP to BL in the absence and presence of 
varying concentrations of 3.2 (UCB, from 5 μM to 20 μM) and 10 M of 3.4 (UCBDE). 
3.6 
3.6 + 3.1 
3.6 + 3.2 
3.6 + 3.3 
3.6 + 3.4 (10M) 
3.6 + 3.2 (5μM) 
3.6 + 3.2 (10μM) 
3.6 + 3.2 (20μM) 
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Interestingly, there were differences in the transported rate of 3.6 (PhIP) in the presence of 3.2 
(UCB) and 3.3 (BV). In the presence of 3.3 (BV), 82.1% of 3.6 (PhIP) was transported to the BL, 
while this was 70.4% with the addition 3.2 (UCB). The latter was not different from the amount of 
3.6 transported in the control experiments indicating that 3.2 (UCB) did not affect the rate of 
transported of 3.6 (PhIP, Table 3.1 and Table 3.3). In contrast, the effects of 3.3 (BV) led to an 
increase of 13% in the amount of 3.6 (PhIP) transported rate. Furthermore, the percentage of 3.6 
(PhIP) associated with the cell monolayers when no BPs were present was 6.4% while this 
increased to 12.6% in the presence of 3.2 (UCB) and decreased to 0% in the presence of 3.3 (BV, 
Table 3.5).  
Table 3.3: Total amount of 3.6 (PhIP) transferred to BL and remained in the AP chamber and associated with the cell 
monolayers (nmol) in the presence of 3.2 (UCB) from 0 to 180 min (n = 3). 
t 
(min) 
Total amount of 3.6 (PhIP) in the presence of 3.2 (UCB) 
transferred to receiver chamber (nmol) 
Remained in apical chamber and associated 
with monolayers (nmol) 
 
Well-1 Well-2 Well-3 Well-1 Well-2 Well-3 
0 0 0 0 0.999 0.999 0.999 
30 0.199 0.207 0.162 0.801 0.793 0.838 
60 0.358 0.369 0.339 0.642 0.6.31 0.660 
90 0.484 0.506 0.476 0.516 0.494 0.524 
120 0.581 0.581 0.568 0.419 0.419 0.431 
150 0.640 0.649 0.637 0.360 0.351 0.363 
180 0.705 0.710 0.695 0.295 0.289 0.305 
 
Moreover, the Papp of 3.6 (PhIP) fluctuated around 1.90 x 10
-5 
(cm/s) in the presence and absence of 
3.1 (PRO) or 3.2 (UCB), whereas the addition of 3.3 (BV), 3.4 (UCBDE), and 3.5 (BVDE) led to 
an increase in the Papp of 3.6 (PhIP) to approximately 2.27 x 10
-5 
(cm/s). The variation in Papp, the 
percentage transferred, associated with the monolayers, and remaining in AP of 3.6 (PhIP) in the 
presence of BPs and their dimethyl esters may be the result of physical interactions between two 
classes of chemicals for the following reasons. 
The differences in the fraction transported of 3.6 (PhIP) in the presence of 3.2 (UCB) and 3.3 (BV) 
may be the results of the differences in their structures. Although both structures of 3.2 (UCB) and 
3.3 (BV) have the same carboxylic groups and similar conjugated aromatic ring systems, the 
unsaturated C10-bridge of 3.2 (UCB) causes a significant difference in the 3D structure of the 
compound compared to 3.3 (BV). This flexible bridge facilitates the free rotation of the two 
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carboxylic groups of 3.2 (UCB) to generate at least six stable isomers and a variety of transition 
structures in solution (for more details see Chapters I and V).
58,59,62
 The two propionic groups can 
freely rotate 360º and generate more interactions between 3.2 (UCB) and the polar cell surface. In 
contrast, 3.3 (BV) possesses a nearly planar, fully conjugated aromatic system that holds the two 
propionic groups on one side and is less able to interact with the cell surface of the monolayers.  
Therefore, this led to a hypothesis that the lipophilic aromatic ring in 3.2 (UCB) interacted with 3.6 
(PhIP) and the hydrophilic carboxylic acid groups then generated interactions with the polar surface 
of the cell monolayer to hold more 3.6 (PhIP) in the monolayers, thus causing the increase in the 
amount of 3.6 (PhIP) remaining associated with the cell monolayers (Table 3.3 and Table 3.5). In 
fact, 3.3 (BV) and 3.1 (PRO) showed less interactions with the cell surface, and the percentage of 
3.6 (PhIP) associated with the monolayers was nearly 0%, while the presence of 3.2 (UCB) led to a 
significant increase of approximately 12% in the amount of 3.6 (PhIP) associated with the cells 
(Table 3.4 and Table 3.5). The hypothesis was also supported by the fact that 0% of 3.6 (PhIP) 
remained associated with the monolayers in the presence of 3.4 (UCBDE) and 3.5 (BVDE). These 
bile pigment derivatives have both carboxylate groups esterified and so would have reduced 
electrostatic interactions with the cell monolayer surface (Table 3.5). The results also indicated that 
BPs and their dimethyl esters supported the permeability of 3.6 (PhIP) through the Caco-2 cell 
monolayer. 
The similar Papp of 3.6 (PhIP) in the presence of 3.4 (UCBDE) and 3.5 (BVDE) indicated that when 
carboxylic acid groups were converted to methyl esters (Table 3.5), there were equal interactions 
between 3.4 (UCBDE) and 3.5 (BVDE) to 3.6 (PhIP). The interactions with the methyl ester 
derivatives increased the Papp of 3.6 (PhIP) which suggests that the interactions between 3.6 (PhIP) 
and BPs are more likely to be associated with the aromatic rings systems of 3.3 (BV), 3.4 
(UCBDE), 3.5 (BVDE) rather than electrostatic interactions with the carboxylate and carboxylic 
acid groups. The similar Papp and fraction absorbed of 3.6 (PhIP, ~2.22 x 10
-5 
cm/s and 80%, 
respectively) that were found in the presence of 3.3 (BV) its ester 3.5 (BVDE) supported the 
hypothesis that carboxylic groups have no effect on the permeability of 3.6 (PhIP).  
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Table 3.4: Total amount of 3.6 (PhIP) transferred to BL and remained in the AP and associated with the cell 
monolayers (nmol) in the presence of 3.3 (BV) from 0 to 180 min (n = 3). 
t (min) 
Total amount of 3.6 (PhIP) in the presence of 3.3 (BV) 
transferred to receiver chamber (nmol) 
Remained in apical chamber and associated 
with monolayers (nmol) 
 
Well-1 Well-2 Well-3 Well-1 Well-2 Well-3 
0 0 0 0 0.999 0.999 0.999 
30 0.202 0.222 0.231 0.797 0.778 0.769 
60 0.343 0.348 0.399 0.657 0.652 0.601 
90 0.480 0.530 0.572 0.520 0.470 0.428 
120 0.586 0.634 0.671 0.414 0.366 0.329 
150 0.687 0.741 0.778 0.313 0.259 0.222 
180 0.772 0.822 0.868 0.228 0.178 0.132 
 
Furthermore, the similar absorption results for 3.6 (PhIP) in the presence of the methyl esters, 3.4 
(UCBDE) and 3.5 (BVDE) indicated that when the carboxylic acid groups of 3.2 (UCB) were 
esterified, the presence of the unsaturated C10-bridge did not create any difference in the 
permeability of 3.6 (PhIP).  Figure 3.3 shows the role of the carboxylic acid groups and the higher 
concentration of 3.2 (UCB) that can reduce the amount of 3.6 (PhIP) crossing the monolayers and 
increase the percentage of 3.6 (PhIP) that associated with the monolayer cells (Figure 3.3 and Table 
3.5). The results indicate that addition of 3.1 (PRO) did not create any change in the permeability of 
3.6 (PhIP). This suggests that 3.1 (PRO) did not interact strongly with 3.6 (PhIP, Table 3.5).  
Table 3.5 A comparison of Papp and the percentage of 3.6 (PhIP) remaining in AP, trapped in or on the cell monolayer 
and transported to BL over 180 min in the presence and absence of 3.1 (PRO), 3.2 (UCB), 3.3 (BV), 3.4 (UCBDE), 3.5 
(BVDE). 
3.6 (10 μM) 
added 
Papp (cm/s) % transferred to 
BL 
% associated with 
monolayer 
% remained in 
AP 
Nil 1.74x10
-5
 ± 1.59x10
-7
 69.3 ± 1.9 6.4 ± 3.5 24.2 ± 2.9 
3.1 (10 μM) 1.97x10-5 ± 2.59x10-7 71.7 ± 1.6 2.7 ± 3.1 25.5 ± 2.7 
3.2 (5 μM) 1.86x10-5 ± 5.41x10-7 70.3 ± 3.1 11.4 ± 3.1 18.2 ± 0.3 
3.2 (10 μM) 1.94x10-5 ± 1.48x10-7 70.4 ± 1.5 12.6 ± 1.7 16.9 ± 0.8 
3.2 (20 μM) 1.95x10-5 ± 9.29x10-7 69.3 ± 3.8 14.0 ± 3.8 16.7 ± 0.4 
3.3 (10 μM) 2.25x10-5 ± 1.32x10-6 82.1 ± 1.8 0.0 17.3 ± 0.5 
3.4 (10 μM) 2.27x10-5 ± 6.16x10-8 83.1 ± 2.6 0.0 21.3 ± 1.6 
Chapter III: Effect of bile pigments on the permeability of PhIP 
49 
 
3.5 (10 μM) 2.22x10-5 ± 5.82x10-7 79.9 ± 3.3 0.0 21.2 ± 1.8 
 
When there was a high concentration of 3.2 (UCB) in the 3.6 (PhIP) assay, the percentage of 3.6 
(PhIP) associated with the cell monolayers increased from 6.47% (without 3.2) to 11.4% (5 μM of 
3.2), 12.6% (10 μM of 3.2), and 14.0% (20 μM of 3.2) (Table 3.5). These results strongly support 
the hypothesis that carboxylic acid groups interact with the cell surface, and are in agreement with 
the literature, as reported by Phelan et al.
29
 The amount of 3.6 (PhIP) remaining in the AP reduced 
from 24.2% (without 3.2) to 16.7% (20 μM of 3.2) indicating that the interactions with 3.2 (UCB) 
supported the absorption of PhIP through the cell monolayers, and this is also true of 3.3 (BV) and 
3.4 (UCBDE), 3.5 (BVDE) (Figure 3.3 and Figure 3.4).  
The comparison of Papp, percent transferred to the BL, percent associated with monolayers and 
percent remaining in the AP between 3.2 (UCB) and 3.4 (UCBDE) provided more evidence to 
confirm that the difference in conformation of 3.2 (UCB) from 3.4 (UCBDE) caused the increase in 
percent transferred to the BL from 70.4 to 83.1%, respectively. There was a similar increase in the 
percent associated with the monolayers of 3.2 (UCB). When the carboxylic acid groups of 3.2 
(UCB) are protected the complex H-bonding system that establishes the folded three dimensional 
conformation of UCB is disrupted and the molecule presumably adopts more open, less constrained 
conformations. Thus, the significant change we see in the Caco-2 cell monolayer permeability and 
interactions we observe between PhIP incubated with 3.2 (UCB) or the dimethyl ester derivative 
could be due to the loss of the carboxylate groups but may also be due to the change in overall 
conformation of the molecule.  Since we do not observe the same large effects on the monolayers 
when BV is incubated with PhIP it could be argued that the presence or absence of carboxylic acid 
groups may not be the most important effects but the conformation change in 3.4 (UCBDE) may be 
the predominant effects.   
The presence of BPs and their methyl esters increases the permeability of 3.6 (PhIP), with the 
exception of 3.1 (PRO). The BPs with free carboxylic acids also increased the amount of 
compounds that become associated with the Caco-2 cell monolayers. This led to a conclusion that it 
may be the physical interactions of the lipophilic parts of 3.1 (PRO), 3.2 (UCB), 3.3 (BV), 3.4 
(UCBDE) and 3.5 (BVDE) with those of 3.6 (PhIP) which leads to the increase in electrostatic 
interactions with the cell surface that are responsible for the increased adsorption onto the cell 
surface.  
3.2.2 Permeability of benzo[]pyrene in the presence and absence of bile pigments 
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Benzo[α]pyrene (3.7, BP) is insoluble in water and HBSS buffer. As a result, 3.7 (BP) did not 
cross the cell monolayers in the experiments. Similarly, 3.7 (BP) exhibited negligible permeability 
in the presence of BPs (Figure 3.4). Therefore, the permeability method could not be used to test the 
physical interactions between 3.7 (BP) and BPs.        
  
Figure 3.4: RPHPLC results of standard solution of 3.7 (BP) at 0.5 μM, overlaid with the results from samples 
collected from the receiver chamber after 30, 60 and 90 min incubation  
3.3 Conclusion and future developments  
The study was successful in using Caco-2 cell monolayers to determine the physical interactions 
between 3.6 (PhIP) and BPs, 3.4 (UCBDE), and 3.5 (BVDE). The study explored novel physical 
interactions occurring between the aromatic ring system of 3.6 (PhIP) and those of the BPs and their 
derivatives which resulted in a change of Papp of 3.6 (PhIP) through the Caco-2 cell monolayers. 
The larger amount of 3.6 (PhIP) remained either on or in the monolayers in the presence of 3.2 
(UCB) suggested that carboxylic groups played an important role in the interactions between 3.2 
(UCB) and the polar Caco-2 cell monolayer surface. As a consequence, when the carboxylic acid 
groups were protected as the dimethyl esters, the amount of compound associated with the cell 
monolayers dropped to 0% and the transported rate increased to just over 83%. Therefore, it led to a 
general conclusion that the physical interactions between aromatic rings in 3.2 (UCB), 3.3 (BV), 
their dimethyl esters and 3.6 (PhIP) affected the rate at which 3.6 (PhIP) crossed the cell 
monolayers.  
3.7 (0.5 μM) peak  
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These findings explored an important biological mechanism in which the lipophilic parts of 3.2 
(UCB) and 3.3 (BV) interact with the lipophilic part of 3.6 (PhIP) to minimise its exposure in 
aqueous biological systems and maximise its hydrophilic properties. As a result of its increased 
hydrophilicity, pro-mutagen 3.6 (PhIP) bound to BPs (3.2 (UCB) or 3.3 (BV) in biology system) 
becomes easy to excrete out of the body, thus minimising further chemical interactions with DNA.    
This study also found that the presence of 3.1 (PRO) did not affect the apparent permeability of 3.6 
(PhIP), as the two compounds did not interact strongly enough to affect the permeability of 3.6 
(PhIP).  
This study introduces a new key technique to explore the physical interactions occurring in 
biological systems that can be used for testing other mutagenic compounds (2-aminofluorene, 
aflatoxin B1, 2,4,7-TNFone…) with BPs and other potential inhibitors in the future. 
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3.4 Experimental 
3.4.1 Chemicals and Biological Materials 
BPs were purchased from Frontier Scientific, USA, and the dimethyl esters of the BPs (3.4 
(UCBDE), 3.5 (BVDE)) were synthesised (see the previous chapter) and used to test the physical 
interactions with 3.6 (PhIP) and 3.7 (BP) obtained from Sigma Aldrich, Australia, together with 
Hanks Balance Salt Powder, DMSO and HEPES. The human cell line Caco-2/15 was obtained from 
American Type Cell Culture, Tockville VA. DMEM, FBS, and trypsin were purchased from Themo 
Fisher Scientific, USA. Other solvents were of analytical and HPLC grade. Transwell permeable 
supports diameter 6.5 mm, 24 wells, insert membrane growth area 0.33 cm
2
 were obtained from 
Lifesciences, USA. Transepithelial electrical resistance (TEER) was measured with an epithelial 
Volt-ohm-metre obtained from Millipore Millicell-ERS, USA.  
Analytical reverse phase high performance liquid chromatography (RPHPLC) was performed using 
a Shimadzu system and LCsolution software and 3 µm and 5 µm Grace Vydac Denali C18 250 x 
4.6 mm columns. Retention time (tR) was obtained from the eluent gradient with mixtures of MQ-
water (solvent A) and MeOH (solvent B – Sigma Aldrich, Sydney, Australia). MeOH and MQ-
water were pumped at a standard flow rate of 1 ml/min. The gradient for PhIP was from 30% B to 
70% B in 40 min. After injecting 5 samples, the HPLC analytical column was washed with 100% B 
for 1 hour to remove all remaining BPs from the column. Isocratic 90% B was used to elute 3.7. 
Salt and BPs remaining in the column were also removed by 20% B for 15 min then increasing to 
100% B over 20 min and held at 100% B for an hour. The eluent was detected on a UV detector set 
at 317 nm for 3.6 (PhIP) and 385 nm for 3.7 (BP). Low resolution mass spectra were acquired on 
a Bruker Esquire HCT spectrometer (positive and negative ion ESI mode). 
3.4.2 Caco-2 cell culture 
Frozen Caco-2 cells were thawed in a water bath at 37 ºC for 2 min before being transferred to a 10 
mL centrifuge tube with 8 mL incomplete DMEM-10 (Dulbecco‘s Modified Essential Medium 
(DMEM) supplemented with 10% fetal bovine serum, 1% non-essential amino acids) (37 ºC). The 
mixture was centrifuged for 5 min at 1000 rpm, the cell pellet was resuspended in 10 mL 
incomplete DMEM-10 and placed into 25 cm
2
 tissue culture flask, stored in tissue culture incubator 
at 37 ºC, 95% humidity, 5% CO2.
131,132
 The media in the flask was changed every three days until 
the cells reached 70%-80% confluency (about 12-15 days after seeding). The cells were split by 
removing all old DMEM-10 and 5 mL of PBS solution was added at 37 ºC. They were placed in the 
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incubator for 5 min before PBS was drawn and 3 mL trypsin solution at 37 ºC was added and 
incubated for 4 min at 37 ºC until all cells detached from the flask bottom. DMEM-10 (9 mL) was 
added to inhibit the action of the trypsin. The cells were centrifuged for 5 min at 150xg (1000 rpm) 
before DMEM-10 was aspirated and the cell pellet resuspended in 10 mL fresh DMEM-10. Cell 
density was counted under microscope before seeding at a density of about 1.3 x 10
4
 cells/cm
2 
to a 
new T-75 flask.  The media was changed every other day until 80% confluency when the passaging 
procedure was repeated and cells were seeded onto wells membranes at a density of 2.5 x 10
5
 
cells/well. The media used for the wells was the same DMEM-10 media but with 1% penicillin 
added. The media in both the apical and basolateral chambers of the wells was changed every other 
day. From the 8
th
 day, the apical side was changed every day and the basolateral side was changed 
every two days until the 28
th
 day. 
3.4.3 Caco-2 bioassay preparation and transport experiments 
The monolayer integrity was monitored by measuring the transepithelial electrical resistance 
(TEER) after 22 days incubation. Wells having a resistance higher than 0.8 to 1.4 kΩ were selected 
and the wells with similar TEER values were used as replicates for the same compound or 
experiment. The apical and basolateral compartments of the wells were washed with PBS solution 
and then with Hanks Balance Salt solution (HBSS) with 25 mM HEPES buffer (twice). The Caco-2 
cell monolayers were equilibrated in HBSS buffer for 30 min at 37 ºC, then HBSS buffer was 
removed from both apical and basolateral sides and the basolateral sides were filled with 0.6 mL of 
fresh HBSS buffer. The apical sides were filled with 0.1 mL HBSS buffer containing 10 μM 
mutagen, (3.6 (PhIP) or 3.7 (BP)), and varying concentrations of BPs from 0 μM (control 
experiments) to 20 μM. The experiments were performed in triplicate and data anaylsed using 
Microsoft Excel 2010. Samples (200 L) were taken from the receiver (BL) compartment and 
replaced with 200 μL of fresh HBSS buffer every 30 min until the completion of the experiment at 
180 min. At the end of each experiment, 80 μL HBSS of samples from the apical (AP) side was 
removed for analysis. All samples were centrifuged for 5 min at 1270xg (2800 rpm) and stored at -
20 ºC for RPHPLC analysis.  At the end of the experiment the monolayers were washed with fresh 
HBSS before TEER values were measured again, and then they were incubated with medium. 
TEER values were measured every 12 hours until the values returned to the initial values (occurred 
after 24-36 hours). Papp values were determined using the following formula 
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Where ΔC is the concentration (μM) in the basolateral side; V is the volume of the basolateral 
chamber, Δt is the time for each transport experiment, C0 is the concentration of mutagens in apical 
chamber at time 0, A is the membrane surface area. 
Table 3.6: TEER values were measured from the first plate before the experiment, immediately after and after 30 hours 
incubation in DMEM-10 after the experiments were completed. 
TEER  (Ω cm2) before assays 
1107 996 1001 1001 1027 1102 
1097 998 1417 1103 1211 1026 
TEER  (Ω cm2) after assays 
667 711 789 791 812 698 
766 765 886 427 439 517 
TEER  (Ω cm2) maintaining 30 hours after assays 
1118 1019 1177 1294 1201 965 
1012 987 1278 977 987 955 
 
Table 3.7: TEER values were measured from the first plate before the experiment, immediately after and after 30 hours 
incubation in DMEM-10 after the experiments were completed.  
TEER  (Ω cm2) before assays 
967 996 925 981 1027 1010 
1078 820 1210 999 1416 1026 
TEER  (Ω cm2) after assays 
525 531 510 679 562 541 
576 702 711 867 412 679 
TEER  (Ω cm2) maintaining 30 hours after assays 
1008 856 988 978 867 1323 
1022 1211 1099 1232 1321 1222 
 
3.4.4 Preparation of Standard Solutions and Calibration Curves  
Stock solutions of 3.1 (PRO), 3.2 (UCB), 3.3 (BV), 3.4 (UCBDE), 3.5 (BVDE), 3.6 (PhIP) and 3.7 
(BP) at 10 mM in DMSO were prepared and stored in a cold, dark place before another dilution in 
HBSS buffer to the final concentrations of 5 μM, 10 μM, 20 μM. Mutagenic standard solutions, 
0.01 μM, 0.05 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, were created from stock solutions and 
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analysed in triplicate by RPHPLC. Calibration curves were assembled using Microsoft Excel 2010. 
The solutions to be tested were prepared as in Table 3.8 and Table 3.9. 
Table 3.8: The solutions of 3.6 (PhIP) and BPs prepared for the permeability assays. 
 Test Mixtures  Test Mixtures 
1 3.6 (10 μM)  + HBSS buffer (control) 4 3.6 (10 μM)  + 3.2 (10 μM)  + HBSS buffer 
2 3.6 (10 μM)  + HBSS buffer 5 3.6 (10 μM)  + 3.3 (10 μM)  + HBSS buffer 
3 3.6 (10 μM) + 3.1 (10 μM) +HBSS buffer 6 3.6 (10 μM)  + 3.4 (10 μM)  + HBSS buffer 
Table 3.9: The solutions of 3.6 (PhIP) and varying concentrations of 3.2 (UCB) prepared for permeability assays. 
 Test Mixtures  Test Mixtures 
1 3.6 (10 μM) + HBSS buffer 3 3.6 (10 μM) + 3.2 (5 μM ) + HBSS buffer 
2 3.6 (10 μM) + 3.5 (10 μM) +HBSS buffer 4 3.6 (10 μM) + 3.2 (10 μM )+ HBSS buffer 
  5 3.6 (10 μM) + 3.2 (20 μM ) +HBSS buffer 
Table 3.10: The solutions of 3.7 (BP) and BPs prepared for the permeability assays. 
 Test Mixtures  Test Mixtures 
1 3.7 (10 μM) + HBSS buffer (control) 4 3.7 (10 μM) + 3.2 (10 μM) + HBSS buffer 
2 3.7 (10 μM) + HBSS buffer 5 3.7 (10 μM) + 3.3 (10 μM) +HBSS buffer 
3 3.7 (10 μM)+ 3.1 (10 μM)+HBSS buffer 6 3.7 (10 μM) + 3.4 (10 μM) +HBSS buffer 
 
            
Figure 3.5: The standard curves for 3.6 (PhIP) and 3.7 (BP) in HBSS were obtained from RPHPLC. 
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3.4.5 Statistical analysis  
Table 3.11: A summary of rules for combining standard deviation error.
176
 
Relationship Statistical uncertainty 
p=x+y  
p=x-y  
p=xy 
 
p=x/y 
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Chapter 4: Synthesis of pyrroles, dipyrroles and bile pigment esters 
4.1 Introduction 
Current investigations into the reactivity and biological activities of bile pigments (BPs) required 
substituted pyrroles and dipyrroles and BPs dimethyl esters as model compounds to determine the 
reactivity of various positions in the BP structures towards styrene epoxide (justification for 
synthesis of pyrroles and dipyrroles can be found in chapter V). We therefore endeavored to 
synthesise pyrroles, dipyrroles and BP dimethyl esters by published procedures, optimizing the 
efficiency of the syntheses where possible. 
In addition, substituted pyrroles and dipyrroles exhibit a wide range of interesting physicochemical 
and biochemical properties. These properties have been exploited in nanomaterials comprising 
metal and BF2 complexes of dipyrrolylmethenes (BODIPY)
177
 which generate a strongly polarised 
-electron system, and have proved useful as optical limiters,178 sensors, fluorescent markers,179,180 
photosensitisers,
181,182
 antioxidants,
183
 and laser radiation limiters.
184,185
 Other important pyrrole 
containing compounds, for example, bile pigments and their dimethyl esters, are also reported in 
many reviews of their potential biological properties, such as antioxidant
18-20,183
 and anti-mutagenic 
acivities
15,18,19,186
. In spite of these promising properties and a variety of syntheses which aim to 
optimise the yield and efficiency, the need of pyrroles and dipyrroles for chemical interaction 
studies is not commercially available. Their production is still plagued by low yields, partly due to 
their instability, light sensitivity and reactivity with oxygen.
66,187,188
 
The classical syntheses of substituted pyrroles and dipyrroles were reported by German chemists 
Paal and Knorr,
189,190
 modified by MacDonald and Stedman
191
 and further developed by 
Kleinspehn.
192
. Cyclizations involving the acid-catalyzed condensation of a ketone and amine 
(Figure 4.1) have been a well-established synthetic approach to substituted pyrroles for over a 
century. However, the use of this method to synthesise substituted dipyrroles such as  4,4‘-diethyl-
3,3‘,5,5‘-tetramethyldipyrromethene hydrobromide has produced yields ranging from 58% (Wood 
et al.
193
) to 98% (Tsu et.al.
194
), and 85% (Yutanova et al.
195
), a fact perplexing to multiple 
reviewers.  
In order to possess sufficient quantities of BPs dimethyl esters for the current project optimizing the 
efficiency and yield of the esterification reaction of BPs with diazomethane was another aim of this 
study. Moreover, after esterification of bilirubin-IXα, the complex 3D structure of bilirubin-IXα 
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with 6 intrahydrogen bonds forming between carboxylic groups and amides no longer exists. This 
simplified some aspects of the analysis of the assays and spectroscopic investigations. 
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4.2 Results and discussion 
4.2.1 Synthesis of 2,3,4,5-tetramethylpyrrole (4.3) 
Several previously published synthetic routes reported simple methods to synthesise 2,3,4,5-
tetramethylpyrrole (4.3), including the treatment of racemate (d,l) of (3,4)-dimethyl-2,5-
hexanedione in the presence of NH3 in chloroform under an argon atmosphere for 18 hours at room 
temperature (rt).
188
 By meticulously following the experimental procedure of Venkataraman et 
al.,
188
 compound 4.3 was generated with 40% yield,
188
 slightly better than the 35% yield reported by 
Juergen,
196
 who used 1,2,3,4-tetramethylcyclobut-3-ene-1,2-diol in place of 3,4-dimethyl-2,5-
hexanedione.
196
 Although Juergen‘s method was simple, the yield was low and the reactants 
particularly expensive and so it was not attempted in this study. In another simple approach to 
achieve the desired compound, 4.3 in 44% yield was reported by Johnson and Price
187
 via a 
different synthetic route in which diacetyl monoxime (4.2) was treated directly with 3-methyl-2,4-
pentanedione (Figure 4.1).
78,187
 Therefore, in our experiments the desired compound 4.3 was 
synthesised directly in only two steps from butan-2-one (4.1), which was first treated with nitrous 
acid generated from the reaction of EtONO or NaONO and HCl at 0-5 ºC overnight, to give diacetyl 
monoxime (4.2) in 92% yield. The second step was the reduction of 4.2 by zinc dust and glacial 
acetic acid at 40 ºC to create the α-aminoketone. Then, in the presence of 3-methyl-2,4-
pentanedione, α-aminoketone condensed to form the intermediate imine which then tautomerised to 
the enamine and cyclised to eliminate water and acetic acid  and isomerised to the pyrrole (Figure 
4.1).
197,280
  
 
Figure 4.1: Synthesis of 2,3,4,5-tetramethylpyrrole from butan-2-one (4.1) and diacetyl monoxime (4.2) 
The yield of 4.2 (92%) obtained from the procedure described in Figure 4.1 was similar to previous 
reports.
198,199,200
 Attempts were made to optimise the synthesis with a method in which Me3SiCl and 
CHMe2CH2CH2NO2 in DCM were allowed to react at -20 ºC for 3 hours, giving an 82% yield of 
4.2.
201
 An attempt to generate 4.2 by treatment of 4.1 at 40-45 ºC for 1 hour with NaONO and HCl 
also gave an 82% yield.
202
 An attempt to synthesise 4.2 in KOH at rt overnight in the presence of 
NH4OH gave only a 21% yield.
198
 Thus, the conditions described in Figure 4.1 were deemed to be 
the most efficient in producing the diacetyl monoxime (4.2). 
Chapter IV: Synthesis of dipyrrole and BPs dimethyl ester  
60 
 
 
 
Figure 4.2: The 
1
H NMR spectrum of 4.3 performed on a 500 MHz instrument in CDCl3.  
The cyclisation of 4.2 to the pyrrole was less efficient, resulting in only a 30% yield. Compound 4.3 
was identified by 
1
H NMR with two singlets at δH 1.96 and δH 2.35 each integrated for 6 protons, 
suggesting  two sets of equivalent methyl groups. Attempts to collect mass spectral data on this 
compound through ESIMS methods failed due to the instability of 4.3 and its reluctance to ionise. 
Compound 4.3 was rapidly oxidised in the presence of oxygen to an unidentified green 
compound.
187
  
4.2.2 Synthesis of substituted dipyrroles 
Using an approach analogous to that described above (4.2.1) gave the desired substituted dipyrroles 
in moderate yields; however, there were large variations in the yields reported.
193-195
 The self-
condensation of pyrrole-2-carboxylate derivatives such as 3,4,5-trimethylpyrrole-2-carboxylate 
(4.7a) and ethyl 4-ethyl-3,5-dimethylpyrrole-2-carboxyliate (4.7b), by refluxing with formic acid in 
the presence of concentrated hydrobromic acid, produced dipyrrole products, 3,3‘,4,4‘,5,5‘-
hexamethyldipyrromethene (4.9) and 4,4‘-diethyl-3,3‘,5,5‘-tetramethyldipyrromethene (4.10) 
respectively (Figure 4.3).
193-195
 While Tu et al.
194
 reported a 98% yield for this reaction, Yutanova et 
al.
195
 and Wood et al.
193
 reported yields of only 85% and 58% respectively. In addition, Omar et 
al.
203
 achieved the same condensation starting with 3-ethyl-2,4-dimethylpyrrole (4.8b) and acyl 
halides to obtain the desired dipyrrole, 4.10 with 93% yield.
203
 Another approach was reported by 
Semeikin et al.
204
 who used 2,3,4-trimethylpyrrole reacting with 3,4,5-trimethylpyrrole-2-
carbaldehyde and gave only a 70% yield. The methods of Omar and Semeikin used starting 
materials that are not readily available in our laboratory. Tu‘s method for the synthesis of 
dipyrromethanes, 4.9 and 4.10 involved the self-condensation of pyrroles, 4.7a or 4.7b which we 
had synthesised previously. In this synthetic method, pyrrole-2-carboxylic acid was formed by the 
de-esterification of 4.7a or 4.7b, catalysed by strong acid HCl or HBr, followed by rapid 
decarboxylation to form 2-unsubstituted pyrrole which then reacts with formic acid under strongly 
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acidic conditions to release water and pyrrole-2-carboxaldehyde. Finally, the condensation of 2-
unsubstituted pyrrole with pyrrole-2-carboxaldehyde produced dipyrromethanes (4.9 and 4.10) 
(Figure 4.3). The slow condensation of pyrrole-2-carboxaldehyde with 2-unsubstituted pyrrole is 
the rate determining step. Therefore, the use of less water and a strong acid speeds up the reaction. 
In fact, Tu et al.
194
 and Yutanova et al.
195
 used 98% formic acid and concentrated HBr or HCl for 
the reaction to obtained a greater than 90% yield.  
 
 
Figure 4.3: The synthesis of 4.9 and 4.10 from the self-condensation of pyrrole-2-carboxylates in hydrobromic acid. 
One goal of this work was to find a simple method that has the efficiency and reproducibility of this 
reaction. We also aimed to link the previously described synthesis of pyrroles with this dipyrrole 
synthesis by starting with ethyl 3-oxobutanoate (4.4), producing ethyl 2-(hydroxyimino)-3-
oxobutanoate (4.5) which can then be cyclised to give pyrrole carboxylate derivatives, 4.7a and 
4.7b.  These compounds can then be further elaborated to the corresponding dipyrroles (Figure 4.4).  
 
Figure 4.4: The synthetic route to 4.9 and 4.10 from ethyl 3-oxobutanoate (4.4). 
Compounds 4.9 and 4.10 were synthesised in only three steps from 4.4 in high yields. The yields for 
the self-condensation reactions to produce 4.9 (73%) and 4.10 (94%) were in agreement with 
Yutanova et al.
195
, Tu et al.
194
 and Ali et al.
203
 The yield obtained was higher than that of the 58% 
reported by Wood et al.
193
 who used cold methanol to wash the crystals of 4.9 and 4.10. Our 
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synthesis found that the cold methanol still contained a large amount of these compounds. 
Therefore, the products were isolated from the methanol filtrate by column chromatography. 
Analysis of 4.7a by GC-MS showed the expected molecular ion (m/z 181 (M
+
)) and the appearance 
of three singlet peaks at δH 2.25 (3H), 2.18 (3H), 1.91 (3H) in 
1
H NMR indicated three methyl 
groups having covalent bonds with the pyrrole ring. The presence of the ethyl ester was confirmed 
by the appearance of a 2H quartet at δH 4.49 and a 3H triplet at δH 1.34 (Figure 4.5).  
 
Figure 4.5:  The 
1
H NMR spectrum of 4.7a performed on a 500 MHz instrument in CDCl3. 
HMBC correlations from δC 117.2 to all three methyl signals suggested that this 
13
C signal 
corresponded to C-4. The correlation from δH 1.91 to δC 129.4, 127.6 and 117.2 suggested that this 
1
H signal corresponded to the C-4-CH3 group. Likewise, the HMBC spectrum showed correlations 
from δH 2.18 to only two carbon signals, δC 117.2 (C-4) and δC 129.1, assigning this 
1
H signal to the 
C-5-CH3 group, and the signals at δC 129.1 and δH 2.25 to  C-5 and C-3-CH3, respectively (Figure 
4.5 and Figure 7.20 in appendix-C). 
 
Figure 4.6: The HMBC correlations from protons of three methyl groups to tertiary carbons in pyrrole ring of 4.7b. 
Spectrum performed on a 500 MHz instrument in CDCl3 
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Compound 4.7b was identified by GC-MS m/z 195 (M
+
) and comparison of the 
1
H NMR spectrum 
(Figure 4.7) with that of 4.7a. The spectrum of 4.7b showed two methyl singlets and two sets of 
coupled triplet-quartet signals. This confirmed the presence of two ethyl groups with one CH2 
signal shifted significantly downfield suggesting attachment to an oxygen atom.
205
   
 
Figure 4.7: The 
1
H NMR spectrum of 4.7b performed on a 500 MHz instrument in CDCl3. 
Compound 4.8b is an unstable compound and it is a liquid at room temperature as its boiling point 
is 197 ºC. That compound easily evaporates with the solvent under reduced pressure. Therefore, it 
was necessary to cool the solution in dry ice before removing the solvent under reduced pressure.   
Compound 4.9 was identified by ESIMS m/z 229 [M+H]
+
 and a simple 
1
H NMR with three singlet 
peaks accounting for 18 protons from six methyl groups (δH 2.59, 2.21, 1.94 ) and a singlet at δH 
6.95 belonging to the CH-bridge (Figure 4.8). The HMBC correlation from δH 6.95 to δC 141.8 
suggested that this 
13
C signal could be assigned to C-3, 3‘. The correlation from δH 2.59 to δC 154.0 
and δC 124.1 allowed assignment of these carbon signals to C-5, 5‘ and C-4, 4‘, respectively and the 
proton signal to CH3-C-5‘. The proton signal of CH3-C-4, 4‘ was identified by the cross-peaks 
between δH 1.94 and δC 124.1 (C-4, 4‘), δC 142.8 (C-3, 3‘) and a three-bond coupling to δC 154.0 
(C-5, 5‘). The cross-peaks from δH 2.21 (CH3-C-3, 3‘) to δC 124.1 (C-4, 4‘), 141.8 (C-3, 3‘) and δC 
126.1 confirmed the assignment of the C-2, 2‘ signal (Figure 4.8). The 1H NMR data were in 
agreement with the published data for this compound.
195
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Figure 4.8: The 
1
H NMR and HMBC spectra of 4.9 performed on a 500 MHz instrument in CDCl3. 
Compound 4.10 was identified by ESIMS m/z 257 [M+H]
+
 and the absence of a singlet signal of H-
4‘ at δH 1.94 in comparison to 
1
H NMR of 4.9. In addition, the presence of an ethyl group was 
indicated by the appearance of quartet signal at δH 2.42 and a triplet signal at δH 1.07 (Figure 4.9). 
The HMBC correlations from δH 2.42 (CH3-CH2-C-4, 4‘) to δC 130.4 (C-4, 4‘), 153.6 (C-5, 5‘) and 
δC 141.0 suggested this latter signal corresponded to the C-3, 3‘ positions in the pyrrole ring. The 
HMBC correlation from δH 7.01 to δC 141.0 (C-3,3‘) suggested this proton signal corresponded to 
the CH-bridge, δH 2.26 (CH3-C-3, 3‘) to δC 130.4 (C-4, 4‘), δC 141.0 (C-3, 3‘) and δC 126.2 
identified the latter 
13
C signal as that corresponding to the tertiary carbon of C-2, 2‘ (Figure 4.10). 
All remaining proton data were in agreement with the literature.
195,203,206-208
   
 
Figure 4.9: The 
1
H NMR spectrum of 4.10 performed on a 500 MHz instrument in CDCl3. 
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Figure 4.10: The HMBC spectrum of 4.10 and the insert of the cross-peak from CH-bridge to C-3. All experiments 
were performed on a 500 MHz instrument in CDCl3. 
4.2.3 Synthesis of dimethyl ester of BPs 
Synthesis of bilirubin-IXα dimethyl ester: Although bilirubin- IXα dimethyl ester (4.11) is a well-
known photochemical, there are currently only a few methods to synthesize 4.11 from bilirubin- 
IXα and the yields reported are low due to the instability and light sensitivity of both the free acid 
and the esters.
209-213
 Lightner et al.
212
 esterified bilirubin- IXα by treatment with Me2CO and MeI 
and reported 12.4% yield of 4.11 and 86% yield of bilirubin monomethyl ester.
212
 The report also 
indicated that the esterification rate of the first propionic acid group was higher than the second. In 
contrast, Nichol and Morell
210
 esterified bilirubin- IXα with methanol in hydrochloric acid or 
sulfuric acid and obtained only 4.11 in about 9% yield. Nichol and Morell
210
 also treated bilirubin- 
IXα with diazomethane in MeOH in chloroform and isolated 4.11 in 12% yield. Bilirubin- IXα 
monomethyl ester was not isolated from either reaction.
210
 Kuenzle
209
, performing the esterification 
of Bilirubin- IXα with diazomethane in chloroform and ethyl ether, obtained only 2% yield of 4.11 
and 23% yield of monomethoxybilirubin dimethyl ester (4.15, 4.16) and dimethoxybilirubin 
dimethyl ester (4.14).
209
 Using a different method, Hutchinson et al.
211
 treated bilirubin- IXα in 
chloroform with 1-methyl-3-p-tolyltriazene at room temperature for 12 hours and obtained 46% of 
4.11 and less than 15% of other isomers.
211,213
 Lightner‘s method was the only one of the above 
literature procedures in which bilirubin- IXα monomethyl ester was isolated. 
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In summary, while successful in producing 4.11, the above methods gave a low yield and produced 
biproducts such as bilirubin-IXα monomethyl ester, 4.14, 4.15 and 4.16 which make purification of 
4.11 difficult. Therefore, a modification of Kuenzle‘s method209 was developed to provide  a higher 
yielding and more reliable synthesis of 4.11.        
Diazomethane is an extremely sensitive and a highly reactive reagent used in a number of reactions, 
especially for esterification of carboxylic acids in high yields. However, the reagent can also react 
with other groups such as amide or vinyl groups, to produce unexpected products such as the 
formation of 4.14, 4.15 and 4.16 as seen in Kuenzle‘s reports.209 The mechanism of methyl ester 
formation of UCB begins with the deprotonation of carboxylic acid groups by the diazomethane 
which makes the methyl groups of the protonated diazomethane reactive to attack by the 
carboxylate anion to form the ester. The highly reactive protonated diazo intermediate can also be 
attacked by other nucleophilic groups in UCB and although neutral amides are not as reactive as the 
carboxylate anion, literature reports indicate that the products of amide methylation are isolated in 
small quantities when the reaction was performed at room temperature. By reducing the temperature 
of the reaction to -20 ºC we have successfully slowed the reactions sufficiently that the competing 
amide methylation no longer occurs.  
In order to minimize the reactions of diazomethane with other groups in BPs, the reactions were 
performed at low temperatures (-20 ºC and then -80 ºC). The yields of 4.11 from the reaction 
conducted at -80 ºC was 44% and at the reaction performed at -20 ºC gave a 35% yield. These 
compared well to the 12% yield of the previously published procedures performed at room 
temperature and 4 ºC
210
. 
The formation of 4.11 was supported by ESIMS m/z 613 [M+H]
+
 and the presence of new singlet 
proton signals in the 
1
H NMR at δH 3.42 (s, O-CH3, 3H) and δH 3.41 (s, O-CH3, 3H) in comparison 
to the 
1
H NMR spectrum of bilirubin –IXα  (Figure 4.11). HMBC correlations from δH 3.42 and δH 
3.41 to the carboxylate carbon signal at δC 173.1 (C-12
3
, C-8
3
) suggested the successful 
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esterification of bilirubin-IXα (Figure 4.12). The proton chemical shifts were slightly different to 
Hutchinson et al.
211
 and Kuenzle‘s results46, however these differences may be explained by the use 
of different solvents (literature spectra performed in CDCl3) and a lower field spectrometer.  There 
is also evidence in the published spectra of contamination of the samples with possible reaction 
biproducts.
209,211
 
Table 4.1: 
1
H NMR and 
13
C NMR of 4.11 performed in DMSO-d6 and the published data for the same compound.
210, 
211
  
             4.11     Data reported by Nichol
210
 and Hutchinson
211
 
C       δC (ppm) 
a 
     δH (ppm), mult., J  (Hz)
b
      δH (ppm), mult.
 c       
 δH (ppm), mult.
d
 
1   170.9  --       
2   122.6  --       
2
1
   127.5  6,57, dd, 11.5, 17.5  6.47, m  4.72-6.68, m 
2
2    
117.6  5.29, dd, 11.5, 2.5  6.06, m  4.72-6.68, m 
   6.21, dd, 17.5, 2.5     
3   128.7  --       
3
1
   9.7  2.15, s    2.08, s   1.73-2.08, s 
4   142.5  --       
5   99.7  6.07, brs   5.54, s   4.72-6.68, m 
6   122.5  --       
7   124.7  --       
7
1
   9.5  2.01, d    2.08, s   1.73-2.08, s 
8   120.0  --       
8
1
   19.7  2.46, t, 8.0   2.76, m  2.68 
8
2
   34.2  1.90, m   2.47, m  2.68 
8
3
   173.3  --       
8
4
          51.5  3.43, s    3.65, s   3.69, s 
9   131.3  --       
10   116.0  3.98, s    4.13, s   4.16, s 
11   131.3  --       
12   119.8.0 --       
12
1
   19.7  2.46, t, 8.0   2.76, m  2.68 
12
2
     34.2  1.90, m   2.47, m  2.68 
12
3
   172.0  --       
12
4
   51.5  3.43, s    3.65, s   3.69, s 
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13   124.0  --       
13
1
   9.5  1.97, s    1.96, s   1.73-2.08, s 
14   122.6  --       
15   97.0  6.07, s    5.89, s   4.72-6.68, m 
16   141.0  --       
17   123.8  --      
17
1
   126.8  6.81, dd, 17.5, 11.5  6.47, m  4.72-6.68, m 
17
2
   122.5  5.63, d, 11.5   5.28, m  4.72-6.68, m 
   5.62, d, 17.5      
18   128.0  --       
 18
1
    9.9  1.92, s 1.72, s 1.73-2.08, s 
 19    171.9  --   
 20    --  --   
      
              a
Chemical shift (ppm) referenced to DMSO-H6 δC 39.5 were taken from 1D and 2D NMR (DMSO-d6, 500 MHz); 
             b
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 were taken from 
1
H NMR (DMSO-d6, 500 MHz); 
             c
Chemical shift (ppm) referenced to CDCl3 δH 7.26 from literature
210
 
             d
Chemical shift (ppm) referenced to CDCl3 δH 7.26 from literature
211 
 
 
Figure 4.11: The 
1
H NMR spectrum of 4.11 performed on a 500 MHz instrument in DMSO-d6 
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Figure 4.12: The long range correlations (HMBC) between protons and carbons of 4.11. Spectrum performed on a 500 
MHz instrument in DMSO-d6. 
Synthesis of biliverdin-IXα dimethyl ester (4.12): The diazomethane esterification methods were 
applied to the synthesis of 4.12, and gave 45% yield at -20 ºC and 56% yield at -80 ºC. Compound 
4.12 was identified by ESIMS (m/z 611 [M+H]
+
 and 609 [M-H]
-
) and the presence of a new singlet 
signal in the 
1
H NMR spectrum at δH 3.58 integrating to six protons (Figure 4.13). The HMBC 
correlations from δH 3.58 to the carboxylate carbon signal at δC 172.7 confirmed the formation of 
the methyl esters (Figure 7.12 and Figure 7.13 in appendix-C).  
 
Figure 4.13: The 
1
H NMR spectrum of 4.12 performed on a 500 MHz instrument in DMSO-d6 
Synthesis of protoporphyrin-IXα dimethyl ester: Protoporphyrin-IXα dimethyl ester (4.13) was 
synthesized using the same method. The results indicated no difference in the yield obtained at -80 
ºC and -20 ºC (83%). ESIMS analysis of 4.13 supported the introduction of two methyl groups in 
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place of two hydrogen atoms, m/z 591 [M+H]
+
. The 
1
H NMR spectra showed two new singlet peaks 
at δH 3.56 and 3.55 corresponding to the methyl esters (Figure 4.14). The HMBC correlations from 
carbonyl signal at δC 173.2 to δH 4.33 (H-8
1
, H-12
1
), 3.24 (H-8
2
, H-12
2
) and δH 3.56, 3.55 confirmed 
the formation of 4.13 (Figure 7.17, Figure 7.18 and Figure 7.19 in appendix-C). 
 
Figure 4.14: The 
1
H NMR spectra of 4.13 overlaid with 
1
H NMR of protoporphyrin. Insert: an expanded region of the 
1
H spectrum from 3.50 to 3.75 ppm. All experiments were performed on a 500 MHz instrument in DMSO-d6. 
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4.3 Conclusion 
This chapter outlined the successful synthesis and characterization of a series of substituted 
pyrroles, dipyrroles via the Knorr pyrrole synthesis. The study indicated that the cold methanol 
filtrates of the crystals of 4.9 and 4.10 contained a high concentration of those compounds, 
explaining the low yield reported by Wood et al. (58%).  Changes to the published syntheses were 
also reported which improved efficiency of the synthesis of 4.9 and 4.10. The synthesis of the 
dimethyl ester of the BPs used in this research program via diazomethane esterification was also 
reported. 
We have been successful in synthesizing a number compounds critical for our studies into the 
chemical reactivity of bile pigments and related pyrrole derivatives. Compounds 4.3, 4.9, 4.10, 4.11, 
4.12, 4.13 were  characterized by 
1
H NMR, 
13
C NMR, 
1
H-
1
H COSY, HSQC, HMBC, mp, ESIMS, 
TLC, GC-MS and UV spectroscopy. The full assignment of the 
1
H and 
13
C NMR characteristics of 
4.11, 4.12 and 4.13 will provide valuable guidance in NMR studies of BPs and their derivatives.   
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4.4 Experimental 
4.4.1 2,3,4,5-Tetramethyl pyrrole 
Butanone (302 mg, 4.2 mmol) was kept in ice to maintain the temperature between 0 to 5 ºC, 50 mL 
MQ-water and 870 mg (12.6 mmol) of NaONO was added via a dropping funnel with 20 mL HCl 
(1.0 M) then added slowly under nitrogen gas. The reaction vessel was sealed and protected from 
light and stirred overnight allowing the reaction to reach room temperature. Saturated Na2CO3 was 
added to neutralize to the reaction, bringing the pH to 7-8. Compound 4.2 was extracted into ether 
before purifying by column chromatography with hexane and EtOAc (from 100% of hexane to 50% 
hexane) as the eluent to obtain a white solid (390 mg, 92%), Rf 0.5 (TLC 80% hexane/EtOAc), mp 
73-76 ºC (Lit.,
214
 75-78 ºC); 
1
H NMR (500 MHz, C5D5N) δH 2.18 (s, H-1, 3H), 2.46 (s, H-4, 3H), 
13
C NMR (500 MHz, C5D5N) δC 8.2 (CH3-CN), 24.9 (CH3-CO), 156.1 (C=N), 197.2 (C=O).
215
    
A solution of 1,1-diacetylethane (342 mg, 3 mmol), zinc dust (1170 mg, 18 mmol) and 4.2 (200 mg, 
0.2 mmol) in MQ-water (30 mL) was heated to 40 ºC and glacial acetic acid (9.0 mL, 10M) added 
via a dropping funnel. The reaction was then stirred under a nitrogen atmosphere for 4 hours 
protected from light. Saturated Na2CO3 was added to neutralize the reaction and bring the pH to 7-
8. The product was extracted into hexane and then purified using flash silica column 
chromatography with hexane as the eluent containing increasing quantities of ethyl acetate. 
Compound 4.3 eluted in 95% hexane/EtOAc and was dried to give a yellow solid (110 mg, 45%), 
Rf 0.61 (TLC 80% hexane/EtOAc), Rt (GC) 6.26 min, mp 107 ºC, 
1
H NMR (500 MHz, CDCl3) δH 
1.96 (s, 2CH3, 6H), 2.35 (s, CH3, 6H), 
13
C NMR (500 MHz, CDCl3) δC 8.0 (CH3-C-3, CH3-C-4), 
25.1 (CH3-C-2, CH3-C-5), GC-MS m/z 123 (M
+
). Compound 4.3 was light sensitive and oxidized 
readily to red and then green components in the presence of air.
187,188
  
4.4.2 Synthesis of dipyrroles 
Ethyl 2-(hydroxyimino)-3-oxobutanoate (4.5) 
Ethyl 3-oxobutanate (4.4) (390 mg, 3 mmol) was cooled to between 0 and 5 ºC by placing the 
reaction vessel in ice.  MQ-water (40 mL) and 621 mg (9 mmol) of NaONO were added followed 
by 10 mL HCl (1.0 M) via a dropping funnel under a nitrogen atmosphere. The vessel was protected 
from light and allowed to stir overnight such that the temperature increased to rt. To neutralize free 
acid in the reaction mixture, saturated Na2CO3 solution was added until pH = 7-8. Compound 4.5 
was extracted into ether and isolated from a silica flash column using 70% hexane/ EtOAc as the 
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eluent. The fraction was dried to give a white solid (453 mg, 95%). Rf 0.2 (TLC 50% 
hexane/EtOAc), Rt (GC) 8.0 min, mp 43-45 ºC (Lit.,
216
 45-47 ºC), 
1
H NMR (500 MHz, CDCl3) δH 
1.44 (t, J = 7.1 Hz, CH2-CH3, 3H), 2.79 (s, CH3, 3H), 4.49 (q, J = 7.1 Hz, CH2-CH3, 2H), 
13
C NMR 
(500 MHz, CDCl3) δC 14.3 (CH2-CH3), 22.5 (CH3-CO), 62.6 (CH2-CH3), 151.4 (C=N), 161.8 ( 
COO), 193.9 (C=O); GC-MS m/z 159 (M
+
), 131 (M-C2H4), 113 (M-C2H5O), ESIMS m/z 158 [M-
H]
-
. 
Ethyl 3,4,5-trimethylpyrrole-2-carboxylate (4.7a) and Synthesis of ethyl 4-ethyl-3,5-
dimethylpyrrole-2-carboxylate (4.7b) 
Ethyl 2-(hydroxyimino)-3-oxobutanoate (4.5) (318 mg, 2 mmol), compound 4.6a (342 mg, 3 mmol) 
or compound 4.6b ( 384 mg, 3mmol) and zinc dust (1170 mg, 18 mmol) were heated to 40 ºC, then 
glacial acetic acid (9 mL, 10M) was added via a dropping funnel. The reaction was protected from 
light and stirred for 4 hours under nitrogen gas.  Saturated Na2CO3 was added until pH =7-8 and the 
product extracted into ether and then purified by flash silica column chromatography with hexane 
and EtOAc (from 100% -50% hexane) as the eluent. Compound 4.7a was eluted in 95% 
hexane/EtOAc and was dried to give a white solid (290 mg, 80%). Rf 0.80 (TLC 50% 
hexane/EtOAc), Rt (GC) 9.90 min, mp 119-120 ºC (Lit.,
217
 125-125 ºC), 
1
H NMR (500 MHz, 
CDCl3) δH 1.34 (t, J = 7.1 Hz, CH3-CH2, 3H), 1.91 (s, CH3-C-4, 3H), 2.18 (s, CH3-C-5, 3H), 2.25 
(s, CH3-C-3, 3H), 4.29 (q, J = 7.1 Hz, CH2-CH3, 2H), 
13
C NMR (500 MHz, CDCl3) δC 8.7 (CH3-C-
4), 10.6 (CH3-C-5), 11.4 (CH3-C-3), 14.5 (CH3-CH2), 59.6 (CH3-CH2), 116.9 (C-2), 117.3 (C-4), 
127.4 (C-3), 129.2 (C-5) and 161.8 (C=O), GC-MS m/z 181 (M
+
), 152 (M-C2H5), 136 (M-C2H5O).  
Compound 4.7b was obtained in 95% hexane/EtOAc and dried to give a white solid (370 mg, 95%). 
Rf 0.83 (TLC 50% hexane/EtOAc), Rt (GC) 10.39 min, mp 101-105 ºC (Lit.,
218
 88-89 ºC),
 1
H NMR 
(500 MHz, CDCl3) δH 1.04 (t, J = 7.6 Hz, CH3-CH2-C-4, 3H), 1.34 (t, J = 7.1 Hz, CH3-CH2-O, 3H), 
2.20 (s, CH3-C-3), 2.28 (s, CH3-C-5), 2.38 (q, J = 7.6 Hz, CH3-CH2-C-4, 2H), 4.29 (q, J = 7.1 Hz, 
CH3-CH2-O, 3H); GC-MS m/z 195 (M
+
), 180 (M-CH3), 166 (M-C2H5), ESIMS m/z 196 [M+H]
+
, 
218 [M+Na]
+
.  
2,3,4-Trimethyl-5-(3,4,5-trimethylpyrrole-2-ylidene)methylpyrrole (4.9) and 3-ethyl-5-((4-
ethyl-3,5-dimethylpyrrole-2-ylidene)methyl)-1,2-dimethylpyrrole (4.10)  
A solution of 4.8a (181 mg, 1 mmol) or 4.8b (195 mg, 1 mmol) in a mixture of 0.2 mL of 
concentrated HBr  and 10 mL of 96% formic acid was refluxed under Ar atmosphere for 1 hour. 
The reaction vessel was cooled to rt and then to 4 ºC before washing the solid with ice cold 
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methanol to obtain a yellow solid, 137 mg for 4.9 and 219 mg for 4.10. The methanol filtrates  were 
evaporated to dryness and the residue redissolved in ether.  The ether solution was then washed 
with water, dried over MgSO4 and the ether removed under reduced pressure. The compounds were 
then purified by flash silica column chromatography with hexane and EtOAc. Compounds 4.9 and 
4.10 were eluted in 30% hexane/EtOAc. This provided a further 30 mg of 4.9 and 21 mg of 4.10. 
Compound 4.9 was further purified by column chromatography using 95% DCM/MeOH which 
provided a yellow solid (167 mg, 73%); Rf 0.33 (TLC 95% DCM/MeOH), mp 125-130 ºC, 
1
H 
NMR (500 MHz, CDCl3) δH 1.94 (s, CH3-C-3, 6H), 2.21 (s, CH3-C-4, 6H), 2.59 (s, CH3-C-5, 6H), 
6.95 (s, =CH-, 1H), 
13
C NMR (500 MHz, CDCl3) δC 118.6 (C-bridge), 124.1 (C-4), 126.1 (C-2), 
141.8 (C-3), 154.0 (C-5); ESIMS m/z 229 [M+H]
+
, HRESIMS m/z  229.1703 [M+H]
+
 (calcd for 
C17H24N2, 229.1699).  
Compound 4.10 (240 mg, 94%); Rf  0.61 (TLC, EtOAc), mp 130-132 ºC, 
1
H NMR (500 MHz, 
CDCl3) δH 1.07 (t, J = 7.1 Hz, CH3-CH2, 6H), 2.26 (s, CH3-C-3, 3‘, 6H), 2.43 (q, J = 7.1 Hz, CH3-
CH2, 4H), 2.64 (s, CH3-C-5, 5‘), 7.01 (s, CH=C-2, 2‘), 
13
C NMR (500 MHz, CDCl3) δC 9.9 (CH3-
C-3), 12.7 (CH3-C-5), 14.2 (CH2-CH3), 17.0 (CH2-CH3), 126.2 (C-2, 2‘), 130.4 (C-4, 4‘), 141.0 (C-
4,4‘), 153.6 (C-5,5‘); ESIMS m/z 257 [M+H]+, HRESIMS m/z 257.2016 [M+H]+ (calcd for 
C17H24N2, 257.2012). 
3-Ethyl-2,3,5-trimethylpyrrole (4.8b) 
A solution of 4.7b (780 mg, 4 mmol) in 48 mL of ethylene glycol and 600 mg NaOH was sealed 
into a reaction vessel and protected from light before refluxing for 1 hour under Ar gas. The product 
was extracted into hexane and washed three times with saturated Na2CO3 then dried at low 
temperature (-20 ºC) by rotary evaporation to give a white solid (a yellow liquid at room 
temperature, 248 mg, 50%), Rf 0.67 (TLC 80% hexane/EtOAc), Rt (GC) 6.03 min, 
1
H NMR (500 
MHz, CDCl3) δH 1.11 (m, CH3-CH2, 3H), 2.06 (s, CH3-C-4, 3H), 2.19 (s, CH3-C-3, 2H), 2.41 (m, 
CH3-CH2, 2H), 6.41 (s, H-5), 7.50 (s, N-H), GC-MS m/z 123 (M
+
). 
4.4.3 Synthesis of bilirubin-IXα dimethyl ester (4.11), biliverdin-IXα dimethyl ester (4.12), 
protoporphyrin-IXα dimethyl ester (4.13) 
A reaction vessel containing diazomethane (17 mg, 0.4 mmol) in 4 mL ether was kept at -20 ºC (dry 
ice/ Oxylene) or -80 ºC (dry ice/ acetone) under Ar gas. The vessel was sealed and protected from 
light before bilirubin (117 mg, 0.2 mmol) for synthesis of 4.11 or biliverdin (116 mg, 0.2 mmol) for 
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synthesis of 4.12 or protophorphrin (113 mg, 0.2 mmol) for synthesis of 4.13 was added and the 
mixture stirred or 2 hours before slowly increasing to rt overnight.  
The reaction‘s mixture was dried before purifying quickly by column chromatography with 
DCM/MeOH as the eluent to achieve a yellow solid at 98% DCM/MeOH (compound 4.11, 64 mg, 
44%), Rf 0.23 (TLC 99% DCM/MeOH), mp 197-200 ºC, λabs (MeOH) 450 nm, 
1
H NMR (500 MHz, 
(CD3)2OS) and 
13
C NMR (500 MHz, (CD3)2OS) (Table 4.1 in discussion section), ESIMS m/z 613 
[M+H]
+
.  
The reaction‘s mixture of biliverdin was purified by column chromatography to achieve a green 
solid (4.12, 68 mg, 56%), Rf 0.20 (TLC 30% hexane/EtOAc), mp 195-210 ºC, λabs (MeOH) 375 nm, 
1
H NMR (500 MHz, (CD3)2OS) δH 1.79 (s, CH3-C-18, 3H), 2.02 (s, CH3-C-13, 3H), 2.06 (s, CH3-
C-7, 3H), 2.15 (s, CH3-C-3, 3H), 2.51 (brs, CH2-CH2-CO, 4H), 2.88 (brs, CH2-CH2-CO, 4H), 3.58 
(s, CH3-O, 6H), 5.37 (d, J = 11.5 Hz, CH2=CH-C-2, 1H), 5.67 (dd, J = 17.5, 11.5 Hz, CH2=CH-C-
17, 2H), ), 6.05 (dd, J = 17.5, 2.0 Hz, CH2=CH-C-2, 1H), 6.08-6.11 (s, H-5, H-15, 2H ), 6.55 (dd, J 
= 17.5, 11.5 Hz, CH2=CH-C-17, 1H), 6.81 (dd, J = 17.5, 11.5 Hz, CH2=CH-C-2, 1H), 6.95 (s, H-
10, 1H), 10.01-10.22 (s, NH-CO, 2H); 
13
C NMR (500 MHz, (CD3)2OS) δC 9.1 (C-13
1
, C-7
1
, C-3
1
), 
9.5 (C-18
1
), 19.3 (C-8
2
, C-12
2
), 34.9 (C-8
1
, C-12
1
), 51.3 (CH3-O), 97.3 (C-5, C-15), 116.0 (C-10), 
119.2 (C-2
2
), 122.5 (C-17
2
), 126.6 (C-17
1
), 126.8 (C-2
1
), 128.2 (C-18), 137.2 (C-12, C-8), 139.2 
(C-17), 139.6 (C-7, C-13), 141.1 (C-9, C-11), 141.3(C-2), 141.4 (C-4), 171.7 (C-1, C-19), 172.6 (C-
8
3
, C-12
3
), ESIMS m/z  611 [M+H]
+
, ESIMS m/z  609 [M+H]
-
.   
The dimethyl ester of protoporphyrin in the mixture after reaction was purified by column 
chromatography with hexane and EtOAc to give a red solid at 80% EtOAc/hexane fraction (4.13, 
98 mg, 83%). Rf 0.79 (TLC EtOAc), mp 215-220 ºC, λabs (MeOH) 410 nm, 
1
H NMR (500 MHz, 
(CD3)2OS) δH 3.56-3.57 (2s, CH3-O, 6H), 3.58-3.59 (2s, H-3
1
, H-18
1
, 6H), 3.66-3.68 (2s, , H-7
1
, H-
13
1
, 6H), 4.34 (t, J = 7.7 Hz, H-8
1
, H-12
1
, 4H), 6.19 (d, J = 11.5 Hz, H-17
2
, H-2
2
, 2H), 6.40 (d, J = 
17.5 Hz, H-17
2
, H-2
2
, 2H), 8.38 (ddd, J = 17.5 Hz, 11.5 Hz, 3.5 Hz, H-2
1
, H-17
1
, 2H), 10.08 (s, H-
10), 10.09-10.13 (2s, H-5, H-15, 2H), 10.16 (H-20), 
13
C NMR (500 MHz, (CD3)2OS) δC 11.8 -13.0 
(C-3
1
, C-7
1
, C-13
1
, C-18
1
), 36.9 (C-8
2
, C-12
2
), 36.9 (C-8
1
, C-12
1
), 51.8 (CH3-O), 97.8 (C-5, C-10, 
C-15, C-20), 121.5 (C-2
2
, C-17
2
), 130.5 (C-2
1
, C-17
1
), 136.6 (C-2, C-17), 137.5 (C-7, C-13), 139.5 
(C-8, C-12), ESIMS m/z 591 [M+H]
+
.           
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Chapter 5: Model epoxide studies 
5.1 Introduction 
A leading cause of DNA modification and mutation, resulting in cancerous cells, is the attack of 
environmental carcinogens and mutagens. Therefore, elucidation of the mechanisms by which these 
mutagens react with DNA has become a key interest in biochemistry. One of the most common 
environmental pollutants is benzo[]pyrene (5.1, BP) but research has shown that the compound 
responsible for DNA damage is the metabolite, benzo[]pyrene-7,8-dihydrodiol-9,10-epoxide 
(5.2)
95,219,220
 produced by the action of human cytochrome P450 enzymes (hCYP1A1, hCYP1B1 
and hCYP3A4) on 5.1 (Figure 5.1).
219,221-223
 The highly reactive epoxide 5.2 attacks DNA bases, 
particularly guanine, to produce covalent DNA adducts.
95,101 
Similarly, the action of liver enzymes 
(CYP3A4 and CYP1A2) on Aflatoxin B1 (AFB1) (5.4) produces a reactive epoxide, AFB1-8,9-
epoxide (5.5) that is a highly mutagenic agent which can modify DNA by binding to guanine 
nucleotides (Figure 5.1).
224-226 
One possible way of reducing the impact of these environment 
mutagens is to provide alternate ‗scavenger‘ compounds to react with the mutagenic metabolites 
before they react with DNA. BPs, especially unconjugated bilirubin IXα (5.9), biliverdin IXα (5.10) 
and protoporphyrin IXα (5.8), have been the focus of some attention in this area, due to their highly 
anti-mutagenic
2,18,19,186,227
, anti-cancer
17,18
 and antioxidant properties.
18,27,28,30,33
 To date, however, 
little is known about the mechanisms by which BPs exhibit these properties and thus, the focus of 
the research detailed in this chapter was to investigate if the BPs‘ anti-mutagenic properties were a 
result of covalent adduct formation between the reactive epoxide metabolites and the BPs.   
A key concern in our research is that both epoxides 5.2 and 5.5 are toxic to humans, unstable and 
not commercially available. Styrene epoxide (5.7) is a commercially available aromatic epoxide that 
has previously been demonstrated to be mutagenic in mammalian cells, binding to DNA at the N-7 
position of guanine, and subsequently modifying DNA.
228,229
 This reaction between 5.7 and guanine 
is analogous to the epoxide-opening reaction which occurs between 5.5
230,231
 and 5.2 and the N-2 of 
guanine.
101,102
 Styrene epoxide (5.7) was therefore chosen as a model for 5.2 and 5.5 in studies on 
the reactivity of mutagens towards BPs and their derivatives (Figure 5.2). 
In an effort to evaluate the ability of BPs (poly-heterocyclic compounds) to inhibit the reaction of 
aromatic epoxides with guanine in DNA, we initially studied the reactivity of cheaper, simpler and 
more stable heterocyclic compounds such as indole (5.12) and imidazole (5.11) with model epoxide 
5.7. While aqueous phosphate buffer would be the ideal medium for model reactions to mimic 
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biological conditions, none of the BPs dissolve in aqueous solvents and thus, CHCl3 and DCM were 
chosen as solvents for the reactions.
76
 Addition of silica to the reactions as a catalyst had a crucial 
role in activating 5.7 to nucleophilic attack,
232,233
 replacing the hydrogen bonding role of water 
molecules in an aqueous medium.
234
 The experiments aimed to assess the reactivity of the pyrrole 
ring, as well as other nitrogen containing aromatic rings, toward activated epoxides. They 
represented preliminary examination of the mechanism of reactions that may contribute to the 
inhibition of mutagenic epoxide agents by natural BPs.  
 
 
Figure 5.1 A simplified summary of the metabolism of 5.1 and 5.4 leading to DNA-adduct formation. Insert: the 
structure of 5.7 chosen as a mimic for 5.2 and 5.5 in the reactivity studies. 
 
 
 
 
 
 
 
 
 
 
 
 
5.2 5.1 
5.3 
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Figure 5.2: The structures of the BPs as well as that of imidazole (5.11) and indole (5.12) chosen as mimics for BPs in 
initial reactivity studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protoporphyrin IXα (5.8)     Unconjugated bilirubin IXα (5.9)          Biliverdin IXα (5.10) 
 
Model 
(5.12) (5.11
) 
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5.2 Results and discussion  
5.2.1 Model reactions of indole, imidazole and guanine with styrene epoxide 
5.2.1.1: Reaction of indole with styrene epoxide  
The experiments performed in DCM gave polymers of styrene epoxide as the main products.  
Reactions performed in neat chloroform gave very low yields of any products. Therefore, the 
experiments were performed in 50% DCM and 50% chloroform in the presence of silica. The 
analysis of covalent conjugates from the reaction of 5.7 and 5.12 indicated that silica is an effective 
catalyst for activation of 5.7 to attack by nucleophilic agents. This confirmed similar observations 
by Kotsuki et al. who also used silica in DCM at rt to study the reaction of 5.7 with 5.12. Kotsuki et 
al. found that 88% of 5.12 was converted to 2-(3‘-indolyl)-2-phenylethanol (5.13), however they do 
not report any other minor products.
234
 Similarly, we found 5.13 to be the major product of our 
reaction between 5.7 and 5.12, being isolated in 80% yield but the overall yield of conjugates from 
the reaction was 97% with the remaining 17% being made up of minor products resulting from 
attachment of 5.7 to other sites around the heterocycle. GC/MS, one- and two- dimensional NMR 
spectroscopy, TLC, LRESIMS, HRESIMS, and melting point analysis were used to identify eight 
products from the reaction of 5.7 and 5.12.   
 
 
Figure 5.3: The mechanism of the reaction between 5.7 and 5.12 with silica.
234
 
The main product from the reaction of 5.12 with 5.7 was 2-(3‘-indolyl)-2-phenylethanol (5.13) as 
determined by MS (EIMS m/z 237 [M]
+
, m/z 206 [M-CH2OH]
+.
, LRESIMS m/z 260.1[M+Na]
+
, m/z 
276.1 [M+K]
+
), 
1
H NMR and
 13
C NMR spectroscopy (Table 5.1). The 
1
H spectrum indicated the H-
3‘ of the pyrrole ring was no longer present and a doublet at δH 7.27, which exhibited the 
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characteristic shift for H-2‘, had a long-range HMBC coupling to a benzylic carbon assigned to C-2 
(δC 45.5) (See Figure 5.3 and Figure 7.22 (2D) of appendix-D). The HMBC experiment also 
showed correlations from proton signals associated with a primary alcohol assigned as δH 4.07 and 
4.01 (H-1) to δC 115.9 (C-3‘) of the indole ring and the regiochemistry of the substitution of 5.12 
with one unit of 5.7 was further supported by correlations from H-2 to C-2‘, C-4‘ and C-3‘(HMBC 
spectra can be viewed in Figure 7.22 of appendix-D).   
A regioisomer of 5.13, 5.15 was identified as the next most abundant product being isolated in 6.8% 
yield an possessed MS date consistent with the addition of a unit of 5.7, EIMS m/z 237 [M]
+
, ESI-
MS m/z 260 [M+Na]
+
, 276 [M+K]
+
. The structure of 5.15 was elucidated using NMR spectroscopy 
(Table 3.2). In particular the absence of the H-2‘ signal and the presence of a doublet corresponding 
to H-3‘ at δH 6.22 (d, J = 1.5Hz) were keys in its structure determination. The J = 1.5 Hz coupling is 
the result of an allylic coupling from H-3‘ to H-2. The HMBC experiment confirmed the 1H NMR 
results showing correlations from δH 4.19 (H-2) to δC 141.1 (C-2‘) and δC 99.0 (C3‘) (See Figure 
5.4 for 
1
H NMR spectrum and HMBC spectra can be viewed in Figure 7.23 of appendix-D). A 
minor product (1.7% yield, MS m/z 237 [M]
+.
, ESI-MS m/z 260 [M+Na]
+
, 276 [M+K]
+
) was 
isolated and identified as 5.14 by the absence of the N1-H signal and HMBC correlations from δH 
5.64 (H-2) to δC 126.4 (C-2‘). The 
1
H, 
13
C NMR data for 5.14 is presented in Table 5.2 and the 
1
H 
spectrum in Figure 5.4. 
Table 5.1: NMR Spectroscopic Data (DMSO-d6, 500 MHz) for compound 5.13. 
 
  #         δC (ppm) 
a 
         δH (ppm), mult., J  (Hz)
b
         
1
H-
13
C HMBC
ab
 
 1 63.4  4.07, m   C2, C1‘‘, C3‘ 
4.01, m   C2, C1‘‘, C3‘ 
2  45.5  4.33, (dd, J 7.3 Hz, H-2), C1, C3‘, C2‘C1‘‘, C2‘‘, C4‘ 
1‘ -  10.90, brs   C3‘, C2‘, C9‘, C8‘  
2‘ 122.2  7.27, d, 2.4           C3‘, C8‘, C9‘                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
3‘ 115.9  -    - 
4‘ 118.7  7.37, m   C5‘, C3‘,C6‘, C9‘, C8‘  
5‘ 118.3  6.90, ddd, 7.8, 7.9, 1.1 C6‘, C7‘, C9‘  
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6‘ 121.0  7.04, ddd, 7.6, 8.1, 1.0 C4‘, C8‘ 
7‘ 111.4  7.35, m   C9‘, C5‘  
8‘ 127.0  -    -  
9‘ 136.3  -    -  
1‘‘ 144.0  -    -  
2‘‘ 128.3  7.34, dd, 8.0, 0.9  C3‘‘, C4‘‘  
3‘‘ 128.0  7.24, dd, 7.8, 7.5  C2‘‘, C4‘‘  
4‘‘ 125.9  7.14, t, 7.5   C2‘‘  
              
              a
Chemical shift (ppm) referenced to DMSO-H6 δC 39.5 were taken from 1D and 2D NMR (500 MHz, DMSO-d6); 
              b
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49. HMBC correlations, optimized for 8 Hz, are from 
proton(s) stated to the indicated carbon.  
Table 5.2: 
1
H and 
13
C NMR data for compound (5.14, 5.15). 
 
                                    5.14      5.15 
C         δC (ppm) 
a 
     δH (ppm), mult., J  (Hz)
b
      δC (ppm) 
a 
      δH (ppm), mult., J  (Hz)
b
 
 1 61.5  4.06, dd, 11.6, 5.0  64.8  3.92, m 
    4.23, m     4.04, m 
 2 63.2  5.64, dd, 8.4, 5.1,   48.2  4.19, t, 7.0 
1‘ --  --    --    
2‘ 126.4  7.68, d, 3.3   141.1 
3‘ 101.0  6.49, d, 3.2   99.0  6.22, d, 1.5 
4‘ 120.4  7.52, d, 7.8   119.8  7.4, brd, 7.8 
5‘ 119.2  6.97, ddd, 7.0, 8.2, 0.9 119.2  6.91, ddd, 7.6, 7.5, 1.0 
6‘ 121.1  7.03, ddd, 7.5, 7.8, 0.9 120.7  6.97, ddd, 7.8, 7.5, 1.0 
7‘ 110.2  7.35, d, 8.2   111.3  7.25, brd, 7.6 
8‘ 136.2  --    136.4  -- 
9‘ 128.3  --    128.4  -- 
1‘‘ 139.7  --    142.3  -- 
2‘‘ 126.9  7.24, m   126.6  7.29, m 
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3‘‘ 128.5  7.26, m   128.6  7.28, m 
4‘‘ 127.6  7.21,m    126.8  7.19, m  
 
              a
Chemical shift (ppm) referenced to DMSO-H6 δC 39.5 were taken from 1D and 2D NMR (DMSO-d6, 500 MHz); 
              b
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 
 
Figure 5.4: The 
1
H NMR spectra of three mono-phenylethanol substituted adducts of 5.12 and the spectrum of 5.12 is 
provided for comparison. All experiments performed at 500 MHz in DMSO-d6. 
Five minor products (8.5% yield in total) possessed MS data consistent with the addition of two 
phenylethanol groups attached to two different positions of the indole ring were also isolated from 
the reaction. The presence of two phenylethanol groups was suggested by the presence of a m/z 380 
signal of [M+Na]
+ 
 in the mass spectra of these compounds. The locations of the substituents were 
determined by 
1
H, 
13
C and HMBC NMR. Compound 5.16, the third major product, was isolated in 
4.5% yield, and was identified by the absence of H-3 and H-7 in the 
1
H NMR spectrum and a 
downfield doublet signal at δH 7.19 (d, J = 2.4 Hz) that had a long range correlation to δC 135.1 (C-
8‘) and δC 116.3 (C-3‘). The HSQC correlation showed the cross-peak between the proton signal at 
δH 7.19 and a carbon at δC 122.0. The HMBC correlation from δC 122.0 to δH 10.82 (s, H-1‘) 
identified the C-2‘ signal as that at δC 122.0 and H-2‘ at δH 7.19. Another deshielded signal at δH 
7.00 (d, J = 7.1 Hz) was identified as the signal of H-6‘ and showed an HMBC correlation to δC 
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47.8 (C-2‘‘) (Table 5.3). In addition, the absence of H-3‘ and H-7‘ signals in the 1H NMR of 5.16 
suggested the location of the substituents (Figure 5.4). Moreover, the HMBC correlations from δH 
4.53 (H-2‘‘) to δC 135.1 (C-8‘), δC 126.0 (C-7‘) and δC 118.5 (C-6‘) (Table 5.3) confirmed the 
substitution of C-3‘ and C-7‘ of 5.12 with two phenylethanol units. Compound 5.19 accounted for 
approximately 1% yield, MS (m/z 357 (M)
+
, ESIMS m/z 380 [M+Na]
+
, 396 [M+K]
+
) and was 
identified due to the absence of H-3‘ and H-1‘ signals in the 1H NMR (Table 5.3). The HMBC 
spectrum showed interactions from δH 4.08 (H-2) and δH 5.62 (H-2‘‘) to δC 123.1 (C-2‘) (Table 
5.3). Other minor isomers, compounds 5.17, 5.18, 5.20 were similarly identified by 1D and 2D 
NMR spectroscopy as showed in Table 5.4 and Table 5.5 and Figure 5.5.  
Table 5.3: 
1
H and 
13
C NMR data for compound (5.16 and 5.19). 
 
        5.16      5.19 
C       δC (ppm) 
a 
        δH (ppm), mult., J  (Hz)
b
        δC (ppm) 
a 
        δH (ppm), mult., J  (Hz)
b
          
1 65.2  3.97, m   65.3  3.98, m 
  3.92, m     4.06, m  
2 45.4  4.21, dd, 7.2, 7.3  45.5  4.08, m 
3 143.9  -    143.8  -- 
4 128.2  7.30, dd, 8.2, 15  128.3  7.33, m 
5 128.0  7.22, m   127.9  7.24, m 
6 125.8  7.12, m   125.8  7.13, t, 7.5 
1‘ -  10.82, brs   --  -- 
2‘ 122.0  7.19, d, 2.4   123.1  7.69, s 
3‘ 116.3  -    115.5  -- 
4‘ 111.6  7.15, d, 7.8   118.8  7.28, m 
5‘ 118.8  6.84, t, 7.7   118.5  6.85, t, 7.0 
6‘ 118.5  7.00, dd, 7.1   120.9  6.97, t, 7.5 
7‘ 126.0  -    110.0  7.30, m 
8‘ 135.1  -    136.4  -- 
9‘ 127.1  -    127.5  -- 
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1‘‘ 64.1  4.03, m   63.2  4.25, m 
   4.02, m     4.08, m 
2‘‘ 47.8  4.53, m   61.0  5.62, dd, 8.5, 5.0 
3‘‘ 142.7  -    139.7  -- 
4‘‘ 128.3  7.39, dd, 8.2, 1.5  126.8  7.30, m 
5‘‘ 128.0  7.22, m   128.3  7.25, m   
6‘‘ 126.1  7.12, m   127.4  7.21, m 
              
              a
Chemical shift (ppm) referenced to DMSO-H6 δC 39.5 were taken from 1D and 2D NMR (DMSO-d6, 500 MHz); 
              b
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 
Table 5.4: 
1
H and 
13
C NMR data for compound (5.18 and 5.20). 
 
 
    5.18          5.20 
C       δC (ppm) 
a 
        δH (ppm), mult., J  (Hz)
b
        δC (ppm) 
a 
        δH (ppm), mult., J  (Hz)
b
          
 1 64.8  3.91, m   63.8  3.79, m 
    3.95, m     4.26, m 
 2 45.5  4.29, t, 7.0   45.2  4.44, dd, 9.0, 6.0 
 3 143.9  --    143.5  -- 
 4 128.2  7.20, m   128.3  7.31, d, 7.5 
 5 128.0  7.24, m   127.8  7.24, t, 7.5 
 6 125.8  7.11, m   126.3  7.16, t, 7.5 
 1‘ --  10.70, brs   --  10.71, s 
 2‘ 121.8  7.14, s    136.0  -- 
 3‘ 115.6  --    112.4  -- 
4‘ 118.4  7.17, d, 8.0   119.2  7.21, m 
5‘ 119.1  6.77, m   118.1  6.75, td, 7.5, 1.0 
6‘ 135.8  --    120.2  6.90, td, 7.0, 1.0 
7‘ 110.5  7.13, m   111.0  7.23, m 
8‘ 136.4  --    136.5  -- 
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9‘ 125.3  --    126.9  -- 
1‘‘ 65.1  3.92, m   63.4  4.05, m 
   3.96, m     4.05, m 
2‘‘ 53.6  4.08, t, 7.0   44.2  4.49, t, 7.5 
3‘‘ 143.8  --    141.7  -- 
4‘‘ 127.9  7.20, m   128.5  7.38, d, 7.5 
5‘‘ 128.0  7.24, m   128.2  7.20, t, 7.5 
6‘‘ 125.7  7.11, m   125.5  7.09, t, 7.0 
              a
Chemical shift (ppm) referenced to DMSO-H6 δC 39.5 were taken from 1D and 2D NMR (DMSO-d6, 500 MHz); 
              b
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 
Table 5.5: 
1
H and 
13
C NMR data for compound (5.17). 
 
 C         δC (ppm) 
a 
       δH (ppm), mult., J  (Hz)
b
                   
1
H-
13
C HMBC
ab
 
1 65.1  3.87-3.97, m    C2   
 2 45.4  4.22, t, 7.0    C1, C3‘, C9‘, C4, C3 C2‘  
 3 143.9  --     --  
 4 128.2  7.22, m    C2, C6  
 5 128.0  7.22, m    C3 
 6 125.8  7.14, m    C4 
 1‘ --  10.72, brs    C8‘, C9‘, C3‘,C2‘ 
 2‘ 122.3  7.14, s     C8‘, C9‘ 
 3‘ 115.6  --     -- 
4‘ 117.5  7.22, m    C6‘, C3‘, C8‘ 
5‘ 132.7  --     -- 
6‘ 121.5  6.90, dd, 8.5, 1.5   C8‘, C4‘  
7‘ 110.0  7.18, m    C5‘, C9‘ 
8‘ 134.8  --     -- 
9‘ 126.9  --     -- 
1‘‘ 65.1  3.87-3.97, m    C2‘‘    
2‘‘ 53.6  4.02, t, 7.0    C6‘, C4‘, C5‘, C3‘‘, C4‘‘ 
3‘‘ 143.8  --     -- 
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4‘‘ 127.9  7.18, m    C2‘‘, C6‘‘ 
5‘‘ 128.0  7.24, m    C3‘‘ 
6‘‘ 125.7  7.11, m    C4‘‘ 
              a
Chemical shift (ppm) referenced to DMSO-H6 δC 39.5 were taken from 1D and 2D NMR (DMSO-d6, 500 MHz); 
              b
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 
 
Figure 5.5: The 
1
H NMR spectrum of five bis-phenylethanol substituted adducts of 5.12. All experiments were run on a 
500 MHz machine in a mixture of DMSO-d6. 
5.2.1.2:  Reaction of imidazole with styrene epoxide  
Imidazole (5.11) was allowed to react with 5.7 in the presence of silica under the conditions 
described above. The reactions produced a 1:1 ratio of compounds 5.21 and 5.22 in a total yield of 
44%. The likely mechanism of this reaction is detailed in Figure 5.3, in which silica activated 5.7 in 
order to facilitate nucleophilic to attack of the imidazole to the epoxide ring. 2-(Imidazole-1-yl)-1-
phenylethanol (5.21) was characterized by a 
1
H-
1
H-COSY correlation from the δH 5.69 (O-H) signal 
to a methine signal at 4.80
235
 (H-2) indicating a secondary alcohol and the HMBC correlations 
from the methylene proton signals at δH 4.02 and δH 4.12
235
 (H-2) to δC 127.7 (C-5‘) and δC 137.9 
(C-2‘) indicating a new bond between C-2 of the phenylethanol unit and N-1‘ of 5.11 (Table 5.6). 
(5.16) 
(5.20) 
(5.18) 
(5.19) 
(5.17) 
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Similarly, the identity of the primary alcohol (5.22) was determined by the correlations from δH 
5.36 (H-2) to δC 128.2 (C-5‘) and δC 136.9 (C-2‘). 
Table 5.6: 
1
H and 
13
C NMR data for 5.21 and 5.22. 
 
    5.21       5.22 
C       δC (ppm) 
a 
     δH (ppm), mult., J  (Hz)
b
         δC (ppm) 
a 
     δH (ppm), mult., J  (Hz)
b
 
 1 72.1  4.80, dd, 4.1, 8.0  63.3  3.97, m 
          4.08, m 
 2 53.6  4.02, dd, 8.0, 13.9  62.6  5.36, dd, 5.0, 8.0 
    4.12, dd, 4.1, 13.9 
 1‘ --  --    --  -- 
 2‘ 137.9  7.51, brs   136.9  7.81, brs 
 3‘ --  --    --  -- 
4‘ 120.2  7.12, brs   120.2  6.91, brs 
5‘ 127.7  6.84, brs   128.2  7.27, brs 
1‘‘ 142.7  --    139.1  -- 
2‘‘ 126.0  7.33, m   127.0  7.30, m 
3‘‘ 128.1  7.32, m   128.3  7.31, m 
4‘‘ 127.4  7.25, m   127.9  7.21, m 
              a
Chemical shift (ppm) referenced to DMSO-H6 δC 39.5 were taken from 1D and 2D NMR (DMSO-d6, 500 MHz); 
              b
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 
5.2.1.3 Reaction of guanine with styrene epoxide    
Styrene epoxide was reported to modify DNA by reacting predominately with guanine (5.23).
236-239
 
In order to evaluate the ability of 5.11 and 5.12 to compete with the reaction of 5.23 with reactive 
epoxides such as 5.7, it was necessary to confirm that 5.23 reacts with 5.7 under the conditions used 
in these model reactions and that covalent adducts can be isolated. Guanine and 5.7 were treated 
under two different reaction conditions. Method A employed those conditions used for the previous 
experiments involving indole (5.12) and imidazole (5.11) and involved allowing the reactions to 
occur in a mixture of 50% CHCl3 and 50% DCM with silica presence to activate the epoxide. As 
guanine exhibited better water solubility than the previous reactants, Method B used 50% 
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ethanol/water to mimic a better biological condition for the reaction between 5.7 and 5.23
237
 (for 
more details about method A and B, see experimental). The total yield of covalent adducts isolated 
under the two conditions was nearly the same. However, analytical RPHPLC of the MeOH fraction 
revealed that the relative abundance of the various products differed from Method A to Method B. 
Figure 5.6 shows the RPHPLC analysis of the MeOH fraction after removed starting materials. 
Mass spectrometric analysis of the collected HPLC products indicated the presence of at least three 
compounds having m/z 272 [M+H]
+ 
(Figure 7.26),
 
corresponding to compounds formed from one 
molecule of 5.7 and one of 5.23, six minor components having m/z 392 [M+H]
+
 suggesting 
compounds consisting of two units of 5.7 and one of 5.23 which was supported by MS/MS analysis 
(Figure 5.7), and four minor components having m/z 512 [M+H]
+
 suggesting three units of 5.7 have 
reacted with one molecule of 5.23 (Figure 5.8). These adducts were isolated in a total yield of 11% 
after the reaction was allowed to proceed for seven days. The results indicated that all nucleophilic 
positions in 5.23 are reactive to 5.7 under both sets of reaction conditions.  
 
Figure 5.6: The RPHPLC trace of the methanol fraction from the reaction of 5.23 and 5.7 using gradients of 0.1% TFA 
in water (solvent A) and 0.1% TFA in MeCN (solvent B).  Insert:  The further resolution of major peak achieved using 
isocratic conditions of 8% solvent B. 
5.24 
2.26 
2.25 
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Figure 5.7: Positive ion mode MS/MS spectra of products from the reaction of 5.23 and 5.7 that consist of two units of 
phenylethanol and one of guanine. 
 
Figure 5.8: Positive ion mode MS/MS spectra of products from the reaction of 5.23 and 5.7 that consist of three units 
of phenylethanol and one of guanine. 
The structures of DNA-5.7 adducts have previously been proposed based on LCMS, UV and EIMS 
analyses, therefore lacking evidence to confirm the precise structures.
229,239-241
 Heminki et al. 
proposed N-7, N-2 and O-6 of guanine were the main sites for 5.7 attacking, based only on the mass 
spectrometric analysis of modified DNA.
235
 Further compounds 5.25 and 5.26 were synthesized and 
their structures confirmed by Novák et al. using 
1
H NMR and 
13
C NMR.
242
 In our experiments, we 
were able to isolate sufficient quantities of products to perform NMR analysis. The formation of O-
6 adducts would cause significant changes to the 
1
H and 
13
C NMR spectra compared to other 
adducts due to the CH2 forming a covalent bond with oxygen, leading to a modified amide group in 
guanine. However, none of the products we isolated exhibited NMR characteristics that would 
suggest an O
6
-linked adduct. The 
1
H NMR and HMBC analysis of the three major products isolated 
from our reactions between 5.23 and 5.7 indicated that the N-7 and C-8 positions of guanine were 
functionalized with a phenylethanol unit.  
- a unit of 5.7 
- another units of 5.7 
- a unit of 5.7 
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Compound 5.25 (Figure 5.6) was obtained as a white powder, ESIMS m/z 272 [M+H]
+
 and 
identified as the adduct formed when N-7 of 5.23 attacks the terminal carbon of the epoxide of 5.7. 
1
H NMR shows a signal at δH 4.96 (dd, J = 3.5, 9.0 Hz, H-2‘) integrating to a proton in a CH group 
connected to the δH 4.45 (dd, J = 3.5, 13.0 Hz) and δH 4.22 (dd, J = 9.0, 13.0 Hz) CH2 group (the 
findings were confirmed by COSY and HMBC). HMBC correlations indicated the new covalent 
bond forming between 5.7 and 5.23 by the cross-peaks for nuclei interacting from δH 4.96 (H-2‘) to 
δC 141.8 (C-8). The findings were in agreement with Novák. J
242
 who synthesized 5.25 from 5.7 and 
one of reaction pathways proposed by Vodicka et al.
238
 and Hemminki et al.
239
 
Similarly, compound 5.24 was identified by ESIMS m/z 272 [M+H]
+
 and the absence of H-8 at δH 
7.58 in 
1
H NMR spectra suggesting the substitution of H-8 by a phenylethanol moiety. The HMBC 
correlations confirmed the new covalent bond by the cross-peaks from δH 4.12 and δH 4.09 (H-1‘) to 
δC 151.0 (C-8).   
Table 5.7: 
1
H and 
13
C NMR data for 5.24, 5.25 and 5.26. 
5.24              5.25              5.26                
H       δH(ppm),mult.,J(Hz)       δH(ppm),mult.,J(Hz)                 δH(ppm),mult.,J(Hz) 
   1‘    4.12, dd, 8.5, 13.5     4.45, dd, 3.5, 13.0          4.22, dd, 9.0, 12.0   
       4.09, dd, 4.0, 13.5     4.22, dd, 9.0, 13.0              4.00, dd, 5.5, 12.0       
   2‘    4.92, dd, 4.0, 8.5     4.96, dd, 3.5, 9.0          5.46, dd, 5.5, 9.0  
   1    10.67, s       --            10.54, s   
   2    --       --          -- 
   2
1
   6.67, brs       6.79, brs           6.39, brs       
   7   8.14, brs        --            --            
   8   --       8.46, s           8.02, s       
   4‘   7.36, m       7.37, m           7.33, m   
   5‘   7.35, m       7.39, m           7.28, m       
   6‘   7.28, m       7.35, m           7.25, m  
             
 Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 were taken from 1D and 2D NMR (DMSO-d6, 500 MHz). 
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The absence of an H-7 signal in the 
1
H NMR of 5.26 and ESIMS m/z 272 [M+H]
+
 suggested a 
connection between a unit of phenylethanol and the N-7 of guanine.
243
 A one proton signal at δH 
5.46 (dd, J = 5.5, 9.0 Hz) suggested a CH group bound to a N-atom adjacent to a CH2 group (δH 
4.22 (dd, J = 9.0, 12 Hz), δH 4.00 (dd, J = 5.5, 12 Hz)) and 
13
C NMR spectrum shown δ 59.5 
(PhCH), 62.4 (CH2OH). These results are in agreement with Novak‘s finding
242
. As a result of the 
attachment directly to N, the CH signal was deshielded compared with the same proton signal in 
compounds 5.24 and 5.25 observed at δH 4.92 and δH 4.96 respectively. This N-linked adduct is 
analogous to compound 5.21 (Scheme 3.1) with the chemical shift and coupling constants of the 
methylene protons in 5.21 (δH 4.02 (dd, J = 8.0, 13.9 Hz), 4.12 (dd, J = 4.1, 13.9 Hz)) being similar 
to those of 5.25. Signals at δH 4.22 (dd, J = 9.0, 13.0 Hz), 4.45 (dd, 3.5, 13.0 Hz) and a 
13
C NMR 
signal at C51.4 were assigned to the CH2OH carbon. Similar NMR data for this compound were 
reported by Novak
242
.  
3.2.1.4 The competitive reactions between guanine and indole or imidazole with 
styrene epoxide   
The experiments were conducted in the presence of 5.23 (guanine), 5.7 (styrene epoxide) and 5.11 
(imidazole) or 5.12 (indole) under the same conditions as previous reactions of 5.23. The products 
obtained from the competitive reactions were all products associated with the reaction of 5.7 with 
indole, (5.13 (2-(3-indolyl)-2-phenylethanol), 5.14 (2-(1-indolyl)-2-phenylethanol), 5.15 (2-(2-
indolyl)-2-phenylethanol), 5.16 (2,2‘‘-(indole-1‘,7‘-diyl)bis(2-phenylethanol)), 5.17 (2,2‘‘-(indole-
3‘,5‘-diyl)bis(2-phenylethanol)), 5.18 (2,2‘‘-(indole-3‘,6‘-diyl)bis(2-phenylethanol)), 5.19 (2,2‘‘-
(indole-1‘,3‘-diyl)bis(2-phenylethanol)), 5.20 (2,2‘‘-(indole-2‘,3‘-diyl)bis(2-phenylethanol)), and 
with imidazole (5.12), 5.21 (2-(imidazole-1-yl)-1-phenylethanol), 5.22 (2-(imidazole-1-yl)-2-
phenylethanol )). No products of the reaction of 5.23 and 5.7 were found in the experiments 
suggesting that indole (5.12) and imidazole (5.11) are more reactive towards the activated epoxide 
than guanine (5.23). 
5.2.2 The reactions of styrene epoxide with bile pigments and its derivatives 
5.2.2.1 The reaction of styrene epoxide with bile pigments  
With the model studies indicating that N-heterocycles of 5.11 and 5.12 can efficiently compete with 
guanine in the reaction with activated epoxides in the competitive reactions, attention turned to the 
reactions of BPs (5.8, 5.9, 5.10) with 5.7. Biliverdin (5.10, BV) was allowed to react with 5.7 in the 
presence of silica in 50:50 DCM/chloroform for one week. Two major products were isolated and 
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their structures (Figure 5.9 and Table 5.8) identified by 1D and 2D NMR. The first fraction 
exhibited an ESIMS m/z 703 [M+H]
+
 indicating one unit of 5.7 had reacted with 5.10 (BV). The 
1
H 
NMR spectrum of the product showed a two-proton signal, at δH 4.04 coupled with a proton signal 
at δH 4.75 which was consistent with the CH2-CH-OH group resulting from the opening of the 
epoxide ring of 5.7 by a carboxylic acid group of 5.10 (BV). A very downfield signal at δH 12.10 
integrating to one proton indicated that one of the carboxylic acid moieties of 5.10 (BV) was 
unreacted (Figure 5.9). The HMBC correlations from δH 4.04 (H-1‘) to a carboxyl carbon signal at 
δC 172.0 confirmed the formation of a phenylethanyl ester (Table 5.8). It is not possible to 
distinguish between esters 5.27 and 5.28 spectroscopically. Compound 5.10 (BV) is pseudo-
symmetrical, differing only in the substitution pattern of the two lactam rings. The NMR spectra for 
5.10 (BV) shows slight differences for the signals associated with the two lactam rings but identical 
signals for the two indole rings and the methyl and carboxylic acid substituents of these rings. It is 
logical to assume therefore, that both esters 5.27 and 5.28 would give essentially identical spectra. 
The two carboxylic acid groups would have similar reactivity and thus it is likely that the mono-
ester product isolated from this reaction is in fact an indistinguishable mixture of 5.27 and 5.28.  
 
Figure 5.9 : An expanded region of the proton NMR spectrum of compounds (5.27, 5.28) performed at 500 MHz in 
DMSO-d6. 
The second fraction contained a single third major product of the reaction was the di-ester, 5.31 
which was characterized initially by the ESIMS m/z 823 [M+H]
+
. The structure was confirmed by 
the absence of 
1H NMR signals around δH 12.00 and the fact that the aromatic proton signals now 
integrated to 10 protons (benzene ring signals). The signal assigned to H-2
‘
, H-2‘‘ was defined as 
two protons at δH 4.74 and δH 4.04 integrated to 4 protons exhibited proton signals of methylene 
groups, H-1‘ and H-1‘‘, (Figure 5.10). The structure of the ester was confirmed by HMBC 
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correlations from δH 4.04 (H-1‘‘ and H-1‘) to δC 172.0 (C-12
3
 and C-8
3
) and to the unprotonated 
aromatic carbons, δC 147.0 (C-3‘‘and C-3‘).  
 
Figure 5.10: An expanded region of the proton NMR spectrum of 5.31 performed at 500 MHz in DMSO-d6. 
The reaction between 5.8 (PRO) and styrene epoxide (5.7) also yielded an inseparable mixture of 
mono-esters, 5.29 and 5.30 (Figure 5.11) as the major products. The identity of 5.29 and 5.30 were 
identified by ESIMS (m/z 683 [M+H]
+
) and the appearance of aromatic signals and the 
hydroxylated methylene group in the 
1
H NMR. The structures of the esters were confirmed by 
HMBC correlations from δH 4.00 and δH 4.08 (m, H-1‘) to δC 172.4 (C-12
3
 or 8
3
). 
Table 5.8: 
1
H and 
13
C NMR data for 5.27, 5.28, 5.29 and 5.30. 
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    5.27;  5.28                        5.29;   5.30 
C       δC (ppm) 
a 
     δH (ppm), mult., J  (Hz)
b
         δC (ppm) 
a 
     δH (ppm), mult., J  (Hz)
b
 
1 170.9  --    136.9  -- 
2 126.1  --    136.9  -- 
2
1
 126.2  6,54, dd, 11.5, 17.5  130.1  8.38, m 
2
2 
119.2  5.38, dd, 11.5, 2.5  120.9  6.16, m 
   6.05, dd, 17.5, 2.5  --  6.37, m 
3 139.8  --    136.9  -- 
3
1
 9.0  2.15, s    12.4  3.59, s 
4 141.3  --    136.9  -- 
5 97.7  6.09, d, 2.0   97.0  9.96, s 
6 127.5  --    137.0  -- 
7 137.7  --    137.0  -- 
7
1
 9.0  2.06, d    11.1  3.51, s 
8 138.5  --    138.9  -- 
8
1
(12
1
)19.2  2.84, m   21.0  4.28, t, 7.0 
8
2
(12
2
)34.9  2.41, t, 7.5   36.5  3.22, t, 7.5 
8
3
(12
3
)173.6  --    172.4  -- 
9 141.0  --    138.9  -- 
10 116.0  6.96, s    97.0  10.02, s 
11 139.5  --    139.1  -- 
12 137.5  --    139.1  -- 
12
1
(8
1
) 19.2  2.84, m   21.0  4.27, t, 7.0 
12
2
(8
2
)35.2  2.49, t, 7.5   36.6  3.13, t, 7.5 
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12
3
(8
3
) 172.0  --    174.0  -- 
13 128.4  --    137.0  -- 
13
1
 9.0  2.04, s    11.1  3.54, s 
14 128.5  --    137.0  -- 
15 97.0  6.11, d, 2.5   97.0  10.02, s 
16 140.0  --    136.9  -- 
17 128.1  --    136.9  -- 
17
1
 126.8  6.81, dd, 17.5, 11.5  130.1  8.38, m 
 
17
2
 122.5  5.70, d, 17.5   120.9  6.16, m 
   5.66, d, 11.5     6.37, m 
18 139.2  --    136.9  -- 
18
1
 9.3  1.79, s    12.4  3.59, s 
19 171.5  --    136.9  -- 
20 --  --    97.0  9.96, s 
 1‘ 68.7  4.04, m   68.8  4.00, m 
          4.08, m 
2‘ 70.2  4.75, dd, 7.5, 5.0  7.01  4.57, m 
3‘ 141.8  --    141.7  -- 
4‘ 126.2  7.32, m   126.1  7.13, m 
5‘ 128.0  7.3, m    127.9  7.08, m 
6‘ 127.3  7.24, m   127.2  7.05, m 
              a
Chemical shift (ppm) referenced to DMSO-H6 δC 39.5 were taken from 1D and 2D NMR (500 MHz, DMSO-d6); 
              b
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 
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Figure 5.11: An expanded region of the proton NMR spectrum of compounds (5.29, 5.30) performed at 500 MHz in 
DMSO-d6. 
The next most abundant product isolated from the reaction was the diester, 5.32 and again identified 
by the ESIMS data (m/z 803 [M+H]
+
) and the appearance of a two-proton signal at δH 4.56 assigned 
to two saturated methine groups and a four-proton signal at δH 3.98 and δH 4.07 assigned to two 
methylene groups of 5.7. The presence of aromatic hydrocarbon signals at 7.35 ppm integrated to 
10 protons was benzene ring signals. The HMBC spectra for both the mono and diester products 
showed the expected correlations from the methylene‘s protons δH 4.07 and δH 3.98 (H-1‘, H-1‘‘) to 
the carboxyl carbon signal δH 172.4 (C-8
3
 and C-12
3
) (Figure 5.12 and Table 5.9). 
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Figure 5.12: The structure of 5.32 and an expanded region of the HMBC spectrum of 5.32 showing the key correlations 
used to identify the structure. All experiments were performed at 500 MHz in DMSO-d6. 
Table 5.9: 
1
H and 
13
C NMR data for 5.31 and 5.32. 
              
    5.31      5.32 
C       δC (ppm) 
a 
     δH (ppm), mult., J  (Hz)
b
         δC (ppm) 
a 
     δH (ppm), mult., J  (Hz)
b
 
1 171.5  --    136.3  -- 
2 140.0  --    136.1  -- 
2
1
 127.3  6.81, dd, 17.5, 11.5  130.0  8.37, dd, 18.5, 11.5  
2
2 
119.6  6.05, dd, 17.5, 2.0          121.0  6.37, dd, 18.5, 0.9 
   5.37, dd, 11.5, 2.0    6.17, dd, 11.5, 0.9 
3 141.5  --    137.2  -- 
3
1
 9.6  2.15, s    11.30  3.53, s 
4 126.0  --    136.1  -- 
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5 97.5  6.10, s    97.1  10.05  
6 148.0  --    137.2  -- 
7 128.0  --    137.2  -- 
7
1
 9.5  2.05, s    11.3  3.53, s 
8 137.0  --    137.0  -- 
8
1
 19.5  2.50, m   36.5  4.30, t, 7.0  
8
2
 35.5  2.84, m   21.1  3.22, t, 7.5  
8
3
 172.2  --    172.4  --   
9 137.2  --    137.2  -- 
10 116.4  6.94, s    96.6  10.02, s 
11 138.2  --    139.0  -- 
12 138.5  --    139.0  -- 
12
1
 35.5  2.50, m   36.5  3.22, t, 7.0  
12
2
 19.5  28.4, m   21.1  4.30, t, 7.5 
12
3
 172.2  --    172.4  --   
13 128.2  --    137.0  -- 
13
1
 9.5  2.03, s     12.5  3.53, s 
14 151.0  --    137.2  -- 
15 98.0  6.11, s    97.0  9.99, s 
16 139.0  --    136.1  -- 
17 139.8  --    136.1  -- 
17
1
 127.1  6.54, dd, 17.5, 11.5  130.0  8.37, dd, 18.5, 11.5  
17
2
 123.0  5.70, d, 17.5   121.0  6.37, dd, 18.5, 0.9 
   5.70, d, 11.5     6.17, dd, 18.5, 09 
18 128.2  --    137.2  -- 
18
1
 10.0  1.79    12.5  3.62, s 
19 171.6  --    136.1  -- 
20       97.1  10.04, s 
1‘,1‘‘ 6.92  4.04, m   70.1  4.07, m  
3.98, m 
2‘,2‘‘ 71.5  4.74, brs   68.8  4.56, m 
3‘,3‘‘ 147.0  --    141.7  -- 
4‘,4‘‘ 126.8  7.31, m   126.1  7.06, m 
5‘,5‘‘ 128.5  7.28, m   127.9  7.11, m 
6‘,6‘‘ 127.2  7.21, m   127.2  7.08, m 
              a
Chemical shift (ppm) referenced to DMSO-H6 δC 39.5 were taken from 1D and 2D NMR (500 MHz, DMSO-d6); 
              b
Chemical shift (ppm) referenced to DMSO-H6 δH 2.49 
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The products of the reaction of 5.9 (UCB) with 5.7 were unstable and light sensitive, therefore they 
were not isolable. However, the ESIMS analysis of the crude reaction mixture indicated an m/z 703 
[M-H]
-
 (Figure 7.22) and m/z 823 [M-H]
-
 which corresponded to the mono- and diphenylethanol 
esters which would be expected based on the results of the reactions of 5.10 (BV) and 5.8 (PRO). 
The ESIMS analysis also indicated the presence of 5.10 (PRO) and the mono-phenylethanol and di-
phenylethanol esters of 5.10 (PRO) (Figure 5.14). The reaction‘s mixture was turned from yellow to 
green over the course of the reaction which also indicates the conversion of 5.9 (UCB) to 5.10 
(BV).  
 
Figure 5.13:  The negative ESIMS result of bilirubin mono phenylethanol ester.  
 
Figure 5.14: The mixture of one to four units of 5.7 bonding to 5.9 (UCB) and 5.10 (BV) in the reaction‘s mixture 
between 5.9 (UCB) and 5.7. 
The conversion of 5.9 (UCB) to 5.10 (BV) in in the presence of silica is a spontaneous oxidation 
that is unavoidable over the time of the experiment (the findings was identified in a control reaction 
and it was also found in vitro studies by Abu-Bakar et al.
30
). Detailed analysis of the MS results 
from the reaction mixture reveal that the ratio of biliverdin-monoester (m/z 701) to bilirubin-
monoester (m/z 703) is 8:2. However the ratio of the two diesters is ~1:1 while the bilirubin adducts 
bearing three and four units of 5.7 are more abundant than the equivalent biliverdin adducts (m/z 
941:943 = 3:7, m/z 1061:1063 = 2:8, Figure 5.14). These data suggest that reaction with 5.7 to form 
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an ester is somehow stabilizing to 5.9 (UCB) and the initial adduct can continue to react with other 
units of 5.7 without oxidation to 5.10 (BV). It also suggests that 5.9 (UCB) is more reactive to 5.7 
than 5.10 (BV) and has additional sites of the reaction after the two carboxylic acid groups have 
been esterified. 
5.2.2.2 The oligimersation of styrene epoxide 
In reactions of 5.7 with all other compounds, major isolated products were polymers of 5.7 and the 
hydrolysed product 5.40. They were detected by ESIMS (m/z 161 [M+Na]
+
 (5.40)) with dimers (m/z 
281 [M+Na]
+
), trimers (m/z 401 [M+Na]
+
) and sequential oligomers of 5.7 (see Figure 7.21 in 
appendix-D).
243-245
 
 
5.2.2.3 Reaction between bile pigment dimethyl esters and substituted pyrrole and 
dipyrroles with styrene epoxide 
The ESIMS results show that all BPs (5.8, 5.9, 5.10) can react with more than four units of 5.7. 
However, only the mono- and di- phenylethanol esters were isolable from 5.8 (PRO) and 5.10 (BV). 
There are two hypotheses that could explain these high molecular weight products. The first is that 
the secondary alcohol of the phenylethanol attacks an additional molecule of 5.7 resulting in 
oligomeric chains forming from the initial esters. This hypothesis is supported by the above 
mentioned formation of oligomers of 5.7. The second hypothesis is that other nucleophilic positions 
on BPs are capable of reacting with 5.7.  In order to test these hypotheses, the dimethyl esters of the 
BPs (5.33, 5.34, 5.35) were synthesized and treated with 5.7 under the reaction conditions 
previously described.   
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                       (5.33)         (5.34)    (5.35) 
Guanine adducts were not found in the competitive reactions of 5.33, 5.34 and 5.35 with 5.7 in the 
presence of 5.23 suggesting that 5.33, 5.34 and 5.35 still intercepted the reaction of 5.7 with 5.23 
(more details can be found in experimental section). However, products of 5.33 with 5.7 were not 
found and the reaction of compound 5.34 and 5.7 produced minor unstable products having m/z = 
731 [M+H]
+
, 851 [M+H]
+
 and 971 [M+H]
+
 accounting for one, two and three units of 5.7 binding to 
5.34. The starting materials (5.33 and 5.34) in competitive reactions decomposed to give yellow, 
pink, blue, and yellow components while in the control reactions the 5.33 and 5.34 were stable. The 
esterification of these BPs may react with 5.7 to produce very unstable components. This hypothesis 
is supported by the detection of unstable products bearing more than two units of 5.7 in the 
reactions of 5.7 with 5.8 (PRO) and 5.10 (BV).  
In contrast, ESIMS analysis of the reaction of 5.35 with 5.7 showed evidence that the products of 
one unit of 5.7 with 5.35 had a violet colour, m/z 755 [M+Na]
+
 and two and three units of 5.7 with 
5.35 were violet-yellow, with m/z 853 [M+Na]
+
 and m/z 973 [M+Na]
+
, respectively. These products 
constituted approximately 15% of the starting material (Figure 5.17, Figure 5.18 in experimental 
section). Although the fraction containing the mono-adduct (m/z 755) appeared to be pure by 
ESIMS, it is a mixture by 
1
H NMR. Therefore, all attempts to isolate the product failed. However, 
given the documented higher reactivity of 5.35 to 5.7 than that of 5.34 and 5.33 suggested the 
unconjugated C10-bridge may play an important role in the increase of the reactivity of 5.35. 
In order to investigate the role of C10-bridge group in bilirubin, the substituted pyrrole 5.36 and 
dipyrroles 5.37-5.39 were synthesized and reacted with 5.7 under the same conditions as previously 
described.  
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                5.36                        5.37                        5.38                                    5.39 
Compounds 5.36 showed no reaction with 5.7 which eliminated the possibility that the reaction 
with the epoxide occurs at saturated methyl groups. Compound 5.37 and 5.39 reacted with 5.7 to 
produce minor unstable products, (m/z 469 [M+H]
+
) and (m/z 497 [M+H]
+
) respectively. In 
addition, 5.38 having a saturated carbon bridge similar to C10-bridge of 5.9 and 5.35, reacted with 
5.7 to form a yellow product having m/z 512 [M+Na]
+
 (5.38 + 2 units of 5.7) which appeared to 
constitute up to approximately 22% of the starting material. Once again, this product was too 
unstable to be isolated. Therefore, the structure was not identified by NMR. However, these results 
suggested that the aromatic ring-system of bilirubin and its derivatives may be additional sites of 
reaction with activated epoxides.  
5.2.3 Competition reactions 
The reactions of 5.23 with 5.7 in the presence of 5.8 (PRO), 5.9 (UCB), 5.10 (BV), 5.33, 5.34, 5.35, 
5.36, 5.37, 5.38 and 5.39 clearly indicated that none of the products of the reaction of 5.7 with 5.23 
that were isolated previously were present in these competition reactions. The results suggested that 
5.9 (UCB), 5.10 (BV), 5.33, 5.34, 5.35, 5.36, 5.37, 5.38 and 5.39 were very effective inhibitors of 
the reaction of 5.7 with 5.23. In spite of no products forming between 5.36 or 5.33 and 5.7 after 
reactions, those compounds were decomposed in the presence of 5.7. All cases, isolated adducts and 
the ratio of products were identical to those isolated from the reactions of 5.9 (UCB), 5.10 (BV), 
5.33, 5.34, 5.35, 5.36, 5.37, 5.38 and 5.39 conducted in the absence of 5.23. 
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5.3 Conclusions  
Although the inhibitory effects of BPs (5.8, 5.9, 5.10) on environmental mutagens (5.1, 5.4) has 
been reported in a variety of studies,
14,17,19,35,186
 the inhibition mechanism has not been explored. 
Therefore, the investigation of possible chemical reactions between activated mutagens and BPs is a 
focus of our study to elucidate the mechanism of this inhibition. Reactions between these two 
classes of compounds performed in biological systems both in vitro and in vivo produce very tiny 
amounts of products that can only be analysed by MS.
121,122,222,272
 Having a larger amount of 
products for structure analyses has been a challenge for biological studies. Therefore, developing 
and using a mimic of the biological conditions and using more readily available compounds as 
mimics for the biologically generated compounds is a vital strategy in our study into the chemical 
interactions of BPs and mutagens. This study was successful in developing a set of conditions to 
mimic the biological conditions. 
This chapter also explored some important novel aspects. Firstly, indole and imidazole possess 
higher reactivity to the activated epoxide than guanine. The chemical interactions of BPs with 5.7, 
the epoxide chosen to mimic the reactive epoxide metabolites of BP and Aflatoxin B, were 
investigated. Our studies showed that the carboxylic groups on the BPs were the main sites of 
reaction with 5.7. In addition, nitrogen atoms and the methylene C10-bridge in BPs may also have 
made a minor contribution to the reactions of 5.7 with BPs which may contribute to their inhibition 
of the reaction of 5.7 with guanine. Our results clearly demonstrated that, under our in vitro reaction 
conditions, indole, imidazole, and all of BPs studied totally inhibited the reaction of 5.7 with 
guanine. 
The reactions of 5.7 with the various substrates gave rise to 14 new compounds (2-(1-Indolyl)-2-
phenylethanol (5.14), 2-(2-Indolyl)-2-phenylethanol (5.15), 2,2‘‘-(Indole-1‘,7‘-diyl)bis(2-
phenylethanol) (5.16), 2,2‘‘-(Indole-3‘,5‘-diyl)bis(2-phenylethanol) (5.17), 2,2‘‘-(Indole-3‘,6‘-
diyl)bis(2-phenylethanol) (5.18), 2,2‘‘-(Indole-1‘,3‘-diyl)bis(2-phenylethanol) (5.19), 2,2‘‘-(Indole-
2‘,3‘-diyl)bis(2-phenylethanol) (5.20), 8-(2-Hydroxy-2-phenylethyl)guanine (5.24), 5.27, 5.28, 
5.29, 5.30, 5.31, 5.32) and five known compounds (2-(3-Indolyl)-2-phenylethanol (5.13), 2-
(Imidazole-1-yl)-1-phenylethanol (5.21), 2-(Imidazole-1-yl)-2-phenylethanol (5.22), 7-(2-Hydroxy-
1-phenylethyl)guanine (5.25), 7-(2-Hydroxy-2-phenylethyl)guanine (5.26)) which were isolated and 
characterised by TLC, mp, HPLC, UV, GC/MS, ESIMS, 
1
H NMR and 
13
C NMR. In addition, 11 
components were detected from the products of guanine, BPs, BP dimethyl esters and substituted 
dipyrroles with 5.7 by ESI-MS. 
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The major finding in our study of the reactions of BPs and 5.7 was that the sites of reactions of BPs 
with the epoxide is the carboxylic acid groups and other groups such as tertiary amines or C10-
bridge may play a minor role. However, despite being poorly reactive toward the model epoxide, 
the dimethyl esters of the BPs completely protected guanine from reactions with the activated 
epoxide in competition reactions. This is in agreement with recent studies that have clearly shown 
that the bile pigment dimethyl esters are as effective inhibitors of mutagens in some biological 
systems as the parent BPs.
19,186
 Free carboxylic acid groups are ubiquitous in biological systems 
thus it seems unlikely that this reaction is a major contributor to the unique inhibition activity 
exhibited by BPs towards the mutagenic effects of activated epoxides.  
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5.4 Experimental 
5.4.1 General materials and methods 
Solvents, mutagens and reagents were purchased from Sigma Aldrich Pty Ltd (Melbourne, Vic, 
Australia). Bile pigments were purchased from Frontier Scientific (Logan, UT, USA) unless 
otherwise stated. Thin layer chromatography (TLC) was performed on Merck Silica 60 F254 sheets. 
Flash column chromatography was performed on Lomb silica 60 (0.04-0.06 mm; 230-400 mesh). 
All bile pigments and mutagens were visualized with 254 nm UV light (λmax bilirubin = 450 nm, 
biliverdin = 375 nm, protoporphyrin = 409 nm, biliverdin dimethyl ester = 375 nm, bilirubin 
dimethyl ester = 450 nm, protoporphyrin dimethyl ester = 409 nm). Analytical reverse phase high 
performance liquid chromatography (RPHPLC) was performed using a Shimadzu system and 
running Shimadzu CLASS VP, LCsolution software and using a Waters 3.5 µm C18 column (150 x 
4.6 mm), 3 µm and 5 µm Grace Vydac Denali C18 250x4.6 mm and 250x10 mm columns. 
Analytical analyses (tR) was performed using gradient mixtures of water and MeOH. The eluent 
was monitored using a dual wavelength UV detector set at 214 nm and the second wavelength was 
varied depending on which BP was used and other compounds in the experiments. UV-Visible 
absorption measurements were recorded on a Perkin Elmer Lambda 35 Spectrometer. 
1
H, 
13
C, DEPT, COSY, HSQC, and HMBC NMR spectra were recorded on either Bruker AV400 or 
a Bruker AV500 spectrometer with CDCl3 (99.8 atom %D), CD3OD (99.8 atom %D) or DMSO 
(99.8 atom %D) used as solvents. 
1
H and 
13
C signals are recorded in parts per million (ppm) on the 
δ scale referenced to residual CHCl3 at δH 7.24 and CDCl3 at δC 77.0 ppm; DMSO: δH 2.49 and δC 
35.9; CD3OD: δH 3.30 and δC 49.0. GC/MS analyses (positive ion EI mode) were performed on a 
Shimadzu GC/MS QP2010-plus, gas chromatograph mass spectrometer, operating at 70 eV, 
connected to a GC-2010 Standard GC/MS programs: Shimadzu GC/MS, ZB-5MS column (length 
30.0, thickness 0.25um, diameter 0.25mm) : split mode; column flow 3.14 ml min
-1
; total flow 97.5 
ml min
-1
; injector 250 °C; detector 250 °C; oven 50 °C (2.0 min equilibration) held for 14.0 min, 
ramp 50 °C min-1 to 250° C and held for 4.0 min (total program time 20.0 min). Melting points 
were recorded on a Buchi Dr Tottoli apparatus and were uncorrected. Low resolution mass spectra 
were acquired on a Bruker Esquire HCT spectrometer (positive and negative ion ESI mode). High 
resolution mass spectra were recorded on a Bruker micrOTOF-Q spectrometer (positive ion ESI 
mode) or on a Finnigan MAT 900XL Trap instrument (positive ion EI mode, 70eV) at the Mass 
Spectrometry Facility, School of Chemistry and Molecular Biosciences, at the University of 
Queensland. 
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5.4.2 Experimental 
5.4.2.1 Reaction of indole (5.12) with styrene epoxide (5.7) in the presence and 
absence of guanine (3.35) 
The experiments were conducted in a mixed solvent consisting of 50% CH2Cl2 and 50% CHCl3 
(150 mL). Silica (500 mg) was suspended in the solvent. Compound 5.12 (117 mg, 1 mmol) was 
dissolved into the solvent and 5.7 (360 mg, 3 mmol) was added and the reaction held at 37 °C under 
argon atmosphere for one week. The competition experiments were performed as above with the 
addition of 5.23 (151 mg, 1 mmol). The stability of 5.11 and 5.12 under current reaction conditions 
were also determined in the control experiments in the absence of 5.7 and 5.23 by TLC analysis 
every 24 hours. The result from TLC analysis showed that 5.11 and 5.12 were stable with single 
spot being observed.  
At the conclusion of the reactions, the solvents were removed under reduced pressure to provide 
products adsorbed onto silica that were purified by flash chromatography (hexane/EtOAc from 9:1 
to 0:10) Compounds 5.13, 5.14, 5.15 and 5.16 were isolated. Compounds 5.17, 5.18, 5.19, 5.20 
remained as an intractable mixture in EtOAc fraction which was separated by RPHPLC using a 
gradient from 38% MeOH in water to 53% MeOH over 15 min then increasing to 65% MeOH in 25 
min and holding at 65% MeOH for 10 min.  
2-(3-Indolyl)-2-phenylethanol (5.13):  White solid (189.6 mg, 80%), Rf 0.44 (TLC 50% hexane/ 
EtOAc), Rt (GC) 5.22 min, mp 98-100 °C, UV (methanol) λmax 229 nm, GCMS m/z 237 (M
+
), m/z 
206 [M-CH2OH]
+.
, ESIMS m/z 260.1 [M+Na]
+
, m/z 276.1 [M+K]
+
, HRESIMS m/z 260.1053 
[M+Na]
+
 (calcd for C16H15NNaO, 260.1046) 
2-(1-Indolyl)-2-phenylethanol (5.14): White solid (4.0 mg, 1.7%) Rf 0.64 (TLC 50% 
hexane/EtOAc), Rt (GC) 4.2 min, UV (methanol) λmax 220 nm, GCMS m/z 237 (M
+
), ESIMS m/z 
260 [M+Na]
+
, 276 [M+K]
+
, HRESIMS m/z 260.1056 [M+Na]
+
 (calcd for C16H15NNaO, 260.1046). 
2-(2-Indolyl)-2-phenylethanol (5.15): White solid (16.1 mg, 6.8%), Rf 0.56 (TLC 50% hexane/ 
EtOAc), Rt (GC) 5.0 min, UV (methanol) λmax 224 nm, GCMS m/z 237 (M
+
), ESIMS m/z 260 
[M+Na]
+
, 276 [M+K]
+
. 
2,2’’-(Indole-1’,7’-diyl)bis(2-phenylethanol) (5.16): White solid (17.4 mg, 4.5%), mp 118 °C, Rf 
0.3 (TLC 50% hexane/EtOAc), Rt (GC) 11.42 min, UV (methanol) λmax 222 nm, GCMS m/z 357 
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(M
+
), ESIMS m/z 380 [M+Na]
+
, 396 [M+K]
+
, HRESIMS m/z 380.1628 [M+Na]
+
 (calcd for 
C24H22NNaO2, 380.1621).  
 2,2’’-(Indole-1’,3’-diyl)bis(2-phenylethanol) (5.19): White solid (3.6 mg, 1%), Rf 0.4 (TLC 50% 
hexane/EtOAc), Rt (GC) 10.0 min,  tR (RPHPLC) 15.2 min, UV (methanol) λmax 224 nm, GCMS 
m/z 357 (M)
+
, ESIMS m/z 380 [M+Na]
+
, 396 [M+K]
+
, HRESIMS m/z 380.1616 [M+Na]
+
 (calcd for 
C24H22NNaO2, 380.1621).  
2,2’’-(Indole-3’,6’-diyl)bis(2-phenylethanol) (5.18): Yellow solid (3.5 mg, <1%), Rf ) 0.44 (TLC 
50% hexane/EtOAc, Rt (GC) 14.6 min, tR (RPHPLC) 16.8 min, UV (methanol) λmax 229 nm, 
GCMS m/z 357 (M
+
), 326 (M-CH2OH), 295 (M-2CH2OH), ESIMS m/z 380 [M+Na]
+
, 396 [M+K]
+
, 
HRESIMS m/z 380.1611 [M+Na]
+
 (calcd for C24H22NNaO2, 380.1621).  
2,2’’-(Indole-2’,3’-diyl)bis(2-phenylethanol) (5.20): Yellow solid (3.3 mg, <1%), Rf 0.43 (TLC 
50% hexane/EtOAc), Rt (GC) 9.8, tR (RPHPLC) 18.6 min, UV (methanol) λmax 229 nm, GCMS m/z 
357 (M
+
), ESIMS m/z 380 [M+Na]
+
, 396 [M+K]
+
, HRESIMS m/z 380.1619 [M+Na]
+
 (calcd for 
C24H22NNaO2, 380.1621). 
2,2’’-(Indole-3’,5’-diyl)bis(2-phenylethanol) (5.17): Yellow solid (4.2 mg, 1.2%), Rf 0.42 (TLC 
50% EtOAc/hexane), Rt (GC) 9.2 min, tR (RPHPLC) 19.5 min, UV (methanol) λmax 229 nm, GCMS 
m/z 357 (M
+
), 326 (M-CH2OH),  295 (M-2CH2OH), ESIMS m/z 380 [M+Na]
+
, 396 [M+K]
+
, 
HRESIMS m/z 380.1608 [M+Na]
+
 (calcd for C24H22NNaO2, 380.1621). 
5.4.2.2 Reaction of imidazole with styrene epoxide in the presence and absence of 
guanine 
The reaction between of 5.11 (68 mg, 1 mmol) and 5.7 (360 mg, 3 mmol) was performed in 6 mL 
DCM/CHCl3 (1:1) under Ar gas in the presence of silica (1 g) at 37 °C for 1 week.  The competition 
reaction was performed under the same conditions with the addition of 5.23 (151 mg, 1 mmol). At 
the end of the reaction the solvent was removed, isolated 3.7 and its polymers by extracting with 
ether, then a mixture of products was isolated from column chromatography using AcOEt/MeOH 
(9:1) as the eluting solvent. These two compounds, 5.21 and 5.22, were separated by RPHPLC 
using an isocratic elution solvent method (35% MeOH /H2O) and a flow rate of 4 mL/min. 
2-(Imidazole-1-yl)-1-phenylethanol (5.21), White solid (39.5 mg, 21%), Rf 0.27 (TLC 90% 
EtOAc/MeOH), (GC) 2.77 min, tR (RPHPLC) 15.94 min, mp 138 °C, UV (methanol) λmax 270 nm, 
GCMS m/z 188 (M
+
), 82 (M-C7H6O), ESIMS m/z 189.1 [M+H]
+
, HRESIMS m/z 189.1027 [M+H]
+
 
(calcd for C11H12N2O, 189.1022). 
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2-(Imidazole-1-yl)-2-phenylethanol (5.22), White solid (43.2 mg, 23%), Rf 0.27 (TLC 90% 
EtOAc/MeOH), tR (RPHPLC) 17.23 min, Rt (GC) 2.85 min, UV (methanol) λmax 212 nm, GCMS 
m/z 188 (M
+
), 157 (M-CH2OH), ESIMS m/z 189 [M+H]
+
), HRESIMS m/z 189.1025 [M+H]
+
 (calcd 
for C11H12N2O, 189.1022). 
5.4.2.3 Reaction of 5.23 with 5.7 
Method A: Silica (1g) was suspended in a mixture of 50% CHCl3 and 50% CH2Cl2 and 5.23 (151 
mg, 1 mmol) and 5.7 (360 mg, 3 mmol) were added and incubated under Ar gas at 37 °C for a 
week. The crude reaction mixture was then dried under nitrogen gas, resuspended in 
methanol/DCM (3:7) and filtered, dried and then resuspended again in methanol/water (7:3). This 
methanol solution was extracted with hexane to eliminate compound 5.7 and its polymers. 
Method B: Compound 5.23 (151 mg, 1 mmol) of and 5.7 (360 mg, 3 mmol) were dissolved in 
ethanol : water (1:1) at 37 °C under Ar gas and allowed to react for one week (method based on 
published procedure of Wolfgang and Michael
237
). The crude reaction mixture was dried under 
nitrogen gas before being redissolved in 70% methanol and extracted with hexane to eliminate 
compound 5.7 and its polymers. 
The methanol fractions from both methods were filtered for HPLC analysis. The mobile phases 
were gradients of 0.1% TFA in water (solvent A) and 0.1% TFA in MeCN (solvent B) and the 
stationary phase was a Grace Vydac C18 monomeric, 120 Å column (250 x 4.6 mm). The UV 
detector was set at 214 and 257 nm and the analytical RPHPLC elution gradient began at 18% B for 
10 min, increasing to 20% B over 20 min and continuing to 50% B over the next 10 min.  At this 
point the solvent was held at 50% B for 10 min before increasing to 90% B in 10 min and held for 
10 min. A fraction collected at 28.7 min was subjected to further resolution by RPHPLC (isocratic 
conditions of 8% B) to give two compounds, 5.25 and 5.26. Ten other minor products were 
collected from the initial HPLC purification in the later part of the HPLC spectrum (Figure 5.6). 
The same products were detected in from two different methods however, the total yield of 25% 
obtained from method B was more than double that obtained from method A (11% yield).  
8-(2-Hydroxy-2-phenylethyl)guanine (5.24): White solid (1.9 mg, 1%), tR (RPHPLC) 27.8 min, 
1
H NMR (500 MHz, (CD3)2OS) δH  4.09 (dd, J = 4.0, 13.5 Hz, H1a‘), 4.12 (dd, J = 8.5, 13.5 Hz, 
H1b‘), 4.92 (dd, J = 4.0, 8.5 Hz, H2‘), 6.67 (brs, NH2-C2), 7.28-7.36 (m, Ph), 8.14 (brs, NH-C8), 
10.67 (s, NH-C6), 
13
C NMR obtained from HSQC and HMBC spectra (500 MHz, (CD3)2OS) δC 
50.3 (C1‘), 70.3, (C2‘), 125.8 (C4‘), 127.6 (C6‘), 128.1 (C5‘), 142.0 (C3‘), UV (methanol) λmax 278 nm, 
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ESIMS m/z 272 [M+H]
+
, HRESI-MS m/z 272.1150 [M+H]
+
 (calcd for C13H14N5O2, 272.1142), 
294.0961 [M+Na]
+
 (calcd for C13H13N5O2Na, 294.0966), 301.0710 [M+K]
+
 (calcd for 
C13H13N5O2K 301.0701).  
7-(2-Hydroxy-1-phenylethyl)guanine (5.25): White solid (2.8 mg, 1.5%), tR (RPHPLC) 10.9 min, 
1
H NMR (500MHz, (CD3)2OS) δH  4.22 (dd, J = 9.0, 13.0 Hz, H1a‘), 4.45 (dd, J = 3.5, 13.0 Hz, 
H1b‘), 4.96 (dd, J = 3.5, 9.0 Hz, H2‘), 6.79 (brs, NH2-C2), 7.35-7.39 (m, Ph), 8.46 (brs, H8), 
13
C 
NMR obtained from HSQC and HMBC spectra (500 MHz, (CD3)2OS) δC 54.4 (C1‘), 70.8, (C2‘), 
125.6 (C4‘), 127.6 (C6‘), 128.2 (C5‘), 140.9 (C3‘), UV (methanol) λmax 278 nm, ESIMS m/z 272 
[M+H]
+
, HRESIMS m/z 272.1148 [M+H]
+
 (calcd for C13H14N5O2, 272.1142).  
7-(2-Hydroxy-2-phenylethyl)guanine (5.26): White solid (2.9 mg, 1.5%), tR (RPHPLC) 11.5 min, 
1
H NMR (500MHz, (CD3)2OS) δH  4.00 (dd, J = 5.5, 12.0 Hz, H1a‘), 4.22 (dd, J = 9.0, 12.0 Hz, 
H1b‘), 5.46 (dd, J = 5.5, 9.0 Hz, H2‘), 6.39 (brs, NH2-C2), 7.25-7.33 (m, Ph), 8.02 (brs, H8), 
13
C 
NMR obtained from HSQC and HMBC spectra (500 MHz, (CD3)2OS) δC 59.5 (C2‘), 62.4, (C1‘), 
126.7 (C4‘), 127.6 (C6‘), 128.4 (C5‘), 138.2 (C3‘), UV (methanol) λmax 278 nm, ESIMS m/z 272 
[M+H]
+
, HRESI-MS m/z 272.1143 [M+H]
+
 (calcd for C13H14N5O2, 272.1142). 
Table 5.10: Ten minor products created from the reaction between 5.23 and 5.7 collected from RPHPLC. 
Compounds Rt (RP-HPLC) 
(min) 
LRESI-MS 
[M+H]
+
 
HRESI-MS (calcd) 
[M+H]
+
 
HRESI-MS (found) 
5.39 39.36 392 392.1717 392.1707 
5.40 40.80 392 392.1717 392.1715 
5.41 41.24 392 392.1717 392.1719 
5.42 42.00 392 392.1717 392.1710 
5.43 42.39 392 392.1717 392.1724 
5.44 43.08 392 392.1717 392.1711 
5.45 48.89 512 -- -- 
5.46 49.15 512 -- -- 
5.47 49.76 512 -- -- 
5.48 50.32 512 -- -- 
5.4.2.4 The reaction of styrene epoxide with bile pigments  
In these experiments, each BPs (5.9, 5.10, 5.8) (0.1 mmol) was added to a 100 ml flask containing a 
50/50 mixture of CHCl3 and CH2Cl2 (50 mL), 5.7 (0.3 mmol) and silica (10 mg). The reactions 
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were placed under Ar gas and incubated for a week at 37 °C. The control and the competitive 
reactions were also performed under the same conditions. The products of the experiments were 
isolated by flash chromatography using hexane/EtOAc/MeOH (from 9:1:0 to 0:10:0 then 0:8:2, in 
v/v) then DCM/MeOH (from 10:0 to 7:3) and finally toluene/acetone (from 10:0 to 5:5) as eluting 
solvents. Compounds 5.27, 5.28, 5.29, 5.30, 5.31, 5.32 were isolated.   
Products from reaction of protoporphryn and styrene epoxide 
Compounds 5.29 and 5.30 were isolated as a red solid (15 mg, 22%) which was an inseparable 
mixture that the compounds were visible as a broad spot on thin layer chromatography, Rf 0.16-0.28 
(TLC, EtOAc) but gave one set of 
1
H NMR signals (Table 3.8), UV (methanol) λmax 400 nm, 
ESIMS m/z 683 [M+H]
+
, HRESIMS m/z 683.3237 [M+H]
+
 (calcd for C42H43N4O5, 683.3228).   
Compound 5.32 presented as a red solid (7 mg, 8.7%), Rf 0.57-0.67 (TLC EtOAc), UV (methanol) 
λmax 399 nm, ESIMS m/z 803 [M+H]
+
, HRESIMS m/z 803.3785 [M+H]
+
 (calcd for C42H43N4O5, 
803.3803), 825.3602 [M+Na]
+
 (calcd for C42H43N4O5, 825.3623). 
Products from reaction of biliverdin and styrene epoxide 
Compounds 5.27, 5.28 were isolated as a green solid (14 mg, 20%) which is assumed to be an 
inseparable mixture of compounds that give identical 
1
H NMR proton data (Table 5.8), Rf (100% 
EtOAc) 0.41-0.48, UV (methanol) λmax, nm: 381, ESIMS m/z 703 [M+H]
+
, HRESIMS m/z: [M+H]
+
 
calcd for C41H43N4O7, 703.31263; found, 703.31419).  
Compound 5.31 was isolated as a green solid (10 mg, 12%), Rf 0.68-0.75 (TLC EtOAc), UV 
(methanol) λmax 380 nm, ESIMS m/z 823 [M+H]
+
, HRESIMS m/z 823.3686 [M+H]
+
 (calcd for 
C49H51N4O8, 823.3701). 
Four minor inseparable and unstable products from the reactions of 5.8 (PRO) and 5.10 (BV) with 
5.7 were detected on UV (methanol) λmax 400 nm, ESIMS m/z 923.4 [M+H]
+
, 921.4 [M-H]
-
, m/z 
1043.5 [M+H]
+
, 1041.4 [M-H]
-
 and m/z 943.4 [M+H]
+
, 941.4 [M-H]
-
; m/z 1063.5 [M+H]
+
, 1061.5 
[M-H]
- 
respectively (Figure 5.15 and Figure 5.16). The reaction between 5.9 (UCB) and 5.7 also 
produced eight very unstable components possessing ESIMS m/z 701.5 [M-H]
-
, 703.4 [M-H]
-
, 
821.5 [M-H]
-
, 823.5[M-H]
-
, 941.5 [M-H]
-
, 943.5[M-H]
-
, 1061.5[M-H]
-
, 1063.4[M-H]
-
 (Figure 
7.25).  
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Figure 5.15: ESIMS spectrometry of two minor products in positive ion obtaining from the reaction between 5.8 and 
5.7. 
 
Figure 5.16: ESIMS spectrometry of two minor products in positive ion obtaining from the reaction between 5.10 and 
5.7. 
5.4.2.5 Reactions between dimethyl ester of BPs with SO 
The dimethyl esters of BPs (5.33, 5.34, 5.35) (0.01 mmol) were treated with 5.7 (0.03 mmol) under 
the conditions outlined above. The products were purified by flash chromatography and ESIMS/MS 
method was applied to identify the products. While neither no product of 5.33 and 5.7 was found 
nor the majority was not decomposed, more than half of 5.34 was decomposed and very small 
mixture of products (m/z 731 [M+H]
+
, 851 [M+H]
+ 
and 971[M+H]
+
 and polymers of 5.7) (See 
Figure 7.24 of appendix-D ) were found detected by ESIMS. In contrast, the reaction between 5.35 
and 5.7 occurred quite efficiently with at least three unstable components were detected. The main 
product had violet colour in methanol, UV (methanol) λmax 337 nm, m/z 733.2 [M+H]
+
, 755.2 
[M+Na]
+
, ESIMS m/z 853.3 [M+H]
+
 or 875.3 [M+Na]
+
, 891.2 [M+K]
+
 and ESIMS m/z 973.3 
[M+H]
+
 (Figure 5.17 and Figure 5.18). In the competitive reactions with the presence of 5.23, the 
products of 5.23 were not detected while the products of dimethyl ester of BPs and 3.7 were found. 
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Figure 5.17: ESIMS spectrometry of the first fraction that was collected from the reaction between 5.35 and 5.7. 
 
Figure 5.18: ESIMS spectrometry of the second fraction that was collected from the reaction between 5.35 and 5.7. 
5.4.2.6 Substituted dipyrroles and substituted pyrroles with styrene epoxide 
The synthetic compounds 5.36, 5.37, 5.38, 5.39 were reacted with 5.7 under the condition described 
above. The mixtures were monitored by TLC every 24 hours for up to a week. The appearance of a 
new compound at Rf 0.32 was observed, compared to 0.35 belonging to compound 5.38 in 100% 
EtOAc. The solvents were removed before column chromatography using EtOAc and hexane as the 
eluting solvents, and ESIMS was applied to detect the new product m/z 523.2 [M+Na]
+ 
(Figure 
5.21). Although no a formation product between compound 5.36 and 5.7 was detected, the starting 
material (5.36) was decomposed in the presence of 5.7. Compound 5.37 and 5.39 reacted with 5.7 to 
produce minor unstable 2 unit-SO products, ESIMS m/z 469 [M+H]
+
 and m/z 497 [M+H]
+
 
respectively (Figure 5.19 and Figure 5.20). 
 
Figure 5.19: ESIMS spectrometry of a product obtained from the reaction between 5.37 and 5.7. 
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Figure 5.20: ESIMS/MS spectrometry of a product obtained from the reaction between 5.39 and 5.7. 
 
Figure 5.21: ESIMS spectrometry of a product obtained from the reaction between 5.38 and 5.7. 
5.4.2.7 The competition reactions  
Compounds of 5.8 (PRO), 5.9 (UCB), 5.10 (BV), 5.11, 5.12, 5.33, 5.34, 5.35, 5.36, 5.37, 5.38 and 
5.39 were incubated with 5.7, silica in the presence of guanine (5.23) at 37 ᵒC in CHCl3/DCM (1:1) 
for a week. The reaction mixtures were examined by TLC every 24 hours. The mixtures were 
separated by column chromatography using the same method as each above compounds reacting 
with 5.7. The fractions obtaining after purification were analysed by GCMS, ESIMS, RPHPLC and 
1
H NMR to determine the products of each compound with 5.7. No products of the reaction of 5.7 
with 5.23 were detected and all products isolated were identical to those isolated from the reactions 
of 5.7 and the test compounds in question in the absence of 5.23.   
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Chapter 6: Exploring the inhibitory effects of endogenous bile pigments on 2-Amino-1-
methyl-6-phenylimidazo[4,5-b]pyridine and Benzo[α]Pyrene metabolic activation by 
cytochrome P450 enzymes 
6.1 Introduction 
Benzo[α]pyrene (6.1, BP), a polyaromatic hydrocarbon found in coal tar, automobile exhaust 
fumes, cigarette smoke, cooked meat products and charbroiled food
246-248
, is classified as a Group 1 
carcinogen by the International Agency for Research on Cancer (IARC)
103
. The carcinogenicity of 
6.1 is attributed to its oxidation to benzo[α]pyrene diol epoxide (6.3), a reaction catalysed by 
cytochrome P450 1A (CYP1A1), CYP1B1 (reviewed in Badal et al.
221
) and CYP3A
222,223
 (Figure 
6.1). Benzo[α]pyrene diol epoxide is highly carcinogenic, attacking guanine residues in DNA, 
generating DNA adducts and genetic damage in cells, which can lead to the development of lung 
cancer.
104,249,250
 The afore-mentioned CYP enzymes are also known to catalyse the hydroxylation of 
2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (6.4, PhIP), the most abundant heterocyclic 
amine in food which has also been classified by IARC as a Group 2B carcinogen,
103
 leading to the 
formation of 4‘-hydroxy of 6.4 and N2-hydroxy of 6.4 (6.5) (Figure 6.1). There is also strong 
evidence to support the harmful effects of 6.5 in human cells, which are linked to the development 
of cancer.
127,251-253
 Generally, the metabolism of 6.1 and 6.4 produces highly reactive metabolites 
that form DNA adducts that can result in the transformation of a cell into a cancer cell.
127,221
  
 
Figure 6.1: Metabolism of 6.1 and 6.4 by P450 enzymes leading to the formation of macromolecular adducts with 
DNA.
127,221,223
  
Potential endogenous bile pigments (BPs), such as protoporphyrin IXα (6.6, PRO), Uncojugated 
bilirubin IXα (6.7, UCB) and biliverdin IXα (6.8, BV) effectively inhibit bacterial DNA mutation 
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upon exposure to environmental mutagens, such as 6.1 (BP) and 6.4 (PhIP), and oxidative 
stress.
14,15,19,20,186
 Furthermore, recent studies report that 6.7 (UCB) is a potent inhibitor of 
cytochrome P450 2A activities,
30,254
 which is also known to contribute to the activation of some 
environmental carcinogens
36,255,256
. Bulmer et al.
14
 used the S9 fraction of rat liver homogenate and 
bacterial cultures to test the anti-mutagenic properties of 6.7 (UCB) and 6.8 (BV) and showed that 
both compounds efficiently inhibited revertant growth. Investigators from the same group later 
tested the anti-mutagenic effects of a wide range BPs including 6.7 (UCB), 6.8 (BV) and 6.6 (PRO) 
and reported that they potentially inhibited food derived mutagens (aflatoxin B1 and 6.4) induced 
mutation.
19
 Despite these encouraging observations, the mechanisms contributing to BPs anti-
mutagenic effects remain unknown. Interestingly, 6.7 (UCB) has recently shown to be an 
endogenous substrate for CYP2A enzymes.
30,254
 In studies using recombinant human CYP2A6 
protein and mouse liver microsomes with induced CYP2A5 activity, 6.7 (UCB) inhibited CYP2A-
dependent hydroxylation of coumarin by almost 100% with a Ki value in the range of the Km for 
coumarin (0.5 to 2.5 µM).
30,254
Incubation of recombinant CYP2A6 and CYP2A5 with 6.7 (UCB) in 
the presence of NADPH produced 6.8 (BV) and some dipyrroles.
30,254
 Bilirubin IXα (6.7, UCB) 
also interacts with key amino acid residues within the CYP2A6 active site.
30 
Collectively, these 
observations indicate that 6.7 (UCB) is a high affinity substrate of CYP2A. Interestingly, 6.7 (UCB) 
maximally inhibited CYP1A1 and CYP1A2 activities by 30%.
43
 CYP1A1 and 1A2 catalyse the 
activation of 6.4 (PhIP) to mutagenic 6.5 and 6.1 (BP) to 6.2 and 6.3,221 whilst CYP2A6 catalyses 
the transformation of 6.9 to mutagenic AFB1-8,9-epoxide.
257 
Another human P450 catalysing the N-
hydroxylation of 6.4 (PhIP) is CYP1B1. Given that the active site cavities of CYP1A2 and CYP1B1 
are 50% larger than that of the CYP2A6,
258 
and that the CYP1A activity is partially inhibited by 6.7 
(UCB),
[25] 
it is plausible that 6.7 (UCB) and other BPs potentially inhibit activation of 
procarcinogens by these CYP enzymes. Thus, the aims of this study were to explore the potential of 
6.6 (PRO), 6.7 (UCB) and 6.8 (BV) to inhibit the activation of mammalian liver S9 fractions on 
procarcinogenic mutagens (6.4 and 6.1). 
 
                 6.6 (PRO)                     6.7 (UCB)                                 6.8 (BV) 
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6.2 Results and discussion 
6.2.1 In vitro metabolism of 6.4 (PhIP) and 6.1 (BP) by a human liver S9 fraction 
Optimization of incubation parameters with the human liver S9 fraction  
The activation of procarcinogens (6.1, 6.4) by human cytochrome P450 enzymes has been 
extensively studied, with most research focusing on CYP1A1, CYP1A2, CYP3A4 and 
CYP1B1,
127,221,252
 which are also contained within the human liver S9 fraction. As a general rule for 
most biochemical reactions, the longer an enzyme is incubated with its substrate and necessary co-
factors, the greater the amount of products is formed.
259
 Many in vitro studies investigating 
cytochrome P450 metabolism have been performed by using incubation periods varying from 10 to 
60 min.
30,254,260-270
 In general, the incubation time chosen depend upon enzyme used, temperature 
and pH of the environment. Therefore, it is necessary to determine the most efficient incubation 
time for the human liver S9 enzymes for use in future metabolism and inhibition experiments in our 
laboratory. In an effort to determine the most efficient incubation period of 6.4 (PhIP) and 6.1 
(BP) metabolism by the human liver S9 fraction, experiments were conducted under the same 
conditions (see Section 6.3 experimental for details) and samples were taken at baseline (0 min) and 
every 15 min for 45 min to analyse the presence of 6.4 (PhIP) and 6.1 (BP).   
Figure 6.2 shows a distinct 6.1 (BP) peak in baseline samples (tR 13.8 min) which decreased over 
time to a point where the peak was almost undetectable after 45 min of incubation. At 15 min of 
incubation, the metabolism of the 6.1 (BP) peak coincided with the appearance of a smaller peak 
(tR 11.7 min), which then decreased after 30 min of incubation. The new product (tR 11.7 min) was 
hypothesized to be a more polar metabolite of 6.1 given the shorter retention time in RPHPLC. It is 
plausible that this peak represented that of benzo[a]pyrene-9,10-diol or benzo[]pyrene -7,8-
diol,
271,272
 which are oxidized further to more polar compounds (such as benzo[α]pyrene-7,8,9,10-
tetraol) formed from 6.1 (BP) by CYPs. 95,104,271,272 
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Figure 6.2: Overlay of the HPLC chromatograms of 6.1 (BP) analysis from metabolism experiments with the human 
liver S9 fraction from 0-45 min, λmax 317 nm. 
A similar metabolism profile was observed when 6.4 (PhIP) was incubated with human liver S9 
(Figure 6.3). The area of the 6.4 (PhIP) peak (tR 21.4 min) was reduced considerably after 30 min of 
incubation. Although nearly 100% of 6.4 (PhIP) was metabolized, these metabolites (presumably 
6.5 and 4‘-OH of 6.4) could not be detected at λmax 317 nm. It is also plausible that the metabolites 
were conjugated by glucuronidases, that are present in the human liver S9 fraction, to more polar 
products and were eluted with three more polar components (NADPH, glucose 6-phosphate, 
glucose 6-phosphate dehydrogenase).
252,273
 Therefore, may exist below the limit of detection of the 
HPLC used.
 
The metabolism rate of 6.1 (BP) and 6.4 (PhIP) reduced significantly with time, being greatest for 
each compound in the first 15 min (Table 6.4), and still occurring at a significant rate in the 
following 30 min (see Figure 6.2). These data suggest that the most appropriate incubation time for 
the experiments would be between 15 and 30 min. Therefore, to maximise metabolism and reduce 
experimental variability, the inhibition of metabolism experiments were performed over 20 min, 
which is also consistent with other similar studies.
30,254,265 
 
 
 
6.1- 45 
min 
6.1- 30 
min 
6.1- 15 
min 
6.1- 0 min 
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Table 6.1: Time-course of the in vitro degradation of 6.1 and 6.4 by human liver S9 (n = 3). 
Time 
(min) 
Rate of 6.1 metabolism 
(pmol/mg protein/min) 
Rate of 6.4 metabolism 
(pmol/mg protein/min) 
0-15 475 ± 16 309 ± 19  
15-30 172 ± 15 153 ± 13 
30-45 24 ± 11 67 ± 18 
 
 
 
Figure 6.3: Overlay of the HPLC chromatograms of 6.4 (PhIP) analyses from metabolism experiments with the human 
liver S9 fraction at 0-45 min. 
The next parameter to be optimized was the concentration of 6.1 (BP) and 6.4 (PhIP) to be used in 
the inhibition experiments. Under the optimised incubation conditions, the S9 system degraded 6.1 
(BP) and 6.4 (PhIP) (Figure 6.4). The rates of 6.1 (BP) and 6.4 (PhIP) metabolism were no 
longer linear at concentrations of the substrates above 1μM. The degradation rates of these 
compounds followed simple Michaelis-Menten kinetics. The degradation of 6.1 (BP) was about 
2.5 times faster than that of 6.4 (PhIP), which was reflected in the concentrations at which the 
degradation rate was at half-maximum (Table 6.2). These data indicated that the human liver S9 
fraction was more efficient in degrading 6.1 (BP) and 6.4 (PhIP). 
Based on the data presented in Figure 6.4, the lowest concentration of mutagens yielding the highest 
rate of metabolism was determined to be approximately 1.5 µM. This concentration was therefore 
used during subsequent inhibition experiments. 
6.4- 45 min 
6.4- 30 min 
6.4- 15 min 
6.4- 0 min 
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Figure 6.4: Kinetics of 6.1 (BP) and 6.4 (PhIP) degradation by the human liver S9 fraction after 20 min of incubation 
(n = 3 per concentration). 
Table 6.2: Michaelis-Menten kinetics of 6.1 (BP) and 6.4 (PhIP) degradation by the human liver S9 fraction in the 
period of 20 min, EC50 is the concentration of mutagens at which the degradation rate achieves 50%. 
Compound 
Degradation rate 
(pmol/mg protein/min)  
Concentration at degradation rate 
half-maximum (EC50)(µM)  
6.1 481 0.81 
6.4 185 0.30 
 
Detection methods: Several methods exist to measure the metabolism rate of 6.1 (BP) and 6.4 
(PhIP) and other compounds in the enzyme reactions. For example, Bulmer et al.
18
 used HPLC and 
UV spectroscopy to detect the concentration of mutagens in the experiments. Abu-Bakar et al.
30
 
determined the metabolism rate of coumarin by using spectrofluorometric methods. Mölzer at 
al.
19,20
 determined the concentration of tertiary-butyl hydroperoxide by HPLC methods. In our 
studies, we decided to use RPHPLC fitted with a UV detector set to detect at 317 nm for 6.4 (PhIP) 
and at 385 nm for 6.1 (BP) because of the overlay in the absorbance between the two classes of 
compounds (mutagens and BPs) (Figure 6.5). Measurement of mutagen concentrations using 
standard UV spectroscopic methods alone would provide unreliable results due to BPs absorbing in 
the same region of the spectra as the mutagens and thus any absorbance measurement would have 
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some contribution from the BPs.  Furthermore, the addition of the S9 mix to reactions created 
turbidity which would interfere absorbance measurement using single UV/Vis spectroscopy.  
 
Figure 6.5: Representative overlay of UV spectra of 6.4 (left-blue) and 6.1 (right-red) and its mixtures with various 
concentrations of 6.8. 
6.2.2 Inhibitory effects of bile pigments on 6.1 and 6.4 metabolism in the human liver S9 
To determine whether various BPs (6.6-6.8) could inhibit the degradation of 6.1 (BP) and 6.4 
(PhIP), the human liver S9 fraction was incubated with either 6.1 (BP) and 6.4 (PhIP) (1.5 µM 
final concentration) in the presence of BPs at various concentrations ranging from 1.25 µM to 20 
µM. The concentration range of BPs chosen reflected physiological concentrations of 6.7 in 
blood.
53-55  
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Figure 6.6: Effects of BPs on the degradation of 6.4 in human liver S9 fraction (n = 3). 
In human liver S9 experiments, all three BPs, 6.6 (PRO), 6.7 (UCB) and 6.8 (BV) inhibited the 
degradation of 6.4 (PhIP) in a concentration dependent manner up to a BP concentration of 
approximately 10 µM (Figure 6.6). None of the BPs tested could completely inhibit the reaction. 
The order of effectiveness for inhibition of 6.4 (PhIP) degradation was 6.7 (UCB, 83%) > 6.6 (PRO, 
76%) > 6.8 (BV, 67%) at 10 µM, which was commensurate with the IC50 values of 1.0, 1.33, 1.36 
µM, for the BPs respectively (at these concentrations, 50% of 6.4 (PhIP) degradation was inhibited 
by BPs) (Table 6.3 and Table 7.18 in Appendix-E). 
 
Figure 6.7: Effects of BPs on degradation of 6.1 (BP) in human liver S9 fraction (n = 3). 
By contrast, BPs inhibited the degradation of 6.1 (BP) in a concentration dependent manner up to 
5 µM (Figure 6.7). At 5 µM, 6.7 (UCB) inhibited the degradation of 6.1 (BP) by almost 85%, 
whilst at the same concentration 6.8 (BV) and 6.6 (PRO) inhibited the consumption of 6.1 (BP) by 
48% and 71%, respectively (Figure 6.7). Thus, the order of BPs‘ effectiveness at inhibiting the 
degradation of 6.1 (BP) in human S9 was 6.7 (UCB) > 6.6 (PRO) > 6.8 (BV), which was also 
reflected in the IC50 values of 1.00, 1.00, and 1.43 µM, respectively (Table 6.3). 
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Table 6.3: Potency of BPs inhibitory effects on 6.1 (BP) and 6.4 (PhIP) degradation in the human liver S9 fraction, 
IC50 values were derived from the GraphPad Prism using non-linear regression analysis (see Table 7.18 and Table 7.19 
in Appendix-E) 
Bile Pigments 
IC50 (µM) 
50% inhibition of 6.1 degradation 50% inhibition of 6.4 degradation 
6.6 (PRO) 1.00 1.33 
6.7 (UCB) 1.00 1.00 
6.8 (BV) 1.43 1.43 
 
Based on the IC50 values (Table 6.3), the potency of 6.7 and 6.8 to inhibit 6.1 (BP) and 6.4 (PhIP) 
were similar though 6.6 more potently inhibited the degradation of 6.1 than that of 6.4.  
Overall, these results indicated that the human liver S9 fraction effectively degraded 6.1 (BP) and 
6.4(PhIP). The degradation rates followed simple Michaelis-Menten kinetics, which indicated that 
the degradation of these compounds was enzyme mediated. Importantly, BPs, especially 6.7, 
efficiently inhibited the degradation of 6.1 (BP) and 6.4(PhIP). These inhibition profiles also 
followed Michaelis-Menten kinetics. However, from these experiments it was not possible to 
discern the degree of BPs inhibitory effects on CYP-specific 6.4 and 6.1 metabolism. The human 
liver S9 fraction contains a mixture of CYP isoforms (Table 7.17 in appendix-E) and 
glucuronidases that are also involved in the metabolism of 6.1 (BP) and 6.4(PhIP) and therefore, 
inhibitory effects of BPs may have been non-specific. As these CYPs are known to metabolise 6.1 
(BP) and 6.4(PhIP) to mutagenic intermediates, it is plausible that the observed inhibition of 
degradation was partly a consequence of inhibition of these CYPs. This however, requires 
confirmation within selective inhibition studies using recombinant CYP1A, 1B1, and perhaps 
CYP2A as well as CYP3A4. 
The inhibitory capacity of BPs on the metabolism of 6.1 (BP) has also been reported by Bulmer et 
al.
14 
and Arimoto et al.
35
 who performed their experiments on rat liver S9 and bacteria (Salmonella 
typhinurium TA98 and TA100). While Bulmer et al.
14
 reported that the order of effectiveness 
suggested 6.8 (BV) was more effective than 6.7 (UCB), Arimoto‘s results indicated 6.7 (UCB) was 
more effective compared to 6.8 (BV).
34,35
 Therefore, it is also important to determine the BPs‘ 
ability to inhibit mutagens in rat liver S9.  
Although using a different method to determine the effectiveness of BPs to the degradation of 6.1 
(BP) and 6.4 (PhIP), the results are an important evidence for further research on rat liver S9. 
Chapter VI: Cytochrome P450 enzymes 
123 
 
Indeed, the results showed that the degradation rate of 6.1 and 6.4 in rat liver S9 is higher than that 
of in human liver S9. However, it also indicated the order of inhibitory effectiveness of BPs on 6.1 
and 6.4 was 6.7 (UCB) > 6.6 (PRO) > 6.8 (BV), the order observed with human liver S9. The 
comparison of tested results may provide preliminary evidence to evaluate the action of CYP 
enzymes on the metabolism of 6.1, 6.4 and the inhibitory ability of BPs. 
Table 6.4: Effects of BPs (10 μM) on degradation rate of 6.1 (BP, 1.5 μM) and 6.4 (PhIP, 1.5 μM) in rat liver S9 
fraction (n = 3). 
Samples 
The degradation rate 
of 6.4 (pmol /mg 
protein/min) 
% 
inhibition 
The degradation rate 
of 6.1 (pmol /mg 
protein/min) 
% 
inhibition 
S9+ mutagen 309 ± 19 -- 476 ± 16 -- 
S9+ mutagen + 6.6 151 ± 22 51  306 ± 23 36  
S9+ mutagen + 6.7 128 ± 32 59  240 ± 19 50  
S9+ mutagen + 6.8 205 ± 26 34  417 ± 18 12  
 
Table 6.5: Effects of BPs (10 μM) on degradation rate of 6.1 (BP, 1.5 μM) and 6.4 (PhIP, 1.5 μM) in human liver S9 
fraction (n = 3). 
Samples 
The degradation rate 
of 6.4 (pmol /mg 
protein/min) 
% 
inhibition 
The degradation rate 
of 6.1 (pmol /mg 
protein/min) 
% 
inhibition 
S9+ mutagen 244 ± 22 -- 314 ± 12 -- 
S9+ mutagen + 6.6 66 ± 22 72 74 ± 24 76 
S9+ mutagen + 6.7 54 ± 32 77 41 ± 39 87 
S9+ mutagen + 6.8 95 ± 43 60 173 ± 14 45 
 
Multiple hypotheses exist to explain the inhibitory effects and order of effectiveness of BPs towards 
6.1 (BP) and 6.4 (PhIP) mutagenesis (6.7 > 6.6 > 6.8). Compound 6.7 (UCB) may possess the 
most potent inhibitory effect on the metabolism of 6.1 (BP) and 6.4 (PhIP) due to unique physico-
chemical properties, which results in the formation of a ‗ridge-tile‘ structure. Furthermore, four 
different isomers of 6.7 (UCB) exist in an equilibrium mixture, the formation of which is induced 
by photo-isomerization, (4E, 15E)-, (4Z, 15E)-, (4E, 15Z)- and (4Z-15Z)-bilirubin IXα (Figure 
6.8).
58-60
 The most stable isomer is bilirubin IXα (4Z, 15Z), in which six intramolecular hydrogen 
bonds are formed between carboxylic acid and amide pyrrole N-H groups. The intramolecularly 
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hydrogen-bonded conformers create a ridge-tile shape in the central molecule and form 
enantiomeric conformations (M and P) (Figure 6.9).
58-60,65
 All of 6.7‘s photoisomers exist in 
reversible states that will generate greater efficiency and opportunities for 6.7 (UCB) binding to 
enzyme active sites. In addition, the saturated C10-bridge in the structure of 6.7 (UCB) can rotate 
freely and flex to produce more conformational states which may serve to inhibit (either 
competitively or non-competitively) mutagen metabolism.   
 
Figure 6.8: Configurational photo-isomerisation of 6.7 (UCB), leading to the formation of four isomers (4Z,15Z)-, 
(4E,15Z)-, (4Z,15E)-, (4E,15E). 
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Figure 6.9: The enantiomers of (4Z, 15Z)-bilirubin (P=plus, M=minus) demonstrate the presence of ‗ridge-tile‘ 
conformers via the formation of intramolecular hydrogen bonds.
58,59
 
In contrast, the unsaturated C10-bridge in 6.8 (BV) holds the molecule in an almost planar (4Z, 10Z, 
15Z)-configuration, which is quite stable in the presence of light.
66
 As a result, 6.8‘s structure does 
not allow for intramolecular hydrogen bonding. Biliverdin‘s rigid structure may reduce its ability to 
inhibit 6.1 (BP) and 6.4 (PhIP) metabolism and may not possess the strong binding affinity of 6.7 
(UCB) with enzyme active sites. The hypothesis was supported by Abu-Bakar et al.
30
 who found 
that 6.7 (UCB) was substrate of CYP2A6 and one of its metabolism products was 6.8 (BV). 
Although 6.6 (PRO) did not form photo-isomers, it was a more potent inhibitor of 6.1 (BP) and 
6.4 (PhIP) metabolism than 6.8 (BV). The Different structural shape of Compound 6.6 may be easy 
to be metabolised by enzymes or interact efficiently with enzymes. In addition, the four nitrogens in 
6.6 (PRO) are sufficient for forming stable complexes with metal ions.
274,275
 The special structure of 
6.6 (PRO) therefore, may result in unique interactions with enzymes active sites that are stronger 
than 6.6 (PRO), but weaker than 6.7 (UCB).  
6.2.3 Docking simulation of 6.1, 6.4 and BPs on CYP1A1, 1A2 and 1B1 active sites 
Many studies indicated that CYP1A1, 1A2, 3A4 and 1B1 are responsible for the metabolism of 6.1 
(BP) and 6.4 (PhIP).127,221,252 CYP1A2 and 3A4 are known to be present in the human liver S9 
fraction and CPY1A1 and 1B1 are hypothesized to be present in the extract (Table 7.18 and Table 
7.19 in appendix-E). Therefore, the molecular docking of BPs, 6.1 (BP) and 6.4 (PhIP) with 
CYP1A1(4I8V)
258
, 1A2(2HI4)
276
, 3A4(4NY4)
277
 and 1B1(3PM0)
278
 was under taken crystal 
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structures of the protein data bank (PDB) to attempt to explain the inhibitory ability of BPs towards 
6.1 (BP) and 6.4 (PhIP) metabolism (Figure 6.10 and Figure 6.11). 
Table 6.6: Active site amino acid residues of human CYP 1A2
258
, 1A1
258
, 3A4
277
 and 1B1
27,58
, Amino acid residues 
that are conserved in all four P450s are shown. Residues that interact with 6.1 are highlighted using a grey background. 
P450 1B1
258,278
 P450 1A1
258
 P450 1A2
258
 P450 3A4
277
 
Ile
117
 Ile
115
 Val
126
 Phe
215
 
Thr
118
 Ser
116
 Ser
127
 Phe
108
 
Ser
122
 Ser
120
 Val
395
 Arg
106
 
Thr
124
 Ser
122
 Ala
133
 Arg
105
 
Phe
125
 Phe
123
 Phe
134
 Ser
119
 
Asn
223
 Asn
255
 Asn
228
 Ile
120
 
Phe
226
 Phe
224
 Phe
231
 Ala
370
 
Asn
257
 Leu
496
 Asp
333
 Ile
301
 
Phe
260
 Gly
316
 Thr
334
 Ala
305
 
Asp
320
 Phe
258
 Asn
265
 Thr
304
 
Thr
321
 Leu
312
 Phe
268
 Thr
309
 
Leu
382
 Asp
313
 Leu
509
 Arg
212
 
Leu
497
 Asn
222
  Ile
369
 
 Phe
319
  Phe
213
 
 Asp
320
  Phe
241
 
 Thr
321
   
Table 6.6 shows the amino acid sequence of the binding site of 6.1 (BP) and BPs in CYP1A1, 
1A2, 3A4 and 1B1 predicted in the docking studies. Most of the amino acids within the active site 
were the same as those reported by Walsh and Tian
222,258
 and Bronden
277
 who reported a crystal 
structure of a complex of CYP3A4 with an aromatic molecule bound in the active site.
277
 A small 
number of amino acids were not detected in our simulations (Figure 6.9 and Figure 6.10) because 
the residue distance in our docking simulations was set to only 4 Å from the ligand. 
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Table 6.7: A comparison of the active site residues of CYP1A2 found within a range of 4 Å distance from ligands 
docked into the active site (Figure 6.10, Figure 6.14). The grey background shows the same amino acids residues 
of the active site were found in the docking of CYP 1A2 with α-naphthoflavone.276 
6.1, 6.4 and BPs (within a range of 4Å from ligands to amino acid residues of 1A2) 
CYP1A2 (6.1) CYP1A2 (6.4) CYP1A2 (6.7) CYP1A2 (6.8)
 
CYP1A2 (6.4) 
Phe-260 Phe-260 Phe-260 Phe-260 Phe-260 
Phe-226 Phe-226 Phe-226 Phe-226 Phe-226 
Val-227 Val-227 Val-227 Val-227 Val-227 
Leu-497 Leu-497 Lue 497 Leu-497 Lue 497 
Gly-316 Gly-316 -- Gly-316 Gly-316 
Asp-320 Asp-320 Asp-320 Asp-320 Asp-320 
Thr-498 Thr-498 Thr-498 Thr-498 Thr-498 
Thr-321 Thr-321 Thr-321 Thr-321 Thr-321 
Leu-382 Leu-382 Leu-382 Leu-382 Leu-382 
Ile-386 Ile-386 Ile-386 Ile-386 -- 
Thr-124 Thr-124 Thr-124 Thr-124 Thr-124 
Phe-125 Phe-125 Phe-125 Phe-125 Phe-125 
Asn-312 Asn-312 Asn-312 Asn-312 Asn-312 
Ser-122 Ser-122 Ser-122 Ser-122 Ser-122 
Thr-118 Thr-118 Thr-118 Thr-118 Thr-118 
Ala-317 Ala-317 -- Ala-317 Ala-317 
-- -- Thr-223 Thr-223 Thr-223 
-- -- Val-220 Val-220 -- 
-- -- -- Lys-500 Lys-500 
-- -- Phe-256 Phe-256 Phe-256 
-- -- Leu-219 Leu-219 Leu-219 
-- -- -- Met-216 -- 
-- -- Phe-319 -- -- 
-- -- Asp-313 Asp-313 Asp-313 
-- Ile-117 Ile-117 -- -- 
-- -- -- Asn-257 Asn-257 
-- -- -- -- Arg-108 
-- -- -- -- Leu-123 
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-- -- -- -- Arg-456 
-- -- -- -- Phe-381 
-- -- -- Asn-222 -- 
-- -- -- Phe-315 -- 
-- -- Gly-318 -- -- 
-- -- -- Leu-264 -- 
 
Table 6.7 and the Figure 6.10-Figure 7.27 indicated that the active site residues of CYP1A2, 1A1, 
1B1 and 3A4 that interact with 6.1 (BP) and 6.4 (PhIP) are the same amino acid residues that 
interact with BPs. The interactions between BPs and amino acids in the active site are stronger than 
those of 6.1 (BP) and 6.4 (PhIP) due to more hydrogen bonds forming between carboxylic and 
amides groups. For example, 6.7 (UCB) exhibited hydrogen bonds with Ser-122, Thr-498, Asp-313, 
Asp-320; 6.6 (PRO) had hydrogen bonds with Thr-321, Arg-108, Leu-123; 6.8 (BV) had hydrogen 
bonds with Thr-118, Gly-316 and Asp-320. These stronger interactions may facilitate BPs 
dominating the active site residues of enzymes in competitive reactions with 6.1 (BP) and 6.4 
(PhIP). Similarly, the hydrogen bonds were found in other docking simulations between CYP1A1, 
3A4, 1B1 and BPs (Figure 6.12-Figure 6.14). 
         (b) 
(a
) 
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Figure 6.10: The docking of 6.1 (BP) into the active site of CYP1A1 (a), CYP1B1 (b), CYP1A2 (c) and CYP3A4 (d). 
Simulations were performed using Molegro Virtual Docker. 
 
 
Figure 6.11: The docking of 6.4 into the active site of CYP1A1(a), CYP1B1(b) and CYP1A2(c). Simulations were 
performed using Molegro Virtual Docker. 
Although 6.1 (BP) does not have any polar groups, the docking simulation results show that 6.1 
(BP) bound effectively to the active site of CYP enzymes. There are more than 13 amino acids in 
the active site of CYP1A1 within a distance of 4 Å from 6.1 (BP, Figure 6.10). Similarly, more 
than 18 amino acids in the active site of CYP1A2 and 14 amino acids in CYP1B1‘s active site 
enclosed 6.1‘s surface. Benzo[]pyrene is directed toward iron in the haem complex at a distance of 
less than 4.38 Å for CYP1A and 1B1 enzymes. The short distance between enzyme active site 
(a)
) 
(c) 
(c) 
(b) 
(d) 
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residues and the surface of 6.1 (BP) indicates that 6.1 (BP) has very strong interactions with the 
enzyme active site to facilitate the oxidation of 6.1 (BP) to benzo[a]pyrene -7,8-epoxide and 6.3. 
The interactions of 6.4 (PhIP) with the active site residues of CYP enzymes appear stronger than 
those of 6.1 (BP) due to hydrogen bonds between the nitrogen within the pyridine ring of 6.4 
(PhIP) with Ser-122 in the active site of CYP1A1, Thr-124 of CYP1B1 and Ala-305 of CYP3A4. 
The distance between the haem iron of CYP1A1 and 6.4 (PhiP) was 2.97 Å, 3.90 Å for CYP1B1 
and 4.17 Å for CYP1A2 (Figure 6.11). Interestingly, the NH2 group in 6.4 (PhIP) was the closest 
group to the iron within the haem complex. This amine group is oxidised to the carcinogenic N-
hydroxylated metabolite 6.5 (Figure 6.1).
 127,251-253
  
Molegro Virtual Docker revealed the interactions between amino acids in the active site of 
CYP1A1, 1A2, 3A4 and 1B1 to 6.7 (UCB) showed that 6.7 (UCB) used both its carboxylic acid 
groups and pyrrole nitrogens to form hydrogen bonds and electrostatic interactions with amino 
acids at the active site of the enzymes (Figure 6.12). The docking of 6.6 (PRO) and 6.8 (BV) in the 
active site of CYP1A1, 1A2, 3A4 and 1B1 suggested interactions were mainly by hydrogen bonds 
between carboxylic groups and amino acids (Figure 6.13 and Figure 6.14). Our simulations 
suggested that although BPs possess a larger molecular structure than 6.1 (BP) and 6.4 (PhIP), 
they still could bind with the small active site cavities of CYP1A1, 1A2, 1B1 and 2A6. These 
observations provided evidence to explain the inhibitory action of BPs against 6.1 (BP) versus 6.4 
(BV) metabolisms. 
The cavities of the active sites of CYP1A1 (volume 98.82 Å
3
, surface 291.84 Å
2
)
258
, 1A2 (volume 
74.24 Å
3
, surface 241.92 Å
2
)
276
 and 1B1 (volume 75.26 Å
3
, surface 249.60 Å
2
)
278
 are quite small 
and narrow, and therefore, are difficult for bulky molecules to enter and effectively interact. Due to 
6.7‘s more flexible structure, which accommodates multiple three dimensional conformations,58,59 
this could facilitate 6.7 (UCB) entering the active site and interacting with amino acids. This 
interaction could result in enzyme inhibition. Protoporphyrin possesses a fused macrocycle with a 
narrow surface-unique structure (less steric effect) which could facilitate its movement to the 
enzyme active site. In contrast, 6.8 (BV) has an unsaturated C10-bridge holding its non-planar two 
dipyrrolic halves which creates more steric effect potentially hindering the molecule‘s entry into the 
cavity of the enzyme active site. On this basis, it is not surprising that 6.8 (BV) represents the 
weakest inhibitor. Strong hydrogen bonds and electrostatic interactions forming between carboxylic 
groups of BPs and amino acid residues in the active site also suggest BPs could act as non-
competitive inhibitors. This class of inhibitors does not compete with the substrate for binding to 
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the active site, but rather forms a bond outside of the active site and, in doing so, changes the 
enzymes conformation, thus reducing or increasing the size of the active site. In turn, it may 
influence the affinity of a substrate to the active site. The inhibitor could also dock in the active site 
and reduce the interactions of the active site with substrate.  
        
   
Figure 6.12: The interactions of 6.7 (UCB) with amino acids on the active site of CYP1A1(a), CYP1A2(c), CYP1B1(b) 
and CYP3A4(d). 
(c) 
(b) 
(a) 
(d) 
(d) 
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Figure 6.13: The interactions of 6.6 (PRO) with amino acids in the active site of CYP1A1(a), CYP1A2(c), CYP1B1(b) 
and CYP3A4(d). 
(a) 
(b) 
(c) 
(d) (c) (d) 
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Figure 6.14: The interactions of 6.8 (BV) with amino acids in the active site of CYP1A1(a), CYP1A2(c), CYP1B1(b) 
and CYP3A4 (d). 
 
 
 
 
 
 
 
 
 
 
(c) 
(b) (a) 
(d) 
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6.3 Conclusions  
The ability of BPs to inhibit mutagens (6.1 (BP) and 6.4 (PhIP)) degradation has successfully been 
explored in vitro whilst human and rat liver S9 fractions were employed. Preliminarily data 
indicated the concentrations of 6.1 (BP) and 6.4 (PhIP) that resulted in the saturation of 6.1 (BP) 
and 6.4 (PhIP) degradative enzymes in the S9 mixtures. The results of the inhibition studies indicate 
that 6.7 (UCB) had the greatest inhibitory effect on the metabolism of both 6.1 (BP) and 6.4 
(PhIP), followed by 6.6 (PRO) and then 6.8 (BV).  
Simulated docking studies using published crystal structures of the CYP enzymes known to 
metabolise 6.1 (BP) and 6.4 (PhIP) indicated multiple interactions between the mutagens and the 
BPs (inhibitors) with active site amino acids of the CYPs. This provided new data to suggest that 
BPs could competitively inhibit mutagens binding and thus metabolism. These data largely agreed 
with the in vitro data presented in this chapter, indicating that 6.7 (UCB) was the most potent 
inhibitor of mutagen metabolism.   
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6.4 Experimental 
Material and methods 
The S9 fraction from pooled human and rat liver (Sigma Aldrich, Sydney, Australia; Cat No S2442 
and S2067, Lot number 031M1399 and SLBG4796V, respectively) were used as a source of CYP 
enzymes. Potential inhibition of BPs (Frontier Scientific, USA) to 6.4 (Wako pure chemical 
industries, Japan) and 6.1 (Sigma Aldrich, Sydney, Australia) metabolism was assessed by 
measuring the degradation rate of 6.1 (BP) and 6.4 (PhIP) in the absence and presence of BPs in 
vitro. Phosphate-buffered saline (PBS) 100 mL, 1M, pH 7.4 (stock solution) was created from 8 g 
NaCl (1.37 M), 0.2 g KCl (27 mM), 1.44 g Na2HPO4 (100 mM), 0.24 g KH2PO4 (18 mM). pH of 
PBS was adjusted to 7.4 with HCl and then sterilized by autoclaving for 20 min with steam water at 
120 ºC. The stock NADPH generating system, which increased CYP enzyme activity was prepared 
including fresh NADPH (26 mM), 66 mM glucose 6-phosphate, MgCl2 (5 mM) and eight units/ml 
of glucose 6-phosphate dehydrogenase which was stored at 4 ºC before performing the experiments 
with S9.
259,279
 The human liver S9 fraction was stored at -80 ºC and then warmed to room 
temperature and kept on ice before use for S9 experiments at 37 ºC. 
 The concentrations of BPs and mutagens were calculated using the absorption of UV light (λmax 6.7 
= 450 nm, 6.8 = 375 nm, 6.6 = 409 nm). Analytical reverse phase high performance liquid 
chromatography (RPHPLC) was performed using a Shimadzu CLASS VP LCsolution system and 
software and a Waters 3.5 µm C18 column (150 x 4.6 mm). Compound retention times (tR) were 
obtained using gradient mixtures of MQ-water (solvent A) and MeOH (solvent B-Sigma Aldrich, 
Sydney, Australia) at 1 mL/min. An elution gradient for 6.4 (PhIP) was performed from 30% B to 
70% B over 20 min returning to 30% B for 5 min and held for 5 min. After 5 injections, the HPLC 
analytical column was eluted with 100% B for 1 hour to remove any adsorbed BPs. An isocratic 
mobile phase of 90% B was used to elute 6.1 (BP). Salts, BPs and remaining compounds adsorbed 
to the column were removed by pumping 30% B through the column for 10 min, followed by 
increased concentration of solvent B to 100% in 20 min, followed by washing in solvent B for 
another 1 hour. The eluent was monitored using a wavelength UV detector set at 317 nm for 6.4 
(PhIP) and 385 nm for 6.1 (BP). Low resolution mass spectra were acquired on a Bruker Esquire 
HCT spectrometer (positive and negative ion ESI mode). Kinetics and statistical analysis were 
performed using the Michaelis-Menten Equation and dose-response-inhibition on Graphpad Prism 6 
software (La Jolla, CA, USA). The statistics was performed by the distribution of experimental data 
in around 95% confidence of the curve.  
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Molegro Virtual Docker 4.00 simulated an integrated environment for the prediction and 
examination of the interaction between ligands and crystal structures of the enzymes obtained from 
the protein data bank (PDB). Simulation software required 3D-structures of protein and ligands that 
were downloaded from the protein data bank. Structures of 6.1 (BP), 6.4 (PhIP) and BPs were 
created from X-ray structures or ChemBio3D Ultra 13.0 with MM2 energy minimisation.         
6.4.1 Metabolism of 6.1 and 6.4 in vitro 
Determination of 6.1 and 6.4 concentrations in metabolism experiments  
Experiments were conducted separately using the S9 testing method in which 20 μg of S9 fraction 
(10 μL) was mixed with 190 uL of 100 mM potassium phosphate, pH 7.4, 3.3 mM of MgCl2 1.3 
mM of NADPH 3.3 mM of glucose 6-phosphate and 0.4 U/mL of glucose 6-phosphate 
dehydrogenase. A wide range of 6.1 (BP) and 6.4 (PhIP) concentrations were tested by adding 
stock solution (in DMSO) to the tubes in order to obtain final concentrations of 0.1 μM, 0.25 μM, 
0.5 μM, 1 μM, 2 μM, 3 μM of 6.1 (BP) and 6.4 (PhIP) for each experiment (DMSO concentration 
< 0.2%). The reaction mixtures were incubated at 37 
o
C for 20 min. Control reactions were 
performed using the same method; however 10 μL of distilled water replaced the volume of the S9 
fraction. All experiments were performed in triplicate. The reaction was stopped by adding 200 μL 
of methanol to the reaction mixtures before storage at -20 
o
C. The S9 samples were centrifuged at 
860 g (2800 rpm/min) for 5 min to isolate the cell suspension and the aqueous supernatant was used 
for HPLC analysis.  
Determination of the optimal time to assess metabolism of 6.1 and 6.4  
Experiments were performed using the method described above in the presence of 1.5 μM of 6.1 
(BP) and 6.4 (PhIP). Assay tubes were incubated in 37 ºC and a 200 μL of sample from reaction 
mixtures were taken every 15 min for 45 min. To inhibit the metabolic action of enzymes, 200 μL 
of methanol was added to the samples, which were vortexed and then stored in -20 ºC prior to 
centrifugation and HPLC analysis. All experiments were conducted in triplicate.  
6.4.2 The inhibitory effects of BPs on 6.1 and 6.4 degradation in vitro 
In these experiments, each BP (6.7, 6.7 and 6.6) was added to 200 µL of S9 test mixtures in 7 tubes 
to obtain final BP concentrations of 0, 1.25, 2.5, 5, 10, 15 and 20 µM. All tubes were incubated at 
37 ºC for 20 min, the experiments were stopped by adding 200 μL of MeOH. The supernatant was 
isolated by centrifugation at 860 g for 5 min and stored at -20 ºC prior to HPLC analysis. 
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Chapter 7: Conclusion and future direction 
The studies of physical and chemical interactions between bile pigments (BPs) and polycyclic 
aromatic mutagens, described in the preceding chapters, were successful in determining the 
contributions of physical and chemical interactions on the inhibitory action of BPs on 
environmental mutagens. Each chapter describes in detail the significant findings of this PhD 
project. Chapter I demonstrates background knowledge of special chemical and physiological 
properties of BPs and mutagens. This chapter summarises and evaluates a vast range of studies on 
anti-mutagenic function of BPs. It also explains why our studies are key to understanding biological 
mechanisms occurring in vivo and facilitating future cancer research and drug developments. 
The results presented in Chapter II support our hypothesis that the aggregates forming via π-
stacking interactions leading to the modification of their UV and 
1
H NMR spectra of polyaromatic 
mutagens and BPs were unlikely to occur in biological systems. All the slight modifications of 
1
H 
NMR spectra of BPs and mutagens were determined by the changes in the protonation state of the 
compounds. It is unlikely that physical interactions are a major contributing mechanism to the anti-
mutagenic effects of the BPs. 
However, due to the low water solubility of the compounds, these studies were performed in the 
presence of organic solvents (DMSO, D2O and MeOH) and there remains some uncertainty about 
what might occur in a biological system. Therefore, the study was performed further using a caco-2-
cell monolayer in Chapter III. 
The study was successful in using caco-2 cell monolayer to determine physical interactions between 
2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine (PhIP) and BPs (bilirubin, biliverdin, 
protoporphyrin) or bilirubin dimethyl ester or biliverdin dimethyl ester. The study explored novel 
physical interactions occurring between two aromatic ring systems of PhIP and BPs or BPs 
dimethyl esters. The interactions resulted in a slight change of apparent permeability of PhIP 
through the caco-2 cell monolayer. The higher absorption rate of PhIP in the presence of bilirubin 
suggested that carboxylic groups play an important role in the interactions with the polar surface of 
the caco-2 cell monolayer surface. Therefore, this study leads to the general conclusion that the 
physical interactions between aromatic rings of bilirubin, biliverdin, its dimethyl esters and PhIP 
supported the transport rate of PhIP crossing the cell monolayer. The interactions are a result of the 
formation of aggregations between aromatic rings of BPs with polycyclic aromatic rings of PhIP to 
maximise the exposure of hydrophilic property of the aggregates. The increase of the polarity 
facilitates the excretion of foreign agents from the body. The study also found the presence of 
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protoporphyrin did not affect the apparent permeability of PhIP or the physical interactions between 
the two compounds did not occur or were not strong enough for changing the apparent permeability. 
Chapter IV outlines the previous methods used for synthesis of substituted pyrrole, dipyrroles and 
BPs dimethyl ester. Modification of the synthesis methods in order to obtain high yield of the 
desired products was successful. A number of compounds critical for current studies into the 
chemical reactivity of BPs were synthesised and characterised by 
1
H NMR, 
13
C NMR, 
1
H-
1
H 
COSY, HSQC, HMBC, mp, ESIMS, TLC, GC-MS and UV spectroscopy. The full assignment of 
the 
1
H and 
13
C NMR characteristics of pyrrole, dipyrroles and BPs dimethyl ester will provide 
valuable guidance in NMR studies of BPs and their derivatives. 
A previous finding (described in Chapter III) indicated the minor contribution of anti-mutagenic 
environments belonging to physical interactions between PhIP and BPs or its dimethyl esters. 
Therefore, the investigation of possible chemical reactions between activated mutagens and BPs is a 
focus of our study to elucidate the mechanism of this inhibition (Chapter V). Reactions between 
these two classes of compounds performed in biological systems both in vitro and in vivo produce 
very tiny amounts of products that can only be analysed by MS.
121,122,222,272
 Having a larger amount 
of products for structure analyses has been a challenge for biological studies. Therefore, developing 
and using a mimic of the biological conditions, as well as using more readily available compounds 
as mimics for the biologically generated compounds is a vital strategy in our study into the chemical 
interactions of BPs and mutagens. This study was successful in developing a set of conditions to 
mimic the biological conditions in which we explored some important novel aspects. 
Firstly, indole and imidazole possess higher reactivity to the activated epoxide than guanine. The 
chemical interactions of BPs with styrene epoxide, the epoxide chosen to mimic the reactive 
epoxide metabolites of benzo[a]pyrene (BP) and Aflatoxin B, were investigated. Secondly, our 
studies showed that the carboxylic groups on the BPs were the main sites of reaction with styrene 
epoxide. In addition, the aromatic ring system of BPs may also have made a minor contribution to 
the reaction of styrene epoxide with BPs, which may have contributed to their inhibition of the 
reaction of styrene epoxide with guanine. Our results clearly demonstrated that, under our in vitro 
reaction conditions, indole, imidazole, and all of BPs studied totally inhibited the reaction of styrene 
epoxide with guanine. 
The reactions of styrene epoxide with BPs and model of PBs gave rise to 14 new compounds and 
five known compounds which were isolated and characterised by TLC, mp, HPLC, UV, GC/MS, 
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ESIMS, 
1
H NMR and 
13
C NMR. In addition, 11 components were detected from the products of 
guanine, BPs, BP dimethyl esters and substituted dipyrroles with styrene epoxide by ESIMS. 
The major finding in our study of the reaction of BPs and styrene epoxide was that the site of 
reaction of BPs with the epoxide is the carboxylic acid groups and that other groups in the aromatic 
system of BPs may play a minor role. However, despite being poorly reactive toward the model 
epoxide, the dimethyl esters of the BPs completely protected guanine from reactions with the 
activated epoxide in competition reactions. This is in agreement with recent studies that have 
clearly shown that the bile pigment dimethyl esters are as effective inhibitors of mutagens in some 
biological systems as the parent BPs.
19,186
 Free carboxylic acid groups are ubiquitous in biological 
systems, thus it seems unlikely that this reaction is a major contributor to the unique inhibition 
activity exhibited by BPs towards the mutagenic effects of activated epoxides, while the major 
inhibitory action of BPs toward mutagenic environment remain a mystery. 
Therefore, we decided to focus on the inhibition metabolism of mutagens of BPs in vitro by using 
the human liver S9 fraction in which the ability of BPs to inhibit mutagens (PhIP and BP) 
degradation has successfully been explored. Preliminarily data indicated the concentrations of PhIP 
and BP that resulted in the saturation of PhIP and BP degradative enzymes in the S9 mixtures. 
The results of the inhibition studies indicate that bilirubin had the greatest inhibitory effect on the 
metabolism of both PhIP and BP, followed by protoporphyrin and then biliverdin. 
Docking studies using published crystal structures of the CYP enzymes known to metabolise PhIP 
and BP indicated multiple interactions between the mutagens and the BPs (inhibitors) with active 
site amino acids of the CYP1A1, 1A2, 2A6, 3A4. This provided new data to suggest that BPs could 
competitively inhibit mutagen binding to the active site of these enzymes. These data largely agreed 
with the in vitro data presented in this chapter VI, indicating that bilirubin was the most potent 
inhibitor of mutagen metabolism. 
At the very least, our research goes some way to explaining why, though which mutagenic 
chemicals are commonly presented in our environment, the human cancer rate is relatively low. Our 
own physiology contains methods that protect us from these potentially damaging compounds. 
Future work 
Chapter VII: Conclusion and future direction  
140 
 
The study introduced a new key method to explore the physical interactions occurring in biological 
system that can be used for testing all mutagenic environments (2-aminofluorene, aflatoxin B1, 
2,4,7-TNFone and other mutagens) with the inhibitors in the future. 
While the protective effects of BPs and their derivatives are now established, the nature of these 
compounds makes it unlikely that they could be developed as viable supplements or pharmaceutics. 
Thus, the investigation of the anti-carcinogenic effects of substructures such as dipyrroles also 
requires an efficient and robust synthesis of the compounds.  The long term aim of this area of study 
is to develop small molecules that can act to protect patients from the effects of environmental 
mutagens. 
Human liver S9 contains a variety of different enzymes, which makes it difficult to identify which 
enzymes contribute to the metabolism of PhIP and BP. Therefore, determining the contribution of 
each CYP enzyme to mutagen metabolism is vital for future studies in this area. The contribution of 
the various CYP enzymes in human liver S9 to PhIP and BP metabolism could be determined by 
studying the inhibitory effects of known inhibitors of the various CYP enzymes hypothesised to be 
involved in the metabolism of the two mutagens (below). Known specific inhibitors include: 
a) α-naphthoflavone for CYP1A1and CYP1A2;258,276 
b) 2,3′,4,5′-tetramethoxystilbene (TMS) for CYP1B; 
c) coumarin and methoxypsoralen for CYP2A; and 
d) midazolam and ketoconazole for CYP3A. 
Once the contribution of specific CYP forms to PhIP and BP metabolism has been determined, the 
inhibitory effects of BPs can be compared to these known inhibitors for a better understanding of 
which enzymes the BPs are targeting. 
Another essential progression of this work is the expression and isolation of recombinant CYPs, or 
the use of human microsomes containing high activity of specific relevant CYPs. Inhibition studies 
using isolated enzymes would allow for accurate Ki values to be determined and thus a profile of 
the specificity of BPs as inhibitors of CYP enzymes could be generated. CYP enzymes are involved 
in many vital processes within the human body and thus, specificity of inhibition is a key to any 
potential these compounds may have as protective agents against environmental carcinogens. The 
use of recombinant proteins also opens the possibility of crystallisation of the proteins with BPs 
bound to the enzyme, which would allow evaluation of the accuracy of the simulated docking 
studies discussed above. 
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Appendix-A 
 
 
Figure 7.1: 
1
H NMR spectrum of 2.9 performed at 500 MHz in sol B. 
 
Figure 7.2: Overlay of the 
1
H NMR spectra of mixtures of 2.8 (blue) and its mixtures with varying concentrations of 
2.1 performed at 500 MHz in Sol B, the mole ratio between 2.1 and 2.8 are 2:1 (red), 1:1 (green), 1:2 (puple), 1:2 
(black-yellow in the presence of 1 drop of D2O). 
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Figure 7.3: Overlay of the 
1
H NMR spectra of 2.6 (brown) and its mixtures with 2.9 performed at 500 MHz in Sol A, 
the mole ratio between 2.6 and 2.9 are 2:1 (red), 1:1 (puple), 2:1 (blue). 
 
Figure 7.4: Overlay of the 
1
H NMR spectra of 2.6 (brown) and its mixtures with varying concentration of 2.8 
performed at 500 MHz in Sol A, the mole ratio between 2.6 and 2.8 are 1:2 (puple), 1:1 (blue), 2:1 (green). 
 
Figure 7.5: Overlay of the 
1
H NMR spectra of 2.6 (brown) and its mixtures with 2.7 performed at 500 MHz in Sol A, 
the mole ratio between 2.6 and 2.7 are 1:1 (blue). 
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Figure 7.6: Overlay of the 
1
H NMR spectra of 2.4 (puple) and its mixtures with 2.9 performed at 500 MHz in Sol A, 
the mole ratio between 2.4 and 2.9 are 1:1 (green). 
 
Figure 7.7: Overlay of the 
1
H NMR spectra of 2.4 (puple) and its mixtures with 2.8 performed at 500 MHz in Sol A, 
the mole ratio between 2.4 and 2.8 are 1:1 (green).  
 
Figure 7.8: Overlay of the 
1
H NMR spectra of 2.4 (puple) and its mixtures with 2.7 performed at 500 MHz in Sol A, 
the mole ratio between 2.4 and 2.7 are 1:1 (brown). 
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Figure 7.9: Overlay of the UV spectra of the mixture between 2.7 (0.5 μM in methanol (left)), 2.8 (0.5 μM in methanol 
(right) and varying concentrations of 2.2 (from 0.25 μM to 1.0 μM  in methanol). The blue line (left) and red line (right) 
that were in close proximity to baseline (λmax 317 nm 295 nm, respectively) were the UV spectra of 2.7 and 2.8. The 
introduction of 2.2 (from 0.25 μM to 1.0 μM) in the mixture was detected by the increasing UV absorbance at 450 nm 
in other overlaid spectra. 
         
Figure 7.10: Overlay of  the UV spectra of the mixture between 2.9 (1.0 μM in methanol (left) and 0.25 μM in buffer 
(right)) and varying concentrations of 2.1 (from 0.5 μM to 2.0 μM in methanol and from 0.25 μM to 1.5 μM). The black 
line (left) and blue line (right) that were in close proximity to baseline (λmax 288 nm) were the UV spectra of 2.9. The 
introduction of 2.1 (from 0.5 μM to 2.0 μM) in the mixture was detected by the increasing UV absorbance at 401 nm 
and 385 nm in buffer nm in other overlaid spectra. 
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Figure 7.11: Overlay of the UV spectra of the mixture between 2.7 (1.0 μM in methanol (left) and 1.0 μM in buffer 
(right)) and varying concentrations of 2.1 (from 0.5 μM to 2.5 μM in methanol and from 0.25 μM to 1.0 μM). The black 
line (right) and red line (right) that were in close proximity to baseline (λmax 317 nm) were the UV spectra of 2.7. The 
introduction of 2.1 (from 0.5 μM to 2.0 μM) in the mixture was detected by the increasing UV absorbance at 401 nm in 
methanol and 385 nm in buffer nm in other overlaid spectra. 
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Appendix-B 
Concentration of 3.6 in the presence of 3.2 (5 μM) 
Basolateral chamber Apical chamber 
t (min) Well-1 Well-2 Well-3 Well-1 Well-2 Well-3 
0 0.000 0.000 0.000 9.999 9.999 9.999 
30 0.330 0.419 0.404 -- -- -- 
60 0.438 0.449 0.487 -- -- -- 
90 0.510 0.537 0.544 -- -- -- 
120 0.460 0.489 0.497 -- -- -- 
150 0.422 0.404 0.427 -- -- -- 
180 0.398 0.416 0.428 1.818 1.822 1.836 
 
Table 7.1: The concentration of 3.6 collected from the AP and BL chamber of wells during the assays. 
Linear Regression / Apparent Permeability of 3.6 in the presence of 3.2 (5 μM) 
Wells Calculated Intercept Slope r^2 N Papp [cm/s] 
1 3 1.25 x10
-2
 5.99 x10
-4
 0.957 7 1.806 x10
-5
 
2 3 1.64 x10
-2
 6.13 x10
-4
 0.940 7 1.847 x10
-5
 
3 3 1.61 x10
-2
 6.35 x10
-4
 0.945 7 1.913 x10
-5
 
Mean 2.97 1.50 x10
-2
 6.16 x10
-4
     1.86 x10
-5
 
s.d. 0.30 2.17 x10
-3
 1.79 x10
-5
     5.41 x10
-7
 
rel s.d. 10%  14% 3%     3% 
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Table 7.2: The linear regression and Papp of 3.6 in the presence of 3.2 (5 μM).   
Concentration of 3.6 in the presence of 3.2 (10 μM) 
Basolateral chamber Apical chamber 
t (min) Well-1 Well-2 Well-3 Well-1 Well-2 Well-3 
0 0.000 0.000 0.000 9.999 9.999 9.999 
30 0.331 0.345 0.270 -- -- -- 
60 0.487 0.500 0.476 -- -- -- 
90 0.534 0.561 0.544 -- -- -- 
120 0.518 0.499 0.518 -- -- -- 
150 0.444 0.447 0.460 -- -- -- 
180 0.404 0.400 0.403 1.612 1.760 1.691 
 
Table 7.3: The concentration of 3.6 collected from the AP and BL chambers from 0 to 180 min. 
Linear Regression / Apparent Permeability of 3.6 in the presence of 3.2 (10 μM) 
Wells Calculated Intercept Slope r^2 N Papp [cm/s] 
1 3 1.31 x10
-2
 6.39 x10
-4
 0.953 7 1.93 x10
-5
 
2 3 1.43 x10
-2
 6.40 x10
-4
 0.945 7 1.93 x10
-5
 
3 3 1.02 x10
-2
 6.48 x10
-4
 0.959 7 1.95 x10
-5
 
Mean 2.96 1.26 x10
-2
 6.42 x10
-4
     1.94 x10
-5
 
s.d. 0.08 2.12 x10
-3
 4.90 x10
-6
     1.48 x10
-7
 
rel s.d. 3% 17% 1%     1% 
 
Table 7.4: The linear regression and Papp of 3.6 in the presence of 3.2 (10 μM).   
Concentration of 3.6 in the presence of 3.2 (20 μM) 
Basolateral chamber Apical chamber 
t (min) Well-1 Well-2 Well-3 Well-1 Well-2 Well-3 
0 0.000 0.000 0.000 9.999 9.999 9.999 
30 0.282 0.317 0.306 -- -- -- 
60 0.451 0.488 0.503 -- -- -- 
90 0.569 0.590 0.567 -- -- -- 
120 0.474 0.548 0.522 -- -- -- 
150 0.450 0.483 0.466 -- -- -- 
180 0.345 0.391 0.392 1.642 1.657 1.701 
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Table 7.5: The concentration of 3.6 collected from the AP and BL chambers from 0 to 180 min. 
Linear Regression / Apparent Permeability of 3.6 in the presence of 3.2 (20 μM) 
Wells Calculated Intercept Slope r^2 N Papp [cm/s] 
1 3 1.17 x10
-2
 6.12 x10
-4
 0.941 7 1.846 x10
-5
 
2 3 1.25 x10
-2
 6.72 x10
-4
 0.949 7 2.026 x10
-5
 
3 3 1.26 x10
-2
 6.55 x10
-4
 0.949 7 1.974 x10
-5
 
Mean 3.06 1.23 x10
-2
 6.47 x10
-4
     1.95 x10
-5
 
s.d. 0.36 4.89 x10
-4
 3.08 x10
-5
     9.29 x10
-7
 
rel s.d. 12% 4% 5%     5% 
 
Table 7.6: The linear regression and Papp of 3.6 in the presence of 3.2 (20 μM).   
Concentration of 3.6 in the presence of 3.4 (10 μM) 
Basolateral chamber Apical chamber 
t (min) Well-1 Well-2 Well-3 Well-1 Well-2 Well-3 
0 0.000 0.000 0.000 9.999 9.999 9.999 
30 0.352 0.382 0.451 -- -- -- 
60 0.555 0.577 0.616 -- -- -- 
90 0.586 0.627 0.644 -- -- -- 
120 0.607 0.578 0.571 -- -- -- 
150 0.562 0.545 0.529 -- -- -- 
180 0.459 0.481 0.487 1.642 1.657 1.701 
 
Table 7.7: The concentration of 3.6 collected from the AP and BL chambers from 0 to 180 min. 
Linear Regression / Apparent Permeability of 3.6 in the presence of 3.4 (10 μM) 
Wells Calculated Intercept Slope r^2 N Papp [cm/s] 
1 3 1.29 x10
-2
 7.50 x10
-4
 0.962 7 2.259 x10
-5
 
2 3 1.50 x10
-2
 7.53 x10
-4
 0.957 7 2.269 x10
-5
 
3 3 1.90 x10
-2
 7.53 x10
-4
 0.942 7 2.27 x10
-5
 
Mean 1.69 1.56 x10
-2
 7.52 x10
-4
     2.27 x10
-5
 
s.d. 0.23 3.06 x10
-3
 2.04 x10
-6
     6.16 x10
-8
 
rel s.d. 14%  20% 0%     0% 
 
Table 7.8: The linear regression and Papp of 3.6 in the presence of 3.4 (10 μM).   
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Concentration of 3.6 in the presence of 3.5 (10 μM) 
Basolateral chamber Apical chamber 
t (min) Well-1 Well-2 Well-3 Well-1 Well-2 Well-3 
0 0.000 0.000 0.000 9.999 9.999 9.999 
30 0.279 0.370 0.366 -- -- -- 
60 0.467 0.585 0.498 -- -- -- 
90 0.547 0.606 0.582 -- -- -- 
120 0.608 0.598 0.578 -- -- -- 
150 0.509 0.538 0.547 -- -- -- 
180 0.467 0.486 0.483 2.023 2.318 2.002 
 
Table 7.9: The concentration of 3.6 collected from the AP and BL chambers from 0 to 180 min. 
Linear Regression / Apparent Permeability of 3.6 in the presence of 3.5 (10 μM) 
Wells Calculated Intercept Slope r^2 N Papp [cm/s] 
1 3 8.19 x10
-3
 7.16 x10
-4
 0.974 7 2.159 x10
-5
 
2 3 1.44 x10
-2
 7.55 x10
-4
 0.958 7 2.275 x10
-5
 
3 3 1.21 x10
-2
 7.35 x10
-4
 0.971 7 2.215 x10
-5
 
Mean 2.01 1.16 x10
-2
 7.36 x10
-4
     2.22 x10
-5
 
s.d. 0.35 3.15 x10
-3
 1.93 x10
-5
     5.82 x10
-7
 
rel s.d. 17% 27% 3%     3% 
 
Table 7.10: The linear regression and Papp of 3.6 in the presence of 3.5 (10 μM).   
Concentration of 3.6 in the presence of 3.3 (10 μM) 
Basolateral chamber Apical chamber 
t (min) Well-1 Well-2 Well-3 Well-1 Well-2 Well-3 
0 0.000 0.000 0.000 9.999 9.999 9.999 
30 0.337 0.371 0.384 -- -- -- 
60 0.459 0.456 0.537 -- -- -- 
90 0.534 0.607 0.646 -- -- -- 
120 0.533 0.579 0.596 -- -- -- 
150 0.525 0.564 0.576 -- -- -- 
180 0.492 0.511 0.533 1.698 1.712 1.766 
 
Table 7.11: The concentration of 3.6 collected from the AP and BL chambers from 0 to 180 min. 
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Linear Regression / Apparent Permeability of 3.6 in the presence of 3.3 (10 μM) 
Wells Calculated Intercept Slope r^2 N Papp [cm/s] 
1 3 1.01 x10
-2
 7.01 x10
-4
 0.980 7 2.111 x10
-5
 
2 3 1.08 x10
-2
 7.52 x10
-4
 0.977 7 2.266 x10
-5
 
3 3 1.29 x10
-2
 7.88 x10
-4
 0.971 7 2.374 x10
-5
 
Mean 1.79 1.13 x10
-2
 7.47 x10
-4
     2.25 x10
-5
 
s.d. 0.48 1.45 x10
-3
 4.39 x10
-5
     1.32 x10
-6
 
rel s.d. 27% 13% 6%     6% 
 
Table 7.12: The linear regression and Papp of 3.6 in the presence of 3.3 (10 μM).   
Concentration of 3.6 in control experiments  
Basolateral chamber Apical chamber 
t (min) Well-1 Well-2 Well-3 Well-1 Well-2 Well-3 
0 0.000 0.000 0.000 9.999 9.999 9.999 
30 0.275 0.264 0.315 -- -- -- 
60 0.446 0.407 0.458 -- -- -- 
90 0.513 0.471 0.538 -- -- -- 
120 0.482 0.499 0.507 -- -- -- 
150 0.474 0.459 0.490 -- -- -- 
180 0.436 0.424 0.404 2.320 2.756 2.197 
 
Table 7.13: The concentration of 3.6 collected from the AP and BL chambers from 0 to 180 min. 
Linear Regression / Apparent Permeability of 3.6 in control experiments  
Wells Calculated Intercept Slope r^2 N Papp [cm/s] 
1 3 1.66 x10
-2
 5.83 x10
-4
 0.9781 7 1.757 x10
-5
 
2 3 1.42 x10
-2
 5.73 x10
-4
 0.9830 7 1.727 x10
-5
 
3 3 2.11 x10
-2
 5.75 x10
-4
 0.9686 7 1.733 x10
-5
 
Mean  1.73 x10
-2
 5.77 x10
-4
     1.74 x10
-5
 
s.d.  3.49 x10
-3
 5.27 x10
-6
     1.59 x10
-7
 
rel s.d.  20% 1%     1% 
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Table 7.14: The linear regression and Papp of 3.6 in control experiments.   
Concentration of 3.6 in the presence of 3.1 (10 μM) 
Basolateral chamber Apical chamber 
t (min) Well-1 Well-2 Well-3 Well-1 Well-2 Well-3 
0 0.292 0.284 0.319 9.999 9.999 9.999 
30 0.493 0.465 0.489 -- -- -- 
60 0.518 0.538 0.565 -- -- -- 
90 0.484 0.472 0.5177 -- -- -- 
120 0.492 0.466 0.462 -- -- -- 
150 0.431 0.439 0.429 -- -- -- 
180 0.292 0.284 0.320 2.248 2.770 2.629 
 
Table 7.15: The concentration of 3.6 collected from the AP and BL chambers from 0 to 180 min. 
Linear Regression / Apparent Permeability of 3.6 in the presence of 3.1 (10 μM) 
Wells Calculated Intercept Slope r^2 N Papp [cm/s] 
1 3 1.05 x10
-2
 6.54 x10
-4
 0.9675 7 1.97 x10
-5
 
2 3 9.98 x10
-2
 6.45 x10
-4
 0.9684 7 1.944 x10
-5
 
3 3 1.22 x10
-2
 6.62 x10
-4
 0.9582 7 1.996 x10
-5
 
Mean 2.83 1.09 x10
-2
 6.54 x10
-4
     1.97 x10
-5
 
s.d. 0.10 1.16 x10
-3
 8.60 x10
-6
     2.59 x10
-7
 
rel s.d. 4% 11% 1%     1% 
 
Table 7.16: The linear regression and Papp of 3.6 in the presence of 3.1 (10 μM).   
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Appendix-C 
 
Figure 7.12: The HMBC correlations from protons to carbons of 4.12 performed on a 500 MHz instrument in DMSO-
d6. 
 
Figure 7.13: The HMBC correlations from protons to carbons of 4.12 performed on a 500 MHz instrument in DMSO-
d6. 
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Figure 7.14: The 
13
C NMR spectroscopy of 4.12 performed on a 500 MHz instrument in DMSO-d6. 
 
Figure 7.15: The HMBC correlations from protons to carbons of 4.11 performed on a 500 MHz instrument in DMSO-
d6. 
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Figure 7.16: The HMBC correlations from protons to carbons of 4.12 performed on a 500 MHz instrument in DMSO-
d6. 
 
Figure 7.17: The HMBC correlations from protons to carbons of 4.13 performed on a 500 MHz instrument in DMSO-
d6. 
 
Figure 7.18: The HMBC correlations from protons to carbons of 4.13 performed on a 500 MHz instrument in DMSO-
d6. 
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Figure 7.19: The HMBC correlations from protons to carbons of 4.13 performed on a 500 MHz instrument in DMSO-
d6. 
 
Figure 7.20: The HMBC correlation from protons of three methyl groups to tertiary carbon in pyrrole ring of 8b 
performed on a 500 MHz instrument in CDCl3 
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Appendix-D 
Publication 1 arising from this Thesis 
 
http://pubs.acs.org/doi/abs/10.1021/np4005807 
 
Figure 7.21: ESI-MS spectrometry of unexpected products in positive ion obtaining from first fraction of the reaction 
between 5.10 and 5.7. 
 
Figure 7.22: An expanded region of the HMBC spectrum of 5.13 showing the key correlations used to identify the 
structure. All experiments were performed at 500 MHz in DMSO-d6. 
 
Figure 7.23: An expanded region of the HMBC spectrum of 5.15 showing the key correlations used to identify the 
structure. All experiments were performed at 500 MHz in DMSO-d6. 
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Figure 7.24: ESI-MS spectrometry of polymers in positive ion obtaining from first fraction of the reaction between 
5.10 and 5.7. 
 
Figure 7.25: ESI-MS spectrometry of a fraction obtaining from the reaction between 5.9 and 5.7. 
 
Figure 7.26: HRESI-MS spectra of compound 5.24, an example of a 1:1 adduct of 5.23 and 5.7.   
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Appendix-E 
 Enzyme Enzyme activity 
(pmol/min/mg 
protein) 
Substrates‘ products Result 
(pmol/min/mg 
protein) 
1 CYP2C8 ≥ 500 Paclitaxel 6α-hydroxylase 800 
2 CYP2C9 ≥ 1 Diclofenac 4‘-hydroxylase 18 
3 CYP2C19 ≥ 10 (S)-mephenytoin 4‘-hydroxylase 15 
4 CYP2A6 ≥ 1 Coumarin 7-hydroxylase 10 
5 CYP1A2 ≥ 200 Phenacetin O-deethylase 290 
6 CYP2D6 ≥ 500 Bufuralo 1‘-hydroxylase 580 
7 CYP2B6 ≥ 15 (S)-mephenytoin N-demethylase 16 
8 CYP3A4 ≥ 1000 Testosterone 6β-hydroxylase 1000 
9 Other -- -- -- 
 
Table 7.17:  A list of hepatic enzymes and the results of enzyme activity tests performed by Sigma-Aldrich upon 
analysis of S9 human liver. 
 
6.1 -6.7 6.1 -6.6 6.1 -6.8 
log(inhibitor) vs. response (three parameters) Ambiguous Ambiguous 
 Best-fit values 
   Bottom 6.466 55.14 153.0 
Top ~ 289989 ~ 206735 634.8 
LogIC50 ~ -3.035 ~ -3.016 -0.4433 
IC50 ~ 0.0009218 ~ 0.0009631 0.3603 
Span ~ 289982 ~ 206680 481.8 
Std. Error 
   Bottom 26.02 14.99 10.91 
Top ~ 1.932e+008 ~ 1.020e+008 646.1 
LogIC50 ~ 289.7 ~ 214.5 0.7915 
Span ~ 1.932e+008 ~ 1.020e+008 638.2 
95% Confidence Intervals 
   Bottom -48.21 to 61.14 23.65 to 86.64 130.1 to 175.9 
Top (Very wide) (Very wide) -722.7 to 1992 
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LogIC50 (Very wide) (Very wide) -2.106 to 1.220 
IC50 (Very wide) (Very wide) 0.007830 to 16.58 
Span (Very wide) (Very wide) -859.1 to 1823 
Goodness of Fit 
   Degrees of Freedom 18 18 18 
R square 0.7621 0.8426 0.8388 
Absolute Sum of Squares 58700 19474 8118 
Sy.x 57.11 32.89 21.24 
Number of points 
   Analyzed 21 21 21 
 
Table 7.18: Prism statistic applied for the data collected from the inhibition experiments of BPs to 6.1 using dose-
response curves-inhibition for nonlinear regression. 
 
6.4 -6.7 6.4 -6.6 6.4 -6.6 
log(inhibitor) vs. response (three parameters) Ambiguous 
  Best-fit values 
   Bottom 36.41 64.90 75.65 
Top ~ 156002 814.2 743.7 
LogIC50 ~ -2.886 -0.5487 -0.5143 
IC50 ~ 0.001301 0.2827 0.3060 
Span ~ 155966 749.3 668.0 
Std. Error 
   Bottom 11.05 10.96 11.97 
Top ~ 4.122e+007 1015 957.5 
LogIC50 ~ 114.9 0.7547 0.8129 
Span ~ 4.122e+007 1007 948.9 
95% Confidence Intervals 
   Bottom 13.18 to 59.63 41.88 to 87.92 50.50 to 100.8 
Top (Very wide) -1318 to 2947 -1268 to 2755 
LogIC50 (Very wide) -2.134 to 1.037 -2.222 to 1.194 
IC50 (Very wide) 0.007340 to 10.89 0.005997 to 15.62 
Span (Very wide) -1367 to 2865 -1326 to 2662 
 Appendices 
183 
 
Goodness of Fit 
   Degrees of Freedom 18 18 18 
R square 0.9109 0.8921 0.8631 
Absolute Sum of Squares 10587 8595 10113 
Sy.x 24.25 21.85 23.70 
Number of points 
   Analyzed 21 21 21 
 
Table 7.19: Prism statistic applied for the data collected from the inhibition experiments of BPs to 6.4 using dose-
response curves-inhibition for nonlinear regression. 
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Figure 7.27: Prism statistic applyed for the data collected from the inhibition experiments of BPs to 6.4 using dose-
response curves-inhibition for nonlinear regression. 
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T h e  m e ta b o lis m  r a te  o f  6 .1  in  th e  p r e s e n c e  o f  v a r y in g  c o n c e n tr a t io n  o f  B P s  ( fr o m  0  to  2 0  m ic r o m o le /l ite r )
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Figure 7.28: Prism statistic applyed for the data collected from the inhibition experiments of BPs to 6.1 using dose-
response curves-inhibition for nonlinear regression. 
 
 
 
